<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>regeneron_10q.htm
<DESCRIPTION>QUARTERLY REPORT
<TEXT>

<HTML>
<HEAD>
   <TITLE></TITLE>
</HEAD>

<BODY bgcolor="#ffffff">

<P align=center><FONT face=serif size=2>UNITED STATES <BR></FONT><FONT face=serif size=2>SECURITIES AND EXCHANGE COMMISSION <BR>Washington, D.C.
20549</FONT></P>
<P align=center><B><FONT face=serif size=2>Form 10-Q</FONT></B></P>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="40%" colSpan=3><FONT face=serif size=2>(Mark
      One)</FONT>&nbsp;</TD>
    <TD noWrap align=left width="58%">&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>(X)</FONT>&nbsp;</TD>
    <TD noWrap align=left width="1%">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=left width="98%" colSpan=4><FONT face=serif size=2>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
      SECURITIES</FONT>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="40%" colSpan=3><FONT face=serif size=2>EXCHANGE ACT OF 1934</FONT>&nbsp;</TD>
    <TD noWrap align=left width="58%">&nbsp;</TD></TR>
  <TR>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="40%" colSpan=3>&nbsp;</TD>
    <TD noWrap align=left width="58%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>For the quarterly
      period ended</FONT>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="1%"><FONT size=2>June 30, 2009</FONT></TD>
    <TD noWrap align=left width="38%">&nbsp;</TD>
    <TD noWrap align=left width="58%">&nbsp;</TD></TR>
  <TR>
    <TD noWrap align=left width="1%" ></TD>
    <TD noWrap align=left width="1%" ></TD>
    <TD noWrap align=left width="1%" ></TD>
    <TD noWrap align=center width="1%" ></TD>
    <TD noWrap align=left width="38%" ></TD>
    <TD noWrap align=left width="58%" >&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=center width="98%" colSpan=4><FONT face=serif size=2>OR</FONT>&nbsp;</TD></TR>
  <TR>
    <TD noWrap align=left width="1%" ></TD>
    <TD noWrap align=left width="1%" ></TD>
    <TD noWrap align=center width="98%"  colSpan=4>&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>(&nbsp;&nbsp;
      )</FONT>&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="98%" colSpan=4><FONT face=serif size=2>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE
      SECURITIES</FONT>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="40%" colSpan=3><FONT face=serif size=2>EXCHANGE ACT OF 1934</FONT>&nbsp;</TD>
    <TD noWrap align=left width="58%">&nbsp;</TD></TR>
  <TR>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="40%" colSpan=3>&nbsp;</TD>
    <TD noWrap align=left width="58%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="98%" colSpan=4><FONT face=serif size=2>For
      the transition period from ______________</FONT><FONT face=serif size=2>to
      ______________</FONT></TD></TR></TABLE><BR>
<P align=center><FONT face=serif size=2>Commission File Number
<U>0-19034</U></FONT></P>
<P align=center><U><FONT face=serif size=2>REGENERON PHARMACEUTICALS,
INC.</FONT></U> <FONT face=serif size=2><BR>(Exact name of registrant as
specified in its charter)</FONT></P>
<P>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=center width="50%"><U><FONT face=serif size=2>New
      York</FONT></U>&nbsp;</TD>
    <TD noWrap align=center width="49%"><U><FONT face=serif size=2>13-3444607</FONT></U>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=center width="50%"><FONT face=serif size=2>(State or
      other jurisdiction of</FONT>&nbsp;</TD>
    <TD noWrap align=center width="49%"><FONT face=serif size=2>(I.R.S.
      Employer Identification No.)</FONT>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=center width="50%"><FONT face=serif size=2>incorporation
      or organization)</FONT>&nbsp;</TD>
    <TD noWrap align=center width="49%">&nbsp;</TD></TR></TABLE><BR>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=center width="50%"><FONT face=serif size=2>777 Old Saw
      Mill River Road</FONT>&nbsp;</TD>
    <TD noWrap align=left width="49%">&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=center width="50%"><U><FONT face=serif size=2>Tarrytown,
      New York</FONT></U>&nbsp;</TD>
    <TD noWrap align=center width="49%"><U><FONT face=serif size=2>10591-6707</FONT></U>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=center width="50%"><FONT face=serif size=2>(Address of
      principal executive offices)</FONT>&nbsp;</TD>
    <TD noWrap align=center width="49%"><FONT face=serif size=2>(Zip
      Code)</FONT>&nbsp;</TD></TR></TABLE>
<P align=center><U><FONT face=serif size=2>(914) 347-7000</FONT></U> <FONT face=serif size=2><BR></FONT><FONT face=serif size=2>(Registrant&#146;s telephone
number, including area code)</FONT></P>
<P align=justify><FONT face=serif size=2>Indicate by check mark whether the
registrant (1) has filed all reports required to be filed by Section 13 or 15(d)
of the Securities Exchange Act of 1934 during the preceding 12 months (or for
such shorter period that the registrant was required to file such reports), and
(2) has been subject to such filing requirements for the past 90
days.</FONT></P>
<P align=center><FONT face=serif size=2>Yes</FONT> <U><FONT face=serif size=2>X</FONT></U><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
No __</FONT></P>
<P align=justify><FONT face=serif size=2>Indicate by check mark whether the
registrant has submitted electronically and posted on its corporate Web site, if
any, every Interactive Data File required to be submitted and posted pursuant to
Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12
months (or for such shorter period that the registrant was required to submit
and post such files).</FONT></P>
<P align=center><FONT face=serif size=2>Yes
__&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; No __</FONT></P>
<P align=justify><FONT face=serif size=2>Indicate by check mark whether the
registrant is a large accelerated filer, an accelerated filer, a non-accelerated
filer, or a smaller reporting company. See definitions of &#147;large accelerated
filer&#148;, &#147;accelerated filer&#148;, and &#147;smaller reporting company&#148; in Rule 12b-2 of
the Exchange Act.</FONT></P>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>Large accelerated
      filer</FONT>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="2%"><FONT face=serif size=2><FONT size=3>&nbsp;</FONT>
    X</FONT>&nbsp;</TD>
    <TD noWrap align=left width="50%">&nbsp;</TD>
    <TD noWrap align=left width="46%"><FONT face=serif size=2>Accelerated
      filer</FONT>&nbsp; __</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>Non-accelerated
      filer</FONT>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="2%">&nbsp;</TD>
    <TD noWrap align=left width="50%"><FONT face=serif size=2>&nbsp;(Do not
      check if a smaller reporting company)</FONT>&nbsp;</TD>
    <TD noWrap align=left width="46%"><FONT face=serif size=2>Smaller
      reporting company</FONT>&nbsp; __</TD></TR></TABLE>
<P align=justify><FONT face=serif size=2>Indicate by check mark whether the
registrant is a shell company (as defined in Rule 12b-2 of the Exchange
Act).</FONT></P>
<P align=center><FONT face=serif size=2>Yes
__&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; No</FONT> <U><FONT face=serif size=2>X</FONT></U><FONT face=serif size=2></FONT></P>
<P align=justify><FONT face=serif size=2>Number of shares outstanding of each of
the registrant&#146;s classes of common stock as of&nbsp;July 15, 2009:</FONT></P>
<DIV align=center>
<TABLE cellSpacing=0 cellPadding=0 width="60%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=center width="50%"><U><FONT face=serif size=2>Class of
      Common Stock</FONT></U>&nbsp;</TD>
    <TD noWrap align=center width="49%"><FONT face=serif size=2><U>Number of
      Shares</U></FONT>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=center width="50%"><FONT face=serif size=2>Class A Stock,
      $0.001 par value</FONT>&nbsp;</TD>
    <TD noWrap align=center width="49%"><FONT face=serif size=2>&nbsp;2,246,698</FONT>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=center width="50%"><FONT face=serif size=2>Common Stock,
      $0.001 par value</FONT>&nbsp;</TD>
    <TD noWrap align=center width="49%"><FONT face=serif size=2>77,932,500</FONT>&nbsp;</TD></TR></TABLE></DIV><BR>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=center><B><FONT face=serif size=2>REGENERON PHARMACEUTICALS, INC.
<BR>Table of Contents <BR>June 30, 2009 </FONT></B></P>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="86%"></TD>
    <TD noWrap align=center width="11%" colSpan=2><B><FONT face=serif size=2><U>Page Numbers</U></FONT></B> </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><B><FONT face=serif size=2>PART I</FONT></B> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=left width="86%" bgColor=#c0c0c0><B><FONT face=serif size=2>FINANCIAL INFORMATION</FONT></B> </TD>
    <TD noWrap align=left width="5%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="6%" bgColor=#c0c0c0></TD></TR>
  <TR>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="86%">&nbsp;</TD>
    <TD noWrap align=left width="5%"></TD>
    <TD noWrap align=left width="6%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><U><FONT face=serif size=2>Item 1</FONT></U> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="86%" bgColor=#c0c0c0><U><FONT face=serif size=2>Financial Statements</FONT></U> </TD>
    <TD noWrap align=left width="5%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="6%" bgColor=#c0c0c0></TD></TR>
  <TR>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="86%">&nbsp;</TD>
    <TD noWrap align=left width="5%"></TD>
    <TD noWrap align=left width="6%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="86%" bgColor=#c0c0c0><FONT face=serif size=2>Condensed balance sheets (unaudited) at June 30, 2009</FONT> </TD>
    <TD noWrap align=left width="5%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="6%" bgColor=#c0c0c0>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="86%" bgColor=#c0c0c0><FONT face=serif size=2>and December 31, 2008</FONT> </TD>
    <TD noWrap align=left width="5%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="6%" bgColor=#c0c0c0><FONT face=serif size=2>3</FONT> </TD></TR>
  <TR>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="86%">&nbsp;</TD>
    <TD noWrap align=left width="5%"></TD>
    <TD noWrap align=left width="6%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="86%" bgColor=#c0c0c0><FONT face=serif size=2>Condensed statements of operations (unaudited) for the three</FONT>
    </TD>
    <TD noWrap align=left width="5%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="6%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="86%" bgColor=#c0c0c0><FONT face=serif size=2>and six months ended June 30, 2009 and 2008</FONT> </TD>
    <TD noWrap align=left width="5%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="6%" bgColor=#c0c0c0><FONT face=serif size=2>4</FONT> </TD></TR>
  <TR>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="86%">&nbsp;</TD>
    <TD noWrap align=left width="5%"></TD>
    <TD noWrap align=left width="6%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="86%" bgColor=#c0c0c0><FONT face=serif size=2>Condensed statement of stockholders&#146; equity (unaudited) for</FONT>
    </TD>
    <TD noWrap align=left width="5%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="6%" bgColor=#c0c0c0>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="86%" bgColor=#c0c0c0><FONT face=serif size=2>the six months ended June 30, 2009</FONT> </TD>
    <TD noWrap align=left width="5%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="6%" bgColor=#c0c0c0><FONT face=serif size=2>5</FONT> </TD></TR>
  <TR>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="86%">&nbsp;</TD>
    <TD noWrap align=left width="5%">&nbsp;</TD>
    <TD noWrap align=left width="6%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="86%" bgColor=#c0c0c0><FONT face=serif size=2>Condensed statements of cash flows (unaudited) for the</FONT> </TD>
    <TD noWrap align=left width="5%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="6%" bgColor=#c0c0c0>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="86%" bgColor=#c0c0c0><FONT face=serif size=2>six months ended June 30, 2009 and 2008</FONT> </TD>
    <TD noWrap align=left width="5%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="6%" bgColor=#c0c0c0><FONT face=serif size=2>6</FONT> </TD></TR>
  <TR>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="86%">&nbsp;</TD>
    <TD noWrap align=left width="5%"></TD>
    <TD noWrap align=left width="6%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="86%" bgColor=#c0c0c0><FONT face=serif size=2>Notes to condensed financial statements (unaudited)</FONT> </TD>
    <TD noWrap align=left width="5%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="6%" bgColor=#c0c0c0><FONT face=serif size=2>7-16</FONT> </TD></TR>
  <TR>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="86%">&nbsp;</TD>
    <TD noWrap align=left width="5%"></TD>
    <TD noWrap align=left width="6%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><U><FONT face=serif size=2>Item 2</FONT></U> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="86%" bgColor=#c0c0c0><U><FONT face=serif size=2>Management's Discussion and Analysis of Financial
      Condition</FONT></U> </TD>
    <TD noWrap align=left width="5%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="6%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="86%" bgColor=#c0c0c0><U><FONT face=serif size=2>and Results of Operations</FONT></U> </TD>
    <TD noWrap align=left width="5%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="6%" bgColor=#c0c0c0><FONT face=serif size=2>17-40</FONT> </TD></TR>
  <TR>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="86%">&nbsp;</TD>
    <TD noWrap align=left width="5%"></TD>
    <TD noWrap align=left width="6%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><U><FONT face=serif size=2>Item 3</FONT></U> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="86%" bgColor=#c0c0c0><U><FONT face=serif size=2>Quantitative and Qualitative Disclosures About Market
      Risk</FONT></U> </TD>
    <TD noWrap align=left width="5%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="6%" bgColor=#c0c0c0><FONT face=serif size=2>40-41</FONT> </TD></TR>
  <TR>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="86%">&nbsp;</TD>
    <TD noWrap align=left width="5%"></TD>
    <TD noWrap align=left width="6%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><U><FONT face=serif size=2>Item 4</FONT></U> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="86%" bgColor=#c0c0c0><U><FONT face=serif size=2>Controls and Procedures</FONT></U> </TD>
    <TD noWrap align=left width="5%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="6%" bgColor=#c0c0c0><FONT face=serif size=2>41</FONT> </TD></TR>
  <TR>
    <TD width="99%" colSpan=5>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><B><FONT face=serif size=2>PART II</FONT></B> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="86%" bgColor=#c0c0c0><B><FONT face=serif size=2>OTHER INFORMATION</FONT></B> </TD>
    <TD noWrap align=left width="5%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="6%" bgColor=#c0c0c0></TD></TR>
  <TR>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="86%">&nbsp;</TD>
    <TD noWrap align=left width="5%"></TD>
    <TD noWrap align=left width="6%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><U><FONT face=serif size=2>Item 1</FONT></U> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="86%" bgColor=#c0c0c0><U><FONT face=serif size=2>Legal Proceedings</FONT></U> </TD>
    <TD noWrap align=left width="5%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="6%" bgColor=#c0c0c0><FONT face=serif size=2>41</FONT> </TD></TR>
  <TR>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="86%">&nbsp;</TD>
    <TD noWrap align=left width="5%"></TD>
    <TD noWrap align=left width="6%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><U><FONT face=serif size=2>Item 1A</FONT></U> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="86%" bgColor=#c0c0c0><U><FONT face=serif size=2>Risk Factors</FONT></U> </TD>
    <TD noWrap align=left width="5%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="6%" bgColor=#c0c0c0><FONT face=serif size=2>41-56</FONT> </TD></TR>
  <TR>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="86%">&nbsp;</TD>
    <TD noWrap align=left width="5%"></TD>
    <TD noWrap align=left width="6%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><U><FONT face=serif size=2>Item 4</FONT></U> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="86%" bgColor=#c0c0c0><U><FONT face=serif size=2>Submission of Matters to a Vote of Security Holders</FONT></U> </TD>
    <TD noWrap align=left width="5%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="6%" bgColor=#c0c0c0><FONT face=serif size=2>57</FONT> </TD></TR>
  <TR>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="86%">&nbsp;</TD>
    <TD noWrap align=left width="5%"></TD>
    <TD noWrap align=left width="6%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><U><FONT face=serif size=2>Item 6</FONT></U> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="86%" bgColor=#c0c0c0><U><FONT face=serif size=2>Exhibits</FONT></U> </TD>
    <TD noWrap align=left width="5%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="6%" bgColor=#c0c0c0><FONT face=serif size=2>57</FONT> </TD></TR>
  <TR>
    <TD width="99%" colSpan=5>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%" bgColor=#c0c0c0 colSpan=3><B><FONT face=serif size=2>SIGNATURE PAGE</FONT></B> </TD>
    <TD noWrap align=left width="5%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="6%" bgColor=#c0c0c0><FONT face=serif size=2>58</FONT> </TD></TR></TABLE>
<BR>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=left><B><FONT face=serif>PART I. FINANCIAL INFORMATION<BR>ITEM 1.
FINANCIAL STATEMENTS</FONT></B></P>
<P align=left><B><FONT face=serif size=2>REGENERON PHARMACEUTICALS, INC.
<BR></FONT></B><B><FONT face=serif size=2>CONDENSED BALANCE SHEETS AT JUNE 30,
2009 AND DECEMBER 31, 2008 (Unaudited) <BR></FONT></B><B><I><FONT face=serif size=2>(In thousands, except share data)</FONT></I></B></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"></TD>
    <TD noWrap align=center width="5%" colSpan=3><B><FONT face=serif size=2>June 30,</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="7%" colSpan=3><B><FONT face=serif size=2>December 31,</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=center width="87%"><B><FONT face=serif size=2></FONT></B></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=3><B><FONT face=serif size=2>2009</FONT></B></TD>
    <TD noWrap align=center width="1%"><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="7%" colSpan=3><B><FONT face=serif size=2>2008</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="3%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="7%" colSpan=3><I><FONT face=serif size=2>(Revised -</FONT></I></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="3%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="7%" colSpan=3><I><FONT face=serif size=2>see Note 8)</FONT></I></TD></TR>
  <TR>
    <TD noWrap align=center width="87%" bgColor=#c0c0c0><STRONG><FONT size=2>ASSETS</FONT></STRONG></TD>
    <TD noWrap align=center width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=center width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=center width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=center width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=center width="7%" bgColor=#c0c0c0 colSpan=3></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"><FONT face=serif size=2>Current
      assets</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="5%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#c0c0c0><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cash and cash
      equivalents</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>271,466</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>247,796</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif>Marketable
      securities</FONT></FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>120,452</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="5%"><FONT face=serif size=2>226,954</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#c0c0c0><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif>Accounts
      receivable from the sanofi-aventis Group</FONT></FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>54,240</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>33,302</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif>Accounts
      receivable - other</FONT></FONT></TD>
    <TD noWrap align=right width="1%">&nbsp;</TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>5,806</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="5%"><FONT face=serif size=2>1,910</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#c0c0c0><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif>Prepaid
      expenses and other current assets</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>13,068</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>11,480</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      <FONT face=serif>Total current assets</FONT></FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>465,032</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="5%"><FONT face=serif size=2>521,442</FONT></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD></TR>
  <TR>
    <TD width="100%" colSpan=8>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#c0c0c0><FONT face=serif size=2>Restricted cash</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>1,600</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>1,650</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"><FONT face=serif size=2>Marketable
      securities</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>72,845</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="5%"><FONT face=serif size=2>51,061</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#c0c0c0><FONT face=serif size=2>Property, plant, and equipment, at cost, net of
    accumulated</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="5%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#c0c0c0><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif>depreciation
      and amortization</FONT></FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>195,408</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>142,035</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"><FONT face=serif size=2>Other
      assets</FONT>&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face=serif size=2>7,460</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%">&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="5%"><FONT face=serif size=2>8,032</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#c0c0c0><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      <FONT face=serif>Total assets</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>742,345</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>724,220</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR>
    <TD width="100%" colSpan=8>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD align=center width="87%" bgColor=#c0c0c0><B><FONT face=serif size=2>LIABILITIES and STOCKHOLDERS' EQUITY</FONT></B></TD>
    <TD align=center width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD align=center width="3%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD align=center width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD align=center width="1%" bgColor=#c0c0c0></TD>
    <TD align=center width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD align=center width="5%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD align=center width="1%" bgColor=#c0c0c0>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"><FONT face=serif size=2>Current
      liabilities</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="5%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#c0c0c0><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif>Accounts
      payable and accrued expenses</FONT></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>51,881</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>36,168</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif>Deferred
      revenue from sanofi-aventis, current portion</FONT></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>21,553</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="5%"><FONT face=serif size=2>21,390</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#c0c0c0><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif>Deferred
      revenue - other, current portion</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>46,990</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>26,114</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      <FONT face=serif>Total current liabilities</FONT></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>120,424</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="5%"><FONT face=serif size=2>83,672</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR>
    <TD width="100%" colSpan=8>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#c0c0c0><FONT face=serif size=2>Deferred revenue from sanofi-aventis</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>95,362</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>105,586</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"><FONT face=serif size=2>Deferred revenue
      - other</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>51,893</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="5%"><FONT face=serif size=2>56,835</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#c0c0c0><FONT face=serif size=2>Facility lease obligation</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>62,925</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>56,019</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"><FONT face=serif size=2>Other long term
      liabilities</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face=serif size=2>1,235</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="5%"><FONT face=serif size=2>594</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#c0c0c0><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      <FONT face=serif>Total liabilities</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>331,839</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>302,706</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR>
    <TD width="100%" colSpan=8>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#c0c0c0><FONT face=serif size=2>Commitments and contingencies</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="5%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR>
    <TD width="100%" colSpan=8>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#c0c0c0><FONT face=serif size=2>Stockholders' equity</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="5%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif>Preferred
      stock, $.01 par value; 30,000,000 shares authorized; issued
      and</FONT></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="5%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      <FONT face=serif>outstanding-none</FONT></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="5%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#c0c0c0><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif>Class A
      Stock, convertible, $.001 par value; 40,000,000 shares
      authorized;</FONT></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="5%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#c0c0c0><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      <FONT face=serif>shares issued and outstanding - 2,246,698 in 2009 and
      2,248,698 in 2008</FONT></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>2</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>2</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"><FONT size=2><FONT face=serif>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Common Stock, $.001 par
      value; 160,000,000 shares authorized;</FONT></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="5%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      <FONT face=serif>shares issued and outstanding - 77,921,038 in 2009 and
      77,642,203 in 2008</FONT></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>78</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="5%"><FONT face=serif size=2>78</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#c0c0c0><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif>Additional
      paid-in capital</FONT></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>1,313,003</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>1,294,813</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif>Accumulated
      deficit</FONT></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>(903,591</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="5%"><FONT face=serif size=2>(873,265</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#c0c0c0><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif>Accumulated
      other comprehensive income (loss)</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>1,014</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>(114</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      <FONT face=serif>Total stockholders' equity</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face=serif size=2>410,506</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="5%"><FONT face=serif size=2>421,514</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#c0c0c0><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      <FONT face=serif>Total liabilities and stockholders'
    equity</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>742,345</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>724,220</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR></TABLE><BR>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=center width="99%"><B><FONT face=serif size=2>The
      accompanying notes are an integral part of the financial
      statements.</FONT></B> </TD></TR>
  <TR>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="99%">&nbsp;</TD></TR></TABLE><BR>
<P align=center><FONT face=serif size=2>3 </FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><FONT face=serif size=2>REGENERON PHARMACEUTICALS, INC.
<BR></FONT></B><B><FONT face=serif size=2>CONDENSED STATEMENTS OF OPERATIONS
(Unaudited) <BR></FONT></B><B><I><FONT face=serif size=2>(In thousands, except
per share data) </FONT></I></B></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="77%"></TD>
    <TD noWrap align=center width="11%" colSpan=7><B><FONT face=serif size=2>Three months ended June 30,</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="11%" colSpan=7><B><FONT face=serif size=2>Six months ended June 30,</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="77%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=3><B><FONT face=serif size=2>2009</FONT></B></TD>
    <TD noWrap align=center width="1%"><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=3><B><FONT face=serif size=2>2008</FONT></B></TD>
    <TD noWrap align=center width="1%"><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="3%"><B><FONT face=serif size=2>2009</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=3><B><FONT face=serif size=2>2008</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="77%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="3%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%" colSpan=3><I><FONT face=serif size=2>(Revised -</FONT></I></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="3%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%" colSpan=3><I><FONT face=serif size=2>(Revised -</FONT></I></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="77%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="3%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%" colSpan=3><I><FONT face=serif size=2>see Note 8)</FONT></I></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="3%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%" colSpan=3><I><FONT face=serif size=2>see Note 8)</FONT></I></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="77%" bgColor=#c0c0c0><FONT face=serif size=2>Revenues</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="77%"><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contract research and
      development from sanofi-aventis</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>60,732</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>38,606</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>110,392</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>74,340</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="77%" bgColor=#c0c0c0><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other contract research and
      development</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>14,800</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>12,047</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>26,230</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>22,696</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="77%"><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Technology licensing</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>10,000</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>10,000</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>20,000</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>20,000</FONT></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="77%" bgColor=#c0c0c0><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Net product sales</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>4,500</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>8,391</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="77%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face=serif size=2>90,032</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face=serif size=2>60,653</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face=serif size=2>165,013</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face=serif size=2>117,036</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR>
    <TD width="100%" colSpan=16>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="77%" bgColor=#c0c0c0><FONT face=serif size=2>Expenses</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="77%"><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Research and
    development</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>94,231</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>66,777</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>174,538</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>128,246</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="77%" bgColor=#c0c0c0><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Selling, general, and
      administrative</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>11,632</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>13,495</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>23,052</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>24,549</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="77%"><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cost of goods sold</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face=serif size=2>435</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face=serif size=2>827</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="77%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>106,298</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>80,272</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>198,417</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>152,795</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR>
    <TD width="100%" colSpan=16>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="77%" bgColor=#c0c0c0><FONT face=serif size=2>Loss from operations</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>(16,266</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>(19,619</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>(33,404</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>(35,759</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR>
  <TR>
    <TD width="100%" colSpan=16>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="77%" bgColor=#c0c0c0><FONT face=serif size=2>Other income (expense)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="77%"><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Investment income</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>1,328</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>4,535</FONT></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>3,078</FONT></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>11,839</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="77%" bgColor=#c0c0c0><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Interest expense</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>(2,674</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>(5,685</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="77%"><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Loss on early extinguishment
      of debt</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face=serif size=2>(931</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="3%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face=serif size=2>(931</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="77%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>1,328</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>930</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>3,078</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>5,223</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR>
    <TD width="100%" colSpan=16>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="77%" bgColor=#c0c0c0><FONT face=serif size=2>Net loss</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>(14,938</FONT></TD>
    <TD style="PADDING-BOTTOM: 1pt" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>(18,689</FONT></TD>
    <TD style="PADDING-BOTTOM: 1pt" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>(30,326</FONT></TD>
    <TD style="BORDER-BOTTOM: #c0c0c0 2pt solid" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD style="BORDER-BOTTOM: #c0c0c0 2pt solid" noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>(30,536</FONT></TD>
    <TD style="BORDER-BOTTOM: #c0c0c0 2pt solid" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR>
  <TR>
    <TD width="100%" colSpan=16>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="77%" bgColor=#c0c0c0><FONT face=serif size=2>Net loss per share, basic and diluted</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>(0.19</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>(0.24</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>(0.38</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>(0.39</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR>
  <TR>
    <TD width="100%" colSpan=16>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="77%" bgColor=#c0c0c0><FONT face=serif size=2>Weighted average shares outstanding, basic and diluted</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>79,626</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>78,689</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>79,562</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>78,591</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;
</TD></TR></TABLE><BR>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=center width="99%"><B><FONT face=serif size=2>The
      accompanying notes are an integral part of the financial
      statements.</FONT></B> </TD></TR>
  <TR>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="99%">&nbsp;</TD></TR></TABLE>
<P align=center><FONT face=serif size=2>4</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><FONT face=serif size=2>REGENERON PHARMACEUTICALS, INC.
<BR></FONT></B><B><FONT face=serif size=2>CONDENSED STATEMENT OF STOCKHOLDERS'
EQUITY </FONT></B><B><FONT face=serif size=2>(Unaudited)<EM> <BR></EM>For the
six months ended June 30, 2009<EM> <BR>(In thousands) </EM></FONT></B></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="47%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="3%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="3%"></TD>
    <TD noWrap align=center width="3%"></TD>
    <TD noWrap align=center width="2%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="3%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="3%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="4%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="6%" colSpan=3><B><FONT face=serif size=1>Accumulated</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="4%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="4%"></TD>
    <TD noWrap align=center width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="47%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="3%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="3%"></TD>
    <TD noWrap align=center width="3%"></TD>
    <TD noWrap align=center width="2%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="3%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="4%" colSpan=2><B><FONT face=serif size=1>Additional</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="4%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="6%" colSpan=3><B><FONT face=serif size=1>Other</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="6%" colSpan=3><B><FONT face=serif size=1>Total</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="4%"></TD>
    <TD noWrap align=center width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="47%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="9%" colSpan=5><B><FONT face=serif size=1>Class A Stock</FONT></B></TD>
    <TD noWrap align=center width="3%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="7%" colSpan=4><B><FONT face=serif size=1>Common Stock</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="4%" colSpan=2><B><FONT face=serif size=1>Paid-in</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="6%" colSpan=3><B><FONT face=serif size=1>Accumulated</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="6%" colSpan=3><B><FONT face=serif size=1>Comprehensive</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="6%" colSpan=3><B><FONT face=serif size=1>Stockholders'</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="6%" colSpan=3><B><FONT face=serif size=1>Comprehensive</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="47%"></TD>
    <TD noWrap align=center width="1%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=2><B><FONT face=serif size=1>Shares</FONT></B></TD>
    <TD noWrap align=center width="1%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=2><B><FONT face=serif size=1>Amount</FONT></B></TD>
    <TD noWrap align=center width="3%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="2%"><B><FONT face=serif size=1>Shares</FONT></B></TD>
    <TD noWrap align=center width="1%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=2><B><FONT face=serif size=1>Amount</FONT></B></TD>
    <TD noWrap align=center width="1%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=2><B><FONT face=serif size=1>Capital</FONT></B></TD>
    <TD noWrap align=center width="1%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="6%" colSpan=3><B><FONT face=serif size=1>Deficit</FONT></B></TD>
    <TD noWrap align=center width="1%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="6%" colSpan=3><B><FONT face=serif size=1>Income (Loss)</FONT></B></TD>
    <TD noWrap align=center width="1%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="6%" colSpan=3><B><FONT face=serif size=1>Equity</FONT></B></TD>
    <TD noWrap align=center width="1%"><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="6%" colSpan=3><B><FONT face=serif size=1>Loss</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="47%" bgColor=#c0c0c0><B><FONT face=serif size=1>Balance, December 31, 2008 </FONT></B><B><I><FONT face=serif size=1>(Revised- see Note 8)</FONT></I></B></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=1>2,249</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT size=1>$</FONT></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=1>2</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=1>77,642</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT size=1>$</FONT></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=1>78</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=1>$</FONT></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=1>1,294,813</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=1>$</FONT></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=1>(873,265</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=1>)</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=1>$</FONT></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=1>(114</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=1>)</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=1>$</FONT></TD>
    <TD align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=1>421,514</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="47%"><FONT face=serif size=1>Issuance of
      Common Stock in connection with</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="47%"><FONT face=serif size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; exercise of stock options, net
      of shares tendered</FONT></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=right width="3%"></TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=1>196</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=1>1,705</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=1>1,705</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="47%" bgColor=#c0c0c0><FONT face=serif size=1>Issuance of Common Stock in connection with</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="47%" bgColor=#c0c0c0><FONT face=serif size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Company 401(k) Savings Plan
      contribution</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=1>81</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=1>1,391</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=1>1,391</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="47%"><FONT face=serif size=1>Conversion of
      Class A Stock to Common Stock</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=1>(2</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=1>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%">&nbsp;</TD>
    <TD noWrap align=right width="3%"></TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=1>2</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="4%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="47%" bgColor=#c0c0c0><FONT face=serif size=1>Stock-based compensation expense</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=1>15,094</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=1>15,094</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="47%"><FONT face=serif size=1>Net
    loss</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=1>(30,326</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=1>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=1>(30,326</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=1>)</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=1>$</FONT></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=1>(30,326</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=1>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="47%" bgColor=#c0c0c0><FONT face=serif size=1>Change in net unrealized gain (loss) on</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="47%" bgColor=#c0c0c0><FONT face=serif size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; marketable
securities</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="4%" bgColor=#c0c0c0 colSpan=2></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=1>1,128</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=1>1,128</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=1>1,128</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR>
    <TD width="100%" colSpan=31>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #c0c0c0 2pt solid" noWrap align=left width="47%" bgColor=#c0c0c0><B><FONT face=serif size=1>Balance, June 30,
      2009</FONT></B></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=1>2,247</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%" bgColor=#c0c0c0><FONT size=1>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=1>2</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=1>77,921</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%" bgColor=#c0c0c0><FONT size=1>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=1>78</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=1>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=1>1,313,003</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=1>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=1>(903,591</FONT></TD>
    <TD style="BORDER-BOTTOM: #c0c0c0 2pt solid" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=1>)</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=1>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=1>1,014</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=1>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=1>410,506</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=1>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=1>(29,198</FONT></TD>
    <TD style="BORDER-BOTTOM: #c0c0c0 2pt solid" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=1>)</FONT></TD></TR></TABLE><BR>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=center width="99%"><B><FONT face=serif size=2>The
      accompanying notes are an integral part of the financial
      statements.</FONT></B> </TD></TR>
  <TR>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="99%">&nbsp;</TD></TR></TABLE>
<P align=center><FONT face=serif size=2>5</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><FONT face=serif size=2>REGENERON PHARMACEUTICALS, INC.
<BR></FONT></B><B><FONT face=serif size=2>CONDENSED STATEMENTS OF CASH FLOWS
(Unaudited) <BR></FONT></B><B><I><FONT face=serif size=2>(In
thousands)</FONT></I></B></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"></TD>
    <TD noWrap align=center width="13%" colSpan=7><B><FONT face=serif size=2>Six months ended June 30,</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="6%" colSpan=3><B><FONT face=serif size=2>2009</FONT></B></TD>
    <TD noWrap align=center width="1%"><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="6%" colSpan=3><B><FONT face=serif size=2>2008</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="4%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="6%" colSpan=3><I><FONT face=serif size=2>(Revised -</FONT></I></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="4%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="6%" colSpan=3><I><FONT face=serif size=2>see Note 8)</FONT></I></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#c0c0c0><FONT face=serif size=2>Cash flows from operating activities</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif>Net
      loss</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%"><FONT face=serif size=2>(30,326</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%"><FONT face=serif size=2>(30,536</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#c0c0c0><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif>Adjustments
      to reconcile net loss to net cash used in</FONT></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#c0c0c0><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      <FONT face=serif>operating activities</FONT></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      <FONT face=serif>Depreciation and amortization</FONT></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>5,722</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>5,887</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#c0c0c0><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      <FONT face=serif>Non-cash compensation expense</FONT></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>15,094</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>16,500</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      <FONT face=serif>Loss on early extinguishment of debt</FONT></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>931</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#c0c0c0><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      <FONT face=serif>Impairment charge on marketable
    securities</FONT></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>530</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      <FONT face=serif>Changes in assets and liabilities</FONT></FONT></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="4%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#c0c0c0><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      <FONT face=serif>Increase in accounts receivable</FONT></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>(24,834</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>(14,518</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      <FONT face=serif>(Increase) decrease in prepaid expenses and other
      assets</FONT></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>(578</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>3,866</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#c0c0c0><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      <FONT face=serif>Increase in deferred revenue</FONT></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>5,873</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>6,527</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      <FONT face=serif>Increase (decrease) in accounts payable, accrued
      expenses,</FONT></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%">&nbsp;</TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      and other liabilities</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%"><FONT face=serif size=2>13,045</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%"><FONT face=serif size=2>(887</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#c0c0c0><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      <FONT face=serif>Total adjustments</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>14,322</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>18,836</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      <FONT face=serif>Net cash used in operating activities</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%"><FONT face=serif size=2>(16,004</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%"><FONT face=serif size=2>(11,700</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD></TR>
  <TR>
    <TD width="100%" colSpan=8>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#c0c0c0><FONT face=serif size=2>Cash flows from investing activities</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif>Purchases of
      marketable securities</FONT></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>(105,315</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>(346,647</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#c0c0c0><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif>Sales or
      maturities of marketable securities</FONT></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>190,723</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>239,853</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif>Capital
      expenditures</FONT></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>(52,671</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>(9,789</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#c0c0c0><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif>Decrease
      (increase) in restricted cash</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>50</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>(50</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      <FONT face=serif>Net cash provided by (used in) investing
      activities</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%"><FONT face=serif size=2>32,787</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%"><FONT face=serif size=2>(116,633</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD></TR>
  <TR>
    <TD width="100%" colSpan=8>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#c0c0c0><FONT face=serif size=2>Cash flows from financing activities</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif>Extinguishment of long-term debt</FONT></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>(82,148</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#c0c0c0><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif>Proceeds in
      connection with facility lease obligation</FONT></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>5,182</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif>Net proceeds
      from the issuance of Common Stock</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%"><FONT face=serif size=2>1,705</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%"><FONT face=serif size=2>3,685</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#c0c0c0><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      <FONT face=serif>Net cash provided by (used in) financing
      activities</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>6,887</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>(78,463</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR>
  <TR>
    <TD width="100%" colSpan=8>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#c0c0c0><FONT face=serif size=2>Net increase (decrease) in cash and cash equivalents</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>23,670</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>(206,796</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR>
  <TR>
    <TD width="100%" colSpan=8>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#c0c0c0><FONT face=serif size=2>Cash and cash equivalents at beginning of period</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>247,796</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>498,925</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR>
    <TD width="100%" colSpan=8>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #c0c0c0 2pt solid" noWrap align=left width="87%" bgColor=#c0c0c0><FONT face=serif size=2>Cash and cash equivalents at end
      of period</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>271,466</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>292,129</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;
</TD></TR></TABLE><BR>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=center width="99%"><B><FONT face=serif size=2>The
      accompanying notes are an integral part of the financial
      statements.</FONT></B> </TD></TR>
  <TR>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="99%">&nbsp;</TD></TR></TABLE>
<P align=center><FONT face=serif size=2>6</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><FONT face=serif size=2>REGENERON PHARMACEUTICALS, INC.
<BR>Notes to Condensed Financial Statements
(Unaudited)&nbsp;<BR></FONT></B><B><I><FONT face=serif size=2>(Unless otherwise
noted, dollars in thousands, except per share data) </FONT></I></B></P>
<P align=justify><B><FONT face=serif size=2>1.</FONT></B><B><FONT face=sans-serif size=2> </FONT></B><B><FONT face=serif size=2>Interim Financial
Statements </FONT></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>The
interim Condensed Financial Statements of Regeneron Pharmaceuticals, Inc.
(&#147;Regeneron&#148; or the &#147;Company&#148;) have been prepared in accordance with the
instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do
not include all information and disclosures necessary for a presentation of the
Company&#146;s financial position, results of operations, and cash flows in
conformity with accounting principles generally accepted in the United States of
America. In the opinion of management, these financial statements reflect all
adjustments, consisting only of normal recurring accruals, necessary for a fair
presentation of the Company&#146;s financial position, results of operations, and
cash flows for such periods. The results of operations for any interim periods
are not necessarily indicative of the results for the full year. The December
31, 2008 Condensed Balance Sheet data were derived from audited financial
statements, but do not include all disclosures required by accounting principles
generally accepted in the United States of America. These financial statements
should be read in conjunction with the financial statements and notes thereto
contained in the Company&#146;s Annual Report on Form 10-K for the year ended
December 31, 2008. In addition, the previously issued balance sheet of the
Company at December 31, 2008 contained in the Company&#146;s Annual Report on Form
10-K for the year ended December 31, 2008, and the previously issued condensed
statement of operations for the three and six months ended June 30, 2008 and
condensed statement of cash flows for the six months ended June 30, 2008,
contained in the Company&#146;s Quarterly Report on Form 10-Q for the period ended
June 30, 2008, have been revised in this Quarterly Report on Form 10-Q in
connection with the application of Emerging Issues Task Force Statement No.
97-10, </FONT><I><FONT face=serif size=2>The Effect of Lessee Involvement in
Asset Construction</FONT></I><FONT face=serif size=2> (EITF 97-10), to the
Company&#146;s December 2006 lease of office and laboratory facilities in Tarrytown,
New York. See Note 8b below.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Included
in research and development expenses is the Company&#146;s share of VEGF Trap-Eye
development expenses incurred by Bayer HealthCare LLC, including the Company&#146;s
share of Bayer HealthCare&#146;s estimated VEGF Trap-Eye development expenses for the
most recent interim fiscal quarter. The Bayer HealthCare estimate each quarter
is adjusted to agree with actual expenses for such quarter in the subsequent
interim fiscal quarter.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Effective
in the first quarter of 2009, the estimated useful lives of laboratory and other
equipment, which is a component of property, plant, and equipment, has been
extended from 3 &#150; 5 years to 3 &#150; 10 years. The effect of this change in estimate
was to lower depreciation expense by $0.2 million and $0.5 million for the three
and six months ended June 30, 2009. There was no impact on the net loss per
share as a result of this change in estimate. </FONT></P>
<P align=justify><B><FONT face=serif size=2>2.</FONT></B><B><FONT face=sans-serif size=2> </FONT></B><B><FONT face=serif size=2>ARCALYST<SUP>&#174;</SUP></FONT></B><B><FONT face=serif size=2> (rilonacept)
Product Revenue</FONT></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In
February 2008, the Company received marketing approval from the U.S. Food and
Drug Administration (&#147;FDA&#148;) for ARCALYST</FONT><SUP><FONT face=serif size=2>&#174;</FONT></SUP><FONT face=serif size=2> (rilonacept) Injection for
Subcutaneous Use for the treatment of Cryopyrin-Associated Periodic Syndromes
(&#147;CAPS&#148;). For the three and six months ended June 30, 2009, the Company
recognized as revenue $4.5 million and $8.4 million, respectively, of ARCALYST
net product sales for which the right of return no longer existed and rebates
could be reasonably estimated. At June 30, 2009 and 2008, deferred revenue
related to ARCALYST net product sales totaled $4.9 million and $2.3 million,
respectively.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Cost of
goods sold related to ARCALYST sales totaled $0.4 million and $0.8 million for
the three and six months ended June 30, 2009, respectively, and consisted
primarily of royalties. To date, ARCALYST shipments to the Company&#146;s customers
have consisted of supplies of inventory manufactured and expensed prior to FDA
approval of ARCALYST; therefore, the costs of these supplies were not included
in costs of goods sold. At June 30, 2009, the Company had $0.4 million of
inventoried work-in-process costs related to ARCALYST, which is included in
prepaid expenses and other current assets. There were no capitalized inventory
costs at December 31, 2008.</FONT></P>
<P align=justify><B><FONT face=serif size=2>3.</FONT></B><B><FONT face=sans-serif size=2> </FONT></B><B><FONT face=serif size=2>Per Share Data
</FONT></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>The
Company&#146;s basic and diluted net loss per share amounts have been computed by
dividing net loss by the weighted average number of shares of Common Stock and
Class A Stock outstanding. Net loss per share is presented on a combined basis,
inclusive of Common Stock and Class A Stock outstanding, as each class of stock
has equivalent economic rights. For the three and six months ended June 30, 2009
and 2008, the Company reported net losses; therefore, no common stock
equivalents were included in the computation of diluted net loss per share for
these periods, since such inclusion would have been antidilutive. </FONT></P>
<P align=center><FONT face=serif size=2>7</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><FONT face=serif size=2>REGENERON PHARMACEUTICALS,
INC.<BR>Notes to Condensed Financial Statements
(Unaudited)<BR></FONT></B><B><I><FONT face=serif size=2>(Unless otherwise noted,
dollars in thousands, except per share data)</FONT></I></B></P>
<P align=justify><FONT face=serif size=2>The calculations of basic and diluted
net loss per share are as follows: </FONT></P>
<DIV align=center>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="90%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="13%" colSpan=7><FONT face=serif size=2>Three Months Ended June 30,</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="6%" colSpan=3><FONT face=serif size=2>2009</FONT></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="6%" colSpan=3><FONT face=serif size=2>2008</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#c0c0c0><FONT face=serif size=2>Net loss (Numerator)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>(14,938</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>(18,689</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR>
  <TR>
    <TD noWrap align=left width="87%">&nbsp; </TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#c0c0c0><FONT face=serif size=2>Weighted-average shares, in thousands (Denominator)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>79,626</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>78,689</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR>
    <TD noWrap align=left width="87%">&nbsp; </TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#c0c0c0><FONT face=serif size=2>Basic and diluted net loss per share</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>(0.19</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>(0.24</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR>
  <TR>
    <TD noWrap align=left width="87%">&nbsp; </TD>
    <TD noWrap align=center width="13%" colSpan=7>&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="13%" colSpan=7><FONT face=serif size=2>Six Months Ended June 30,</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="6%" colSpan=3><FONT face=serif size=2>2009</FONT></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="6%" colSpan=3><FONT face=serif size=2>2008</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#c0c0c0><FONT face=serif size=2>Net loss (Numerator)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>(30,326</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>(30,536</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR>
  <TR>
    <TD noWrap align=left width="87%">&nbsp; </TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#c0c0c0><FONT face=serif size=2>Weighted-average shares, in thousands (Denominator)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>79,562</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>78,591</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR>
    <TD noWrap align=left width="87%">&nbsp; </TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#c0c0c0><FONT face=serif size=2>Basic and diluted net loss per share</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>(0.38</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>(0.39</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR></TABLE></DIV><BR>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Shares
issuable upon the exercise of stock options, vesting of restricted stock awards,
and conversion of convertible debt, which have been excluded from the June 30,
2009 and 2008 diluted per share amounts because their effect would have been
antidilutive, include the following: </FONT></P>
<DIV align=center>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="90%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="90%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="9%" colSpan=5><FONT face=serif size=2>Three months ended June 30,</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=2><FONT face=serif size=2>2009</FONT></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=2><FONT face=serif size=2>2008</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%" bgColor=#c0c0c0><FONT face=serif size=2>Stock Options:</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%"><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weighted average number, in
      thousands</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>20,106</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>17,583</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%" bgColor=#c0c0c0><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weighted average exercise
      price</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>17.56</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>17.24</FONT></TD></TR>
  <TR>
    <TD width="99%" colSpan=6>&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%" bgColor=#c0c0c0><FONT face=serif size=2>Restricted Stock:</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%"><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weighted average number, in
      thousands</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>500</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>500</FONT></TD></TR>
  <TR>
    <TD width="99%" colSpan=6>&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%" bgColor=#c0c0c0><FONT face=serif size=2>Convertible Debt:</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%"><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weighted average number, in
      thousands</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>5,848</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%" bgColor=#c0c0c0><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Conversion price</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>30.25</FONT></TD></TR>
  <TR>
    <TD width="99%" colSpan=6>&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="9%" colSpan=5><FONT face=serif size=2>Six months ended June 30,</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=2><FONT face=serif size=2>2009</FONT></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=2><FONT face=serif size=2>2008</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%" bgColor=#c0c0c0><FONT face=serif size=2>Stock Options:</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%"><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weighted average number, in
      thousands</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>20,161</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>17,632</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%" bgColor=#c0c0c0><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weighted average exercise
      price</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>17.56</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>17.20</FONT></TD></TR>
  <TR>
    <TD width="99%" colSpan=6>&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%" bgColor=#c0c0c0><FONT face=serif size=2>Restricted Stock:</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%"><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weighted average number, in
      thousands</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>500</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>500</FONT></TD></TR>
  <TR>
    <TD width="99%" colSpan=6>&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%" bgColor=#c0c0c0><FONT face=serif size=2>Convertible Debt:</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%"><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weighted average number, in
      thousands</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>6,229</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%" bgColor=#c0c0c0><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Conversion price</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>30.25</FONT></TD></TR></TABLE></DIV>
<P align=center><FONT face=serif size=2>8</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><FONT face=serif size=2>REGENERON PHARMACEUTICALS,
INC.<BR>Notes to Condensed Financial Statements
(Unaudited)<BR></FONT></B><B><I><FONT face=serif size=2>(Unless otherwise noted,
dollars in thousands, except per share data)</FONT></I></B></P>
<P align=justify><B><FONT face=serif size=2>4.</FONT></B><B><FONT face=sans-serif size=2>&nbsp;</FONT></B><B><FONT face=serif size=2>Statement of
Cash Flows&nbsp;</FONT></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Supplemental disclosure of noncash investing and financing
activities:</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Included
in accounts payable and accrued expenses at June 30, 2009 and December 31, 2008
were $12.1 million and $7.0 million, respectively, of accrued capital
expenditures. Included in accounts payable and accrued expenses at June 30, 2008
and December 31, 2007 were $3.2 million and $1.7 million, respectively, of
accrued capital expenditures. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In
connection with the application of EITF 97-10 to the Company&#146;s lease of office
and laboratory facilities in Tarrytown, New York (see Note 8b), the Company
recognized a facility lease obligation of $1.3 million and $16.9 million for the
six months ended June 30, 2009 and 2008, respectively, in connection with
capitalizing, on the Company&#146;s books, the landlord&#146;s costs of constructing new
facilities that the Company has leased.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Included
in accounts payable and accrued expenses at December 31, 2008 and 2007 were $1.5
million and $1.1 million, respectively, of accrued Company 401(k) Savings Plan
contribution expense. In the first quarter of 2009 and 2008, the Company
contributed 81,086 and 58,575 shares, respectively, of Common Stock to the
401(k) Savings Plan in satisfaction of these obligations. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Included
in marketable securities at June 30, 2009 and December 31, 2008 were $1.3
million and $1.7 million, respectively, of accrued interest income. Included in
marketable securities at June 30, 2008 and December 31, 2007 were $1.3 million
and $2.2 million, respectively, of accrued interest income. </FONT></P>
<P align=justify><B><FONT face=serif size=2>5.</FONT></B><B><FONT face=sans-serif size=2> </FONT></B><B><FONT face=serif size=2>Marketable
Securities </FONT></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Marketable securities at June 30, 2009 and December 31, 2008 consisted of
debt securities, as detailed below, and equity securities, the aggregate fair
value of which was $5.0 million and $3.7 million at June 30, 2009 and December
31, 2008, respectively, and the aggregate cost basis of which was $4.1 million
at both June 30, 2009 and December 31, 2008. The following tables summarize the
amortized cost basis of debt securities included in marketable securities, the
aggregate fair value of those securities, and gross unrealized gains and losses
on those securities at June 30, 2009 and December 31, 2008. The Company
classifies its debt securities, other than mortgage-backed and other
asset-backed securities, based on their contractual maturity dates. Maturities
of mortgage-backed and other asset-backed securities have been estimated based
primarily on repayment characteristics and experience of the senior tranches
that the Company holds.</FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="74%" colSpan=2></TD>
    <TD noWrap align=center width="4%" colSpan=2><FONT face=serif size=2>Amortized</FONT></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="4%" colSpan=2>&nbsp;<FONT face=serif size=2>Fair</FONT></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="16%" colSpan=10><FONT face=serif size=2>Unrealized</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="7%"><FONT face=serif size=2>At June 30, 2009</FONT></TD>
    <TD noWrap align=left width="67%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=2><FONT face=serif size=2>Cost Basis</FONT></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=2><FONT face=serif size=2>Value</FONT></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=2><FONT face=serif size=2>Gains</FONT></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=3><FONT face=serif size=2>(Losses)</FONT></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=3><FONT face=serif size=2>Net</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="74%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>Maturities within one year</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="74%" colSpan=2><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; U.S. government
      obligations</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>95,598</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>95,784</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>186</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>186</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="74%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Corporate
      bonds</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>16,768</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>16,893</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>125</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>125</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="74%" colSpan=2><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mortgage-backed
      securities</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>5,006</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>4,289</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>(717</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>(717</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="74%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other asset-backed
      securities</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>448</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>450</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>2</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>2</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="74%" colSpan=2><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; U.S. government
      guaranteed</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="74%" colSpan=2><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      collateralized mortgage obligations</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face=serif size=2>3,021</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face=serif size=2>3,036</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face=serif size=2>15</FONT> </TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="3%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face=serif size=2>15</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="74%" bgColor=#c0c0c0 colSpan=2></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>120,841</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>120,452</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>328</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>(717</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>(389</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR>
  <TR>
    <TD width="100%" colSpan=18>&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="74%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>Maturities between one and three years</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="74%" colSpan=2><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; U.S. government guaranteed
      corporate bonds</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>48,444</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>48,735</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>296</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>(5</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>291</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="74%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; U.S. government
      obligations</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>10,167</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>10,218</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>51</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>51</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="74%" colSpan=2><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Corporate bonds</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>3,226</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>3,427</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>201</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>201</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="74%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mortgage-backed
      securities</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>1,077</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>1,021</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>(56</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>(56</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="74%" colSpan=2><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; U.S. government
      guaranteed</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="74%" colSpan=2><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      collateralized mortgage obligations</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face=serif size=2>4,382</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face=serif size=2>4,413</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face=serif size=2>31</FONT> </TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face=serif size=2>&nbsp;</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face=serif size=2>31</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="74%" bgColor=#c0c0c0 colSpan=2></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>67,296</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>67,814</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>579</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>(61</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>518</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR>
    <TD width="100%" colSpan=18>&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="74%" bgColor=#c0c0c0 colSpan=2></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>188,137</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>188,266</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>907</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>(778</FONT></TD>
    <TD style="PADDING-BOTTOM: 2pt" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>129</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;
</TD></TR></TABLE>
<P align=center><FONT face=serif size=2>9</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><FONT face=serif size=2>REGENERON PHARMACEUTICALS,
INC.<BR>Notes to Condensed Financial Statements
(Unaudited)<BR></FONT></B><B><I><FONT face=serif size=2>(Unless otherwise noted,
dollars in thousands, except per share data)</FONT></I></B></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="74%" colSpan=2></TD>
    <TD noWrap align=center width="4%" colSpan=2><FONT face=serif size=2>Amortized</FONT></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="4%" colSpan=2><FONT face=serif size=2>Fair</FONT></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="16%" colSpan=10><FONT face=serif size=2>Unrealized</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="8%"><FONT face=serif size=2>At December 31, 2008</FONT></TD>
    <TD noWrap align=left width="66%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=2><FONT face=serif size=2>Cost Basis</FONT></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=2><FONT face=serif size=2>Value</FONT></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=2><FONT face=serif size=2>Gains</FONT></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=3><FONT face=serif size=2>(Losses)</FONT></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=3><FONT face=serif size=2>Net</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="74%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>Maturities within one year</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="74%" colSpan=2><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; U.S. government
      obligations</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>170,993</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>172,253</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>1,260</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>1,260</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="74%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Corporate
      bonds</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>26,894</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>26,662</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>25</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>(257</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>(232</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="74%" colSpan=2><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mortgage-backed
      securities</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>9,098</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>8,420</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>(678</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>(678</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="74%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other asset-backed
      securities</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>7,842</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>7,829</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>(13</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>(13</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="74%" colSpan=2><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; U.S. government
      guaranteed</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="74%" colSpan=2><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      collateralized mortgage obligations</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face=serif size=2>11,742</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face=serif size=2>11,792</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face=serif size=2>50</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face=serif size=2>50</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="74%" bgColor=#c0c0c0 colSpan=2></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>226,569</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>226,956</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>1,335</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>(948</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>387</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR>
    <TD width="100%" colSpan=18>&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="74%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>Maturities between one and three years</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="74%" colSpan=2><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; U.S. government guaranteed
      corporate bonds</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>29,853</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>29,811</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>82</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>(124</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>(42</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="74%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Corporate
      bonds</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>10,446</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>10,414</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>77</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>(109</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>(32</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="74%" colSpan=2><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mortgage-backed
      securities</FONT></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>1,821</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>1,556</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>(265</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>(265</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="74%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; U.S. government
      guaranteed</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="74%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      collateralized mortgage obligations</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>5,297</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>5,570</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>273</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>273</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="74%" colSpan=2></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face=serif size=2>47,417</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face=serif size=2>47,351</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face=serif size=2>432</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face=serif size=2>(498</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face=serif size=2>(66</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD></TR>
  <TR>
    <TD width="100%" colSpan=18>&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="74%" bgColor=#c0c0c0 colSpan=2></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>273,986</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>274,307</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>1,767</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>(1,446</FONT></TD>
    <TD style="PADDING-BOTTOM: 2pt" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>321</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;
</TD></TR></TABLE><BR>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>At June
30, 2009 and December 31, 2008, marketable securities included an additional
unrealized gain of $0.9 million and an additional unrealized loss of $0.4
million, respectively, related to one equity security in the Company&#146;s
marketable securities portfolio.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>The
following table shows the fair value of the Company&#146;s marketable securities that
have unrealized losses and that are deemed to be only temporarily impaired,
aggregated by investment category and length of time that the individual
securities have been in a continuous unrealized loss position, at June 30, 2009
and December 31, 2008. The debt securities listed at June 30, 2009 mature at
various dates through December 2011. </FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="65%" colSpan=3></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="11%" colSpan=6><FONT face=serif size=2>Less than 12 Months</FONT></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="11%" colSpan=6><FONT face=serif size=2>12 Months or Greater</FONT></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="11%" colSpan=6><FONT face=serif size=2>Total</FONT> </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="65%" colSpan=3></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="3%"></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD noWrap align=center width="6%" colSpan=3><FONT face=serif size=2>Unrealized</FONT></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="3%"></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD noWrap align=center width="6%" colSpan=3><FONT face=serif size=2>Unrealized</FONT></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="3%"></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD noWrap align=center width="6%" colSpan=3><FONT face=serif size=2>Unrealized</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="7%"><FONT face=serif size=2>At June 30, 2009</FONT></TD>
    <TD noWrap align=left width="2%">&nbsp;</TD>
    <TD noWrap align=left width="56%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=2><FONT face=serif size=2>Fair Value</FONT></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="6%" colSpan=3><FONT face=serif size=2>Loss</FONT></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=2><FONT face=serif size=2>Fair Value</FONT></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="6%" colSpan=3><FONT face=serif size=2>Loss</FONT></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=2><FONT size=2>Fair Value</FONT></TD>
    <TD noWrap align=center width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="6%" colSpan=3><FONT size=2>Loss</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="65%" bgColor=#c0c0c0 colSpan=3><FONT face=serif size=2>&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; Government
      guaranteed</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="65%" bgColor=#c0c0c0 colSpan=3><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      corporate bonds</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>3,091</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>(5</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>3,091</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>(5</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="65%" colSpan=3><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mortgage-backed
      securities</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="4%">&nbsp;</TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face=serif size=2>5,310</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%"><FONT face=serif size=2>(773</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face=serif size=2>5,310</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%"><FONT face=serif size=2>(773</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="65%" bgColor=#c0c0c0 colSpan=3></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>3,091</FONT></TD>
    <TD style="BORDER-BOTTOM: #c0c0c0 2pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>(5</FONT></TD>
    <TD style="BORDER-BOTTOM: #c0c0c0 2pt solid" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD style="BORDER-BOTTOM: #c0c0c0 2pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>5,310</FONT></TD>
    <TD style="BORDER-BOTTOM: #c0c0c0 2pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>(773</FONT></TD>
    <TD style="BORDER-BOTTOM: #c0c0c0 2pt solid" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD style="BORDER-BOTTOM: #c0c0c0 2pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>8,401</FONT></TD>
    <TD style="BORDER-BOTTOM: #c0c0c0 2pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>(778</FONT></TD>
    <TD style="BORDER-BOTTOM: #c0c0c0 2pt solid" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR>
  <TR>
    <TD width="100%" colSpan=23>&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="9%" colSpan=2><FONT face=serif size=2>At December 31, 2008</FONT></TD>
    <TD noWrap align=left width="56%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="65%" bgColor=#c0c0c0 colSpan=3><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Corporate
      bonds</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>15,559</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>(287</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>2,933</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>(79</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>18,492</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>(366</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="65%" colSpan=3><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Government
guaranteed</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="65%" colSpan=3><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      corporate bonds</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>11,300</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>(124</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>11,300</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>(124</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="65%" bgColor=#c0c0c0 colSpan=3><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mortgage-backed
      securities</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>871</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>(74</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>9,104</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>(869</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>9,975</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>(943</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="65%" colSpan=3><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other asset-backed
      securities</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>7,829</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>(13</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>7,829</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>(13</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="65%" bgColor=#c0c0c0 colSpan=3><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Equity
      securities</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>3,608</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>(436</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>3,608</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>(436</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="65%" colSpan=3></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%"><FONT face=serif size=2>39,167</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="4%"><FONT face=serif size=2>(934</FONT></TD>
    <TD style="PADDING-BOTTOM: 2pt" noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%"><FONT face=serif size=2>12,037</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="4%"><FONT face=serif size=2>(948</FONT></TD>
    <TD style="PADDING-BOTTOM: 2pt" noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%"><FONT face=serif size=2>51,204</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="4%"><FONT face=serif size=2>(1,882</FONT></TD>
    <TD style="PADDING-BOTTOM: 2pt" noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD></TR></TABLE>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Realized
gains and losses are included as a component of investment income. For the three and six
months ended June 30, 2009, realized gains and losses on sales of marketable
securities were not significant. For the three and six months ended June 30,
2008, realized gains on sales of marketable securities totaled $0.1 million and
realized losses on sales of marketable securities were not significant. In
computing realized gains and losses, the Company computes the cost of its
investments on a specific identification basis. Such cost includes the direct
costs to acquire the security, adjusted for the amortization of any discount or
premium.</FONT></P>
<P align=center><FONT face=serif size=2>10</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><FONT face=serif size=2>REGENERON PHARMACEUTICALS,
INC.<BR>Notes to Condensed Financial Statements
(Unaudited)<BR></FONT></B><B><I><FONT face=serif size=2>(Unless otherwise noted,
dollars in thousands, except per share data)</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>The
Company&#146;s assets that are measured at fair value on a recurring
basis</FONT><I><FONT face=serif size=2>,</FONT></I><FONT face=serif size=2> at
June 30, 2009 and December 31, 2008, were as follows: </FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="77%" colSpan=2></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="4%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="17%" colSpan=8><FONT face=serif size=2>Fair Value Measurements at Reporting
      Date Using</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="77%" colSpan=2></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="4%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%" colSpan=2><FONT face=serif size=2>Quoted Prices in</FONT></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%" colSpan=2><FONT face=serif size=2>Significant Other</FONT></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%" colSpan=2><FONT face=serif size=2>Significant</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="77%" colSpan=2></TD>
    <TD noWrap align=center width="5%" colSpan=2><FONT face=serif size=2>Fair
      Value at</FONT></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%" colSpan=2><FONT face=serif size=2>Active Markets for</FONT></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%" colSpan=2><FONT face=serif size=2>Observable</FONT></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%" colSpan=2><FONT face=serif size=2>Unobservable</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="77%" colSpan=2></TD>
    <TD noWrap align=center width="5%" colSpan=2><FONT face=serif size=2>June
      30,</FONT></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%" colSpan=2><FONT face=serif size=2>Identical Assets</FONT></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%" colSpan=2><FONT face=serif size=2>Inputs</FONT></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%" colSpan=2><FONT face=serif size=2>Inputs</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="6%"><FONT face=serif size=2>Description</FONT></TD>
    <TD noWrap align=left width="71%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=2><FONT face=serif size=2>2009</FONT></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=2><FONT face=serif size=2>(Level 1)</FONT></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=2><FONT face=serif size=2>(Level 2)</FONT></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=2><FONT face=serif size=2>(Level 3)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="77%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>Available-for-sale marketable securities</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="77%" colSpan=2><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; U.S. government
      obligations</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>106,002</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>106,002</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="77%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; U.S. government
      guaranteed corporate bonds</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>48,735</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>48,735</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="77%" colSpan=2><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Corporate bonds</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>20,320</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>20,320</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="77%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mortgage-backed
      securities</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>5,310</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>5,310</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="77%" colSpan=2><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other asset-backed
      securities</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>450</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>450</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="77%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; U.S. government
      guaranteed</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="77%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      collateralized mortgage obligations</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>7,449</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>7,449</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="77%" colSpan=2><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Equity securities</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%"><FONT face=serif size=2>5,031</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%"><FONT face=serif size=2>4,931</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="4%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%"><FONT face=serif size=2>100</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="77%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      Total</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>193,297</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>4,931</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>188,266</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>100</FONT></TD></TR>
  <TR>
    <TD width="100%" colSpan=13>&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="77%" colSpan=2></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="4%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="17%" colSpan=8><FONT face=serif size=2>Fair Value Measurements at Reporting
      Date Using</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="77%" colSpan=2></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="4%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%" colSpan=2><FONT face=serif size=2>Quoted Prices in</FONT></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%" colSpan=2><FONT face=serif size=2>Significant Other</FONT></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%" colSpan=2><FONT face=serif size=2>Significant</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="77%" colSpan=2></TD>
    <TD noWrap align=center width="5%" colSpan=2><FONT face=serif size=2>Fair
      Value at</FONT></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%" colSpan=2><FONT face=serif size=2>Active Markets for</FONT></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%" colSpan=2><FONT face=serif size=2>Observable</FONT></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%" colSpan=2><FONT face=serif size=2>Unobservable</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="77%" colSpan=2></TD>
    <TD noWrap align=center width="5%" colSpan=2><FONT face=serif size=2>December 31,</FONT></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%" colSpan=2><FONT face=serif size=2>Identical Assets</FONT></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%" colSpan=2><FONT face=serif size=2>Inputs</FONT></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%" colSpan=2><FONT face=serif size=2>Inputs</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="6%"><FONT face=serif size=2>Description</FONT></TD>
    <TD noWrap align=left width="71%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=2><FONT face=serif size=2>2008</FONT></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=2><FONT face=serif size=2>(Level 1)</FONT></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=2><FONT face=serif size=2>(Level 2)</FONT></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=2><FONT face=serif size=2>(Level 3)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="77%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>Available-for-sale marketable securities</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="77%" colSpan=2><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif>U.S.
      government obligations</FONT></FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>172,253</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>172,253</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="77%" bgColor=#c0c0c0 colSpan=2><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif>U.S.
      government guaranteed corporate </FONT><FONT face=serif>bonds</FONT></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>29,811</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>29,811</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="77%" colSpan=2><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif>Corporate
      bonds</FONT></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>37,076</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>37,076</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="77%" bgColor=#c0c0c0 colSpan=2><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif>Mortgage-backed securities</FONT></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>9,976</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>9,976</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="77%" colSpan=2><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif>Other asset
      backed securities</FONT></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>7,829</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="4%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>7,829</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="77%" bgColor=#c0c0c0 colSpan=2><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif>U.S.
      government guaranteed</FONT></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="77%" bgColor=#c0c0c0 colSpan=2><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      <FONT face=serif>collateralized mortgage obligations</FONT></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>17,362</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>17,362</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="77%" colSpan=2><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif>Equity
      securities</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%"><FONT face=serif size=2>3,708</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%"><FONT face=serif size=2>3,608</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="4%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%"><FONT face=serif size=2>100</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="77%" bgColor=#c0c0c0 colSpan=2><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      <FONT face=serif>Total</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>278,015</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>3,608</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>274,307</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>100</FONT></TD></TR></TABLE>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Marketable securities included in Level 2 were valued using a market
approach utilizing prices and other relevant information, such as interest
rates, yield curves, prepayment speeds, loss severities, credit risks and
default rates, generated by market transactions involving identical or
comparable assets. The Company considers market liquidity in determining the
best price for these securities. During the three and six months ended June 30,
2009 and 2008, the Company did not record any charges for other-than-temporary
impairment of its Level 2 marketable securities.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Marketable securities included in Level 3 were valued using information
provided by the Company&#146;s investment advisors, including quoted bid prices which
take into consideration the securities&#146; current lack of liquidity. During the
three and six months ended June 30, 2009, the Company did not record any charges
for other-than-temporary impairment of its Level 3 marketable securities. During
the three and six months ended June 30, 2008, deterioration in the credit
quality of a marketable security included in Level 3 subjected the Company to
the risk of not being able to recover the carrying value of the investment. As
such, the Company recorded a $0.5 million charge related to this investment.
</FONT></P>
<P align=center><FONT face=serif size=2>11</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><FONT face=serif size=2>REGENERON PHARMACEUTICALS,
INC.<BR>Notes to Condensed Financial Statements
(Unaudited)<BR></FONT></B><B><I><FONT face=serif size=2>(Unless otherwise noted,
dollars in thousands, except per share data) </FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>There
were no unrealized gains or losses related to the Company&#146;s Level 3 marketable
securities for the three or six months ended June 30, 2009 and 2008. In
addition, there were no purchases, sales, or maturities of Level 3 marketable
securities, and no transfers of marketable securities between the Level 2 and
Level 3 classifications, during the three and six months ended June 30, 2009 and
2008. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Changes
in marketable securities included in Level 3 during the three and six months
ended June 30, 2009 and 2008 were as follows: </FONT></P>
<DIV align=center>
<TABLE cellSpacing=0 cellPadding=0 width="70%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="89%">&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="11%" colSpan=6><FONT face=serif size=2>Level 3 marketable securities</FONT>
  </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%">&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=2><FONT face=serif size=2>2009</FONT> </TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=3><FONT face=serif size=2>2008</FONT> </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" bgColor=#c0c0c0><FONT face=serif size=2>Balance, January 1 and April 1</FONT>&nbsp; </TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT> </TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT face=serif size=2>100</FONT> </TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT> </TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>7,950</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%"><FONT face=serif size=2>Settlements</FONT>&nbsp; </TD>
    <TD noWrap align=left width="4%">&nbsp;</TD>
    <TD noWrap align=right width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>(2,425</FONT>
</TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT> </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" bgColor=#c0c0c0><FONT face=serif size=2>Impairments</FONT>&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="4%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%" bgColor=#c0c0c0>&nbsp;&nbsp; </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>(530</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT> </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%"><FONT face=serif size=2>Balance, June
      30</FONT>&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="4%"><FONT face=serif size=2>$</FONT> </TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="1%"><FONT face=serif size=2>100</FONT> </TD>
    <TD noWrap align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face=serif size=2>$</FONT> </TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%"><FONT face=serif size=2>4,995</FONT> </TD>
    <TD noWrap align=left width="1%">&nbsp; </TD></TR></TABLE></DIV><BR>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>On a
quarterly basis, the Company reviews its portfolio of marketable securities,
using both quantitative and qualitative factors, to determine if declines in
fair value below cost are other-than-temporary. With respect to debt securities,
this review process also includes an evaluation of the Company&#146;s (a) intent to
sell an individual debt security or (b) need to sell the debt security before
its anticipated recovery or maturity. With respect to equity securities, this
review process includes an evaluation of the Company&#146;s ability and intent to
hold the securities until their full value can be recovered.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>The
current economic environment, the deterioration in the credit quality of some of
the issuers of securities that the Company holds, and the recent volatility of
securities markets increase the risk that there could be further declines in the
market value of marketable securities in the Company&#146;s investment portfolio and
that such declines could result in charges against income in future periods for
other-than-temporary impairments, and such amounts could be material.
</FONT></P>
<P align=justify><B><FONT face=serif size=2>6.</FONT></B><B><FONT face=sans-serif size=2> </FONT></B><B><FONT face=serif size=2>Accounts Payable
and Accrued Expenses </FONT></B></P>
<P align=justify><FONT face=serif size=2><FONT size=3>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Accounts payable and accrued
expenses as of June 30, 2009 and December 31, 2008 consist of the following:
</FONT></P>
<DIV align=center>
<TABLE cellSpacing=0 cellPadding=0 width="90%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="91%">&nbsp; </TD>
    <TD noWrap align=center width="4%" colSpan=2><FONT face=serif size=2>June
      30,</FONT> </TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="4%" colSpan=2><FONT face=serif size=2>December 31,</FONT> </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="91%">&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=2><FONT face=serif size=2>2009</FONT> </TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=2><FONT face=serif size=2>2008</FONT> </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="91%" bgColor=#c0c0c0><FONT face=serif size=2>Accounts payable</FONT>&nbsp; </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT> </TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>13,034</FONT> </TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT> </TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>6,268</FONT> </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="91%"><FONT face=serif size=2>Payable to Bayer
      HealthCare</FONT>&nbsp; </TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="3%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>9,799</FONT>
  </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="91%" bgColor=#c0c0c0><FONT face=serif size=2>Accrued payroll and related costs</FONT>&nbsp; </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>13,619</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>5,948</FONT> </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="91%"><FONT face=serif size=2>Accrued clinical
      trial expense</FONT>&nbsp; </TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>12,199</FONT>
</TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>4,273</FONT>
  </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="91%" bgColor=#c0c0c0><FONT face=serif size=2>Accrued property, plant, and equipment expenses</FONT>&nbsp; </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>8,641</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>5,994</FONT> </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="91%"><FONT face=serif size=2>Accrued
      expenses, other</FONT>&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face=serif size=2>4,388</FONT> </TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face=serif size=2>3,886</FONT> </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="91%" bgColor=#c0c0c0>&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT> </TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>51,881</FONT> </TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT> </TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>36,168</FONT>
</TD></TR></TABLE></DIV>
<P align=center><FONT face=serif size=2>12</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><FONT face=serif size=2>REGENERON PHARMACEUTICALS,
INC.<BR>Notes to Condensed Financial Statements
(Unaudited)<BR></FONT></B><B><I><FONT face=serif size=2>(Unless otherwise noted,
dollars in thousands, except per share data) </FONT></I></B></P>
<P align=justify><B><FONT face=serif size=2>7.</FONT></B><B><FONT face=sans-serif size=2> </FONT></B><B><FONT face=serif size=2>Comprehensive Loss
</FONT></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>The
Company presents comprehensive income (loss) in accordance with Statement of
Financial Accounting Standards No. (&#147;SFAS&#148;) 130, </FONT><I><FONT face=serif size=2>Reporting Comprehensive Income</FONT></I><FONT face=serif size=2>.
Comprehensive loss of the Company includes net loss adjusted for the change in
net unrealized gain (loss) on marketable securities. For the three and six
months ended June 30, 2009 and 2008, the components of comprehensive loss are:
</FONT></P>
<DIV align=center>
<TABLE cellSpacing=0 cellPadding=0 width="90%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="88%">&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="12%" colSpan=7><FONT face=serif size=2>Three months ended June 30,</FONT>
</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%">&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=3><FONT face=serif size=2>2009</FONT> </TD>
    <TD noWrap align=center width="2%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=3><FONT face=serif size=2>2008</FONT> </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%" bgColor=#c0c0c0><FONT face=serif size=2>Net loss</FONT>&nbsp; </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT> </TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>(14,938</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)<FONT size=3> </FONT></FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT> </TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>(18,689</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT> </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%"><FONT face=serif size=2>Change in net
      unrealized gain (loss) on marketable securities</FONT>&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face=serif size=2>2,262</FONT> </TD>
    <TD noWrap align=left width="1%">&nbsp; </TD>
    <TD noWrap align=left width="2%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face=serif size=2>(1,143</FONT> </TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)<FONT size=3>
      </FONT></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #c0c0c0 2pt solid" noWrap align=left width="88%" bgColor=#c0c0c0>&nbsp; &nbsp;<FONT face=serif size=2>Total comprehensive
      loss</FONT>&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT> </TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>(12,676</FONT> </TD>
    <TD style="BORDER-BOTTOM: #c0c0c0 2pt solid" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)<FONT size=3> </FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #c0c0c0 2pt solid" noWrap align=right width="2%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT> </TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>(19,832</FONT> </TD>
    <TD style="BORDER-BOTTOM: #c0c0c0 2pt solid" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)<FONT size=3>
</FONT></FONT></TD></TR>
  <TR>
    <TD width="100%" colSpan=8>&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%">&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="12%" colSpan=7><FONT face=serif size=2>Six months ended June 30,</FONT> </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%">&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=3><FONT face=serif size=2>2009</FONT> </TD>
    <TD noWrap align=center width="2%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=3><FONT face=serif size=2>2008</FONT> </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%" bgColor=#c0c0c0><FONT face=serif size=2>Net loss</FONT>&nbsp; </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT> </TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>(30,326</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)<FONT size=3> </FONT></FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT> </TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>(30,536</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)<FONT size=3> </FONT></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%"><FONT face=serif size=2>Change in net
      unrealized gain (loss) on marketable securities</FONT>&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face=serif size=2>1,128</FONT> </TD>
    <TD noWrap align=left width="1%">&nbsp; </TD>
    <TD noWrap align=left width="2%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face=serif size=2>(485</FONT> </TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)<FONT size=3>
      </FONT></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #c0c0c0 2pt solid" noWrap align=left width="88%" bgColor=#c0c0c0><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif>Total comprehensive loss</FONT></FONT>&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT> </TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>(29,198</FONT> </TD>
    <TD style="BORDER-BOTTOM: #c0c0c0 2pt solid" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)<FONT size=3> </FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #c0c0c0 2pt solid" noWrap align=right width="2%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT> </TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>(31,021</FONT> </TD>
    <TD style="BORDER-BOTTOM: #c0c0c0 2pt solid" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)<FONT size=3>
  </FONT></FONT></TD></TR></TABLE></DIV><BR>
<P align=justify><B><FONT face=serif size=2>8.</FONT></B><B><FONT face=sans-serif size=2> </FONT></B><B><FONT face=serif size=2>Lease &#150; Tarrytown,
New York Facilities</FONT></B></P>
<P align=justify><B><I><FONT face=serif size=2>a. Lease Amendment
</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>The
Company leases laboratory and office facilities in Tarrytown, New York. In
December 2006, the Company entered into a new agreement (which was amended in
October 2007 and September 2008) to lease laboratory and office space at the
Company&#146;s current Tarrytown location, including space that is now under
construction and expected to be completed in mid-2009 (the &#147;new facilities&#148;).
The term of the lease commenced effective June 2008 and will expire in June
2024. In April 2009, the Company amended the lease agreement to increase the
amount of space the Company will lease. As amended, the lease contains early
termination options for the portion of the space that excludes the new
facilities. Other terms and conditions, as previously described in the Company&#146;s
Annual Report on Form 10-K for the year ended December 31, 2008, remain
unchanged. In connection with the lease amendment, in April 2009, the Company
terminated an April 2008 sublease for space in Tarrytown, New York.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In
connection with the April 2009 lease amendment, the Company&#146;s total estimated
future minimum noncancelable lease commitments, previously disclosed in the
Company&#146;s Annual Report on Form 10-K for the year ended December 31, 2008, will
increase to $9.4 million, $14.5 million, $14.7 million, $13.7 million, and $15.1
million for the years ended December 31, 2009, 2010, 2011, 2012, and 2013,
respectively, and increase to $182.5 million, in the aggregate, for years
subsequent to 2013.</FONT></P>
<P align=justify><B><I><FONT face=serif size=2>b. Revisions of Previously Issued
Financial Statements </FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>The
application of EITF 97-10, </FONT><I><FONT face=serif size=2>The Effect of
Lessee Involvement in Asset Construction</FONT></I><FONT face=serif size=2>,
under certain conditions, can result in the capitalization on a lessee&#146;s books
of a lessor&#146;s costs of constructing facilities to be leased to the lessee.
Recently, the Company became aware that certain of these conditions were
applicable to its December 2006 lease, as amended, of new laboratory and office
facilities being constructed in Tarrytown by the Company&#146;s landlord. As a
result, pursuant to EITF 97-10, the Company is deemed, in substance, to be the
owner of the landlord&#146;s buildings during the construction phase and the
landlord&#146;s costs of constructing these new facilities are required to be
capitalized on the Company&#146;s books as a non-cash transaction during the new
facilities&#146; construction, offset by a corresponding lease obligation on the
Company&#146;s balance sheet. In addition, the land element of the lease should have
been accounted for as an operating lease; therefore, adjustments to non-cash
rent expense previously recognized pursuant to SFAS 13, </FONT><I><FONT face=serif size=2>Accounting for Leases,</FONT></I><FONT face=serif size=2> in
connection with these new facilities are also required. Construction of the new
facilities is not yet completed and actual lease payments will not commence
until August 2009.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>The
Company has revised its previously issued financial statements to capitalize the
landlord&#146;s costs of constructing their new Tarrytown facilities which the
Company is leasing and to adjust the Company&#146;s previously recognized rent
expense in connection with these facilities, as described above. These revisions
primarily resulted in an increase to property, plant, and equipment and a
corresponding increase in facility lease obligation (a long-term liability) at
each balance sheet date. The Company also revised its statements of operations
and statements of cash flows to reflect rent expense in connection with only the
land element of its lease, with a corresponding adjustment to other long-term
liabilities. In addition, the Company&#146;s statement of cash flows for the quarter
ended March 31, 2009 has been revised to reclassify, from an operating activity
to a financing activity, a $5.2 million reimbursement received from the
Company&#146;s landlord for tenant improvement costs that the Company incurred. Under EITF 97-10, such payments that the Company receives from its
landlord are deemed to be a financing obligation.</FONT></P>
<P align=center><FONT face=serif size=2>13</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><FONT face=serif size=2>REGENERON PHARMACEUTICALS,
INC.<BR>Notes to Condensed Financial Statements (Unaudited)
<BR></FONT></B><B><I><FONT face=serif size=2>(Unless otherwise noted, dollars in
thousands, except per share data) </FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>The above
described revisions consisted entirely of non-cash adjustments. They had no
impact on the Company&#146;s business operations, existing capital resources, or the
Company&#146;s ability to fund its operating needs, including the preclinical and
clinical development of its product candidates. The revisions also had no impact
on the Company&#146;s previously reported net increases or decreases in cash and cash
equivalents in any period and, except for the quarter ended March 31, 2009 (as
described above), had no impact on the Company&#146;s previously reported net cash flows
from operating activities, investing activities and financing activities. In
addition, these revisions had no impact on the Company&#146;s previously reported
current assets, current liabilities, and operating revenues. Therefore, after
considering both qualitative and quantitative factors, the Company believes that
the judgment of a reasonable person relying on the Company&#146;s previously issued
financial statements would not have been changed or influenced by the above
described revisions to those financial statements, which result from applying
EITF 97-10.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>For
comparative purposes, the impact of the above described revisions to the
Company&#146;s balance sheets as of the dates set forth below is as follows:
</FONT></P>
<P align=justify><B><FONT face=serif size=2>Balance Sheet Impact at December 31,
2007 and 2008, and March 31, 2009<BR></FONT></B><B><I><FONT face=serif size=2>(in millions)</FONT></I></B><B><FONT face=serif size=2> </FONT></B></P>
<DIV align=center>
<TABLE cellSpacing=0 cellPadding=0 width="90%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="64%">&nbsp; </TD>
    <TD noWrap align=center width="11%" colSpan=3><B><FONT face=serif size=2>December 31,</FONT></B> </TD>
    <TD noWrap align=center width="2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=center width="11%" colSpan=3><B><FONT face=serif size=2>December 31,</FONT></B> </TD>
    <TD noWrap align=center width="2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=center width="10%" colSpan=3><B><FONT face=serif size=2>March 31,</FONT></B> </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="64%">&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="11%" colSpan=3><FONT size=+0><B><FONT face=serif size=2>2007</FONT></B>
    </FONT></TD>
    <TD noWrap align=center width="2%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="11%" colSpan=3><FONT size=+0><B><FONT face=serif size=2>2008</FONT></B>
    </FONT></TD>
    <TD noWrap align=center width="2%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="10%" colSpan=3><FONT size=+0><B><FONT face=serif size=2>2009</FONT></B>
    </FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="64%" bgColor=#c0c0c0><B><FONT style="BORDER-BOTTOM: #000000 1pt solid" face=serif size=2>As originally
      reported</FONT></B> &nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="9%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp; </TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="9%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp; </TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="8%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="64%"><FONT face=serif size=2>Property, plant,
      and equipment, net</FONT>&nbsp; </TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT> </TD>
    <TD noWrap align=right width="9%"><FONT face=serif size=2>58.3</FONT> </TD>
    <TD noWrap align=left width="1%">&nbsp; </TD>
    <TD noWrap align=right width="2%"></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT> </TD>
    <TD noWrap align=right width="9%"><FONT face=serif size=2>87.9</FONT> </TD>
    <TD noWrap align=left width="1%">&nbsp; </TD>
    <TD noWrap align=right width="2%"></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT> </TD>
    <TD noWrap align=right width="8%"><FONT face=serif size=2>109.8</FONT> </TD>
    <TD noWrap align=left width="1%">&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="64%" bgColor=#c0c0c0><FONT face=serif size=2>Total assets</FONT>&nbsp; </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="9%" bgColor=#c0c0c0><FONT face=serif size=2>936.3</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp; </TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="9%" bgColor=#c0c0c0><FONT face=serif size=2>670.0</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp; </TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="8%" bgColor=#c0c0c0><FONT face=serif size=2>681.4</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp; </TD></TR>
  <TR>
    <TD width="100%" colSpan=12>&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="64%" bgColor=#c0c0c0><FONT face=serif size=2>Other long-term liabilities</FONT>&nbsp; </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="9%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp; </TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="9%" bgColor=#c0c0c0><FONT face=serif size=2>5.1</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp; </TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="8%" bgColor=#c0c0c0><FONT face=serif size=2>13.2</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="64%"><FONT face=serif size=2>Total
      liabilities</FONT>&nbsp; </TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="9%"><FONT face=serif size=2>476.0</FONT> </TD>
    <TD noWrap align=left width="1%">&nbsp; </TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="9%"><FONT face=serif size=2>251.2</FONT> </TD>
    <TD noWrap align=left width="1%">&nbsp; </TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="8%"><FONT face=serif size=2>271.1</FONT> </TD>
    <TD noWrap align=left width="1%">&nbsp; </TD></TR>
  <TR>
    <TD width="100%" colSpan=12>&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="64%" bgColor=#c0c0c0><FONT face=serif size=2>Accumulated deficit</FONT>&nbsp; </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="9%" bgColor=#c0c0c0><FONT face=serif size=2>(793.2</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT>&nbsp; </TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="9%" bgColor=#c0c0c0><FONT face=serif size=2>(875.9</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT>&nbsp; </TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="8%" bgColor=#c0c0c0><FONT face=serif size=2>(893.4</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT>&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="64%"><FONT face=serif size=2>Total
      stockholders&#146; equity</FONT>&nbsp; </TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="9%"><FONT face=serif size=2>460.3</FONT> </TD>
    <TD noWrap align=left width="1%">&nbsp; </TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="9%"><FONT face=serif size=2>418.8</FONT> </TD>
    <TD noWrap align=left width="1%">&nbsp; </TD>
    <TD noWrap align=left width="2%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="8%"><FONT face=serif size=2>410.3</FONT> </TD>
    <TD noWrap align=left width="1%">&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="64%" bgColor=#c0c0c0><FONT face=serif size=2>Total liabilities and stockholders&#146; equity</FONT>&nbsp; </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="9%" bgColor=#c0c0c0><FONT face=serif size=2>936.3</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp; </TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="9%" bgColor=#c0c0c0><FONT face=serif size=2>670.0</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp; </TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="8%" bgColor=#c0c0c0><FONT face=serif size=2>681.4</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp; </TD></TR>
  <TR>
    <TD width="100%" colSpan=12>&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="64%" bgColor=#c0c0c0><B><FONT style="BORDER-BOTTOM: #000000 1pt solid" face=serif size=2>As
      revised</FONT></B> &nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="9%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp; </TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="9%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp; </TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="8%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="64%"><FONT face=serif size=2>Property, plant,
      and equipment, net</FONT>&nbsp; </TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT> </TD>
    <TD noWrap align=right width="9%"><FONT face=serif size=2>79.9</FONT> </TD>
    <TD noWrap align=left width="1%">&nbsp; </TD>
    <TD noWrap align=right width="2%"></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT> </TD>
    <TD noWrap align=right width="9%"><FONT face=serif size=2>142.0</FONT> </TD>
    <TD noWrap align=left width="1%">&nbsp; </TD>
    <TD noWrap align=right width="2%"></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT> </TD>
    <TD noWrap align=right width="8%"><FONT face=serif size=2>164.6</FONT> </TD>
    <TD noWrap align=left width="1%">&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="64%" bgColor=#c0c0c0><FONT face=serif size=2>Total assets</FONT>&nbsp; </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="9%" bgColor=#c0c0c0><FONT face=serif size=2>957.9</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp; </TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="9%" bgColor=#c0c0c0><FONT face=serif size=2>724.2</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp; </TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="8%" bgColor=#c0c0c0><FONT face=serif size=2>736.2</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp; </TD></TR>
  <TR>
    <TD width="100%" colSpan=12>&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="64%" bgColor=#c0c0c0><FONT face=serif size=2>Facility lease obligation</FONT>&nbsp; </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="9%" bgColor=#c0c0c0><FONT face=serif size=2>22.5</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp; </TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="9%" bgColor=#c0c0c0><FONT face=serif size=2>56.0</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp; </TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="8%" bgColor=#c0c0c0><FONT face=serif size=2>62.0</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="64%"><FONT face=serif size=2>Other long-term
      liabilities</FONT>&nbsp; </TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="9%"></TD>
    <TD noWrap align=left width="1%">&nbsp; </TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="9%"><FONT face=serif size=2>0.6</FONT> </TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="8%"><FONT face=serif size=2>1.2</FONT> </TD>
    <TD noWrap align=left width="1%">&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="64%" bgColor=#c0c0c0><FONT face=serif size=2>Total liabilities</FONT>&nbsp; </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="9%" bgColor=#c0c0c0><FONT face=serif size=2>498.5</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp; </TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="9%" bgColor=#c0c0c0><FONT face=serif size=2>302.7</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp; </TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="8%" bgColor=#c0c0c0><FONT face=serif size=2>321.1</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp; </TD></TR>
  <TR>
    <TD width="100%" colSpan=12>&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="64%" bgColor=#c0c0c0><FONT face=serif size=2>Accumulated deficit</FONT>&nbsp; </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="9%" bgColor=#c0c0c0><FONT face=serif size=2>(794.1</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT>&nbsp; </TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="9%" bgColor=#c0c0c0><FONT face=serif size=2>(873.3</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT>&nbsp; </TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="8%" bgColor=#c0c0c0><FONT face=serif size=2>(888.7</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT>&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="64%"><FONT face=serif size=2>Total
      stockholders&#146; equity</FONT>&nbsp; </TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=right width="9%"><FONT face=serif size=2>459.4</FONT> </TD>
    <TD noWrap align=left width="1%">&nbsp; </TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="9%"><FONT face=serif size=2>421.5</FONT> </TD>
    <TD noWrap align=left width="1%">&nbsp; </TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=right width="8%"><FONT face=serif size=2>415.1</FONT> </TD>
    <TD noWrap align=left width="1%">&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="64%" bgColor=#c0c0c0><FONT face=serif size=2>Total liabilities and stockholders&#146; equity</FONT>&nbsp; </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="9%" bgColor=#c0c0c0><FONT face=serif size=2>957.9</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=right width="9%" bgColor=#c0c0c0><FONT face=serif size=2>724.2</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp; </TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="8%" bgColor=#c0c0c0><FONT face=serif size=2>736.2</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;
</TD></TR></TABLE></DIV><BR>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>For
comparative purposes, the impact of the above described revisions to the
Company&#146;s statements of operations and statement of cash flows for the period(s)
set forth below is as follows: </FONT></P>
<P align=center><FONT face=serif size=2>14</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><FONT face=serif size=2>REGENERON PHARMACEUTICALS,
INC.<BR>Notes to Condensed Financial Statements (Unaudited)
<BR></FONT></B><B><I><FONT face=serif size=2>(Unless otherwise noted, dollars in
thousands, except per share data) </FONT></I></B></P>
<P align=justify><B><FONT face=serif size=2>Statements of Operations Impact for
the three, six, and nine month periods ended March 31, June 30, and September
30, 2008, the years ended December 31, 2007 and 2008, and the three months ended
March 31, 2009<BR></FONT></B><B><I><FONT face=serif size=2>(in millions, except
per share data)</FONT></I></B><B><FONT face=serif size=2> </FONT></B></P>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="66%">&nbsp; </TD>
    <TD noWrap align=center width="4%" colSpan=3><B><FONT face=serif size=2>March 31,</FONT></B> </TD>
    <TD noWrap align=center width="2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=center width="4%" colSpan=3><B><FONT face=serif size=2>June 30,</FONT></B> </TD>
    <TD noWrap align=center width="2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=center width="4%" colSpan=3><B><FONT face=serif size=2>September 30,</FONT></B> </TD>
    <TD noWrap align=center width="2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="10%" colSpan=7><B><FONT face=serif size=2>December 31,</FONT></B> </TD>
    <TD noWrap align=center width="2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=center width="4%" colSpan=3><B><FONT face=serif size=2>March 31,</FONT></B> </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="66%">&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=3><B><FONT face=serif size=2>2008</FONT></B> </TD>
    <TD noWrap align=center width="2%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=3><B><FONT face=serif size=2>2008</FONT></B> </TD>
    <TD noWrap align=center width="2%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=3><B><FONT face=serif size=2>2008</FONT></B> </TD>
    <TD noWrap align=center width="2%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=3><B><FONT face=serif size=2>2007</FONT></B> </TD>
    <TD noWrap align=center width="2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=3><B><FONT face=serif size=2>2008</FONT></B> </TD>
    <TD noWrap align=center width="2%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=3><B><FONT face=serif size=2>2009</FONT></B> </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="66%" bgColor=#c0c0c0><B><FONT style="BORDER-BOTTOM: #000000 1pt solid" face=serif size=2>As originally
      reported</FONT></B>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp; </TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp; </TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp; </TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp; </TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp; </TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="66%"><FONT face=serif size=2>Research and
      development</FONT>&nbsp; </TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%">&nbsp; </TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%">&nbsp; </TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%">&nbsp; </TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%">&nbsp; </TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%">&nbsp; </TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%">&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="66%"><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif>expenses</FONT></FONT>&nbsp; </TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT> </TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>61.3</FONT> </TD>
    <TD noWrap align=left width="1%">&nbsp; </TD>
    <TD noWrap align=right width="2%"></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT> </TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>127.8</FONT> </TD>
    <TD noWrap align=left width="1%">&nbsp; </TD>
    <TD noWrap align=right width="2%"></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT> </TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>201.7</FONT> </TD>
    <TD noWrap align=left width="1%">&nbsp; </TD>
    <TD noWrap align=right width="2%"></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT> </TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>201.6</FONT> </TD>
    <TD noWrap align=left width="1%">&nbsp; </TD>
    <TD noWrap align=right width="2%"></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT> </TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>278.0</FONT> </TD>
    <TD noWrap align=left width="1%">&nbsp; </TD>
    <TD noWrap align=right width="2%"></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT> </TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>82.1</FONT> </TD>
    <TD noWrap align=left width="1%">&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="66%" bgColor=#c0c0c0><FONT face=serif size=2>Selling, general, and</FONT>&nbsp; </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp; </TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp; </TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp; </TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp; </TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp; </TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="66%" bgColor=#c0c0c0><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif>administrative expenses</FONT></FONT>&nbsp; </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>11.0</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp; </TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>24.5</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp; </TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>35.9</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp; </TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>37.9</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp; </TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>49.3</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp; </TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>11.7</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="66%"><FONT face=serif size=2>Total
      expenses</FONT>&nbsp; </TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>72.3</FONT> </TD>
    <TD noWrap align=left width="1%">&nbsp; </TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>152.3</FONT> </TD>
    <TD noWrap align=left width="1%">&nbsp; </TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>237.9</FONT> </TD>
    <TD noWrap align=left width="1%">&nbsp; </TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>239.5</FONT> </TD>
    <TD noWrap align=left width="1%">&nbsp; </TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>328.3</FONT> </TD>
    <TD noWrap align=left width="1%">&nbsp; </TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>94.2</FONT> </TD>
    <TD noWrap align=left width="1%">&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="66%" bgColor=#c0c0c0><FONT face=serif size=2>Net loss</FONT>&nbsp; </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>(11.6</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT>&nbsp; </TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>(30.1</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT>&nbsp; </TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>(51.2</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT>&nbsp; </TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>(105.6</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT>&nbsp; </TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>(82.7</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT>&nbsp; </TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>(17.5</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT>&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="66%"><FONT face=serif size=2>Net loss per
      share, basic</FONT>&nbsp; </TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%">&nbsp; </TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%">&nbsp; </TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%">&nbsp; </TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%">&nbsp; </TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%">&nbsp; </TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%">&nbsp;</TD>
    <TD noWrap align=left width="1%">&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="66%"><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif>and
      diluted</FONT></FONT>&nbsp; </TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT> </TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>(0.15</FONT> </TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT>&nbsp;
</TD>
    <TD noWrap align=right width="2%"></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT> </TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>(0.38</FONT> </TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT>&nbsp;
</TD>
    <TD noWrap align=right width="2%"></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT> </TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>(0.65</FONT> </TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT>&nbsp;
</TD>
    <TD noWrap align=right width="2%"></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT> </TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>(1.59</FONT> </TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT> </TD>
    <TD noWrap align=right width="2%"></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT> </TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>(1.05</FONT> </TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT>&nbsp;
</TD>
    <TD noWrap align=right width="2%"></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT> </TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>(0.22</FONT> </TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT> </TD></TR>
  <TR>
    <TD width="100%" colSpan=24>&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="66%" bgColor=#c0c0c0><B><FONT style="BORDER-BOTTOM: #000000 1pt solid" face=serif size=2>As
      revised</FONT></B>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp; </TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp; </TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp; </TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp; </TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp; </TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="66%"><FONT face=serif size=2>Research and
      development</FONT>&nbsp; </TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%">&nbsp; </TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%">&nbsp; </TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%">&nbsp; </TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%">&nbsp; </TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%">&nbsp; </TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%">&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="66%"><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif>expenses</FONT></FONT>&nbsp; </TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT> </TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>61.5</FONT> </TD>
    <TD noWrap align=left width="1%">&nbsp; </TD>
    <TD noWrap align=right width="2%"></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT> </TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>128.2</FONT> </TD>
    <TD noWrap align=left width="1%">&nbsp; </TD>
    <TD noWrap align=right width="2%"></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT> </TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>200.3</FONT> </TD>
    <TD noWrap align=left width="1%">&nbsp; </TD>
    <TD noWrap align=right width="2%"></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT> </TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>202.5</FONT> </TD>
    <TD noWrap align=left width="1%">&nbsp; </TD>
    <TD noWrap align=right width="2%"></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT> </TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>274.9</FONT> </TD>
    <TD noWrap align=left width="1%">&nbsp; </TD>
    <TD noWrap align=right width="2%"></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT> </TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>80.3</FONT> </TD>
    <TD noWrap align=left width="1%">&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="66%" bgColor=#c0c0c0><FONT face=serif size=2>Selling, general, and</FONT>&nbsp; </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp; </TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp; </TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp; </TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp; </TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="66%" bgColor=#c0c0c0><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif>administrative expenses</FONT></FONT>&nbsp; </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>11.1</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>24.6</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp; </TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>35.7</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp; </TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>37.9</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp; </TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>48.9</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp; </TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>11.4</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="66%"><FONT face=serif size=2>Total
      expenses</FONT>&nbsp; </TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>72.5</FONT> </TD>
    <TD noWrap align=left width="1%">&nbsp; </TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>152.8</FONT> </TD>
    <TD noWrap align=left width="1%">&nbsp; </TD>
    <TD noWrap align=left width="2%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>236.3</FONT> </TD>
    <TD noWrap align=left width="1%">&nbsp; </TD>
    <TD noWrap align=left width="2%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>240.4</FONT> </TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>324.7</FONT> </TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="2%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>92.1</FONT> </TD>
    <TD noWrap align=left width="1%">&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="66%" bgColor=#c0c0c0><FONT face=serif size=2>Net loss</FONT>&nbsp; </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>(11.8</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT>&nbsp; </TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>(30.5</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT>&nbsp; </TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>(49.6</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT>&nbsp; </TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>(106.5</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT> </TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>(79.1</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT>&nbsp; </TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>(15.4</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT> </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="66%"><FONT face=serif size=2>Net loss per
      share, basic</FONT>&nbsp; </TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%">&nbsp; </TD>
    <TD noWrap align=left width="2%">&nbsp;</TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%">&nbsp; </TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%">&nbsp; </TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%">&nbsp; </TD>
    <TD noWrap align=left width="2%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%">&nbsp;</TD>
    <TD noWrap align=left width="1%">&nbsp; </TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%">&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="66%"><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif>and
      diluted</FONT></FONT>&nbsp; </TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT> </TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>(0.15</FONT> </TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT>&nbsp;
</TD>
    <TD noWrap align=right width="2%"></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT> </TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>(0.39</FONT> </TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT>&nbsp;
</TD>
    <TD noWrap align=right width="2%"></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT> </TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>(0.63</FONT> </TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT>&nbsp;
</TD>
    <TD noWrap align=right width="2%"></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT> </TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>(1.61</FONT> </TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT> </TD>
    <TD noWrap align=right width="2%"></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT> </TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>(1.00</FONT> </TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT>&nbsp;
</TD>
    <TD noWrap align=right width="2%"></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT> </TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>(0.19</FONT> </TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT>
  </TD></TR></TABLE><BR>
<P align=justify><B><FONT face=serif size=2>Statement of Cash Flows Impact for
the three months ended March 31, 2009<BR></FONT></B><B><I><FONT face=serif size=2>(in millions)</FONT></I></B><B><FONT face=serif size=2> </FONT></B></P>
<DIV align=center>
<TABLE cellSpacing=0 cellPadding=0 width="80%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="90%">&nbsp; </TD>
    <TD noWrap align=center width="4%" colSpan=3><B><FONT face=serif size=2>As
      Originally</FONT></B> </TD>
    <TD noWrap align=center width="2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=center width="4%" colSpan=3>&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%">&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=3><B><FONT face=serif size=2>Reported</FONT></B> </TD>
    <TD noWrap align=center width="2%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=3><B><FONT face=serif size=2>As Revised</FONT></B> </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%" bgColor=#c0c0c0><FONT face=serif size=2>Net cash used in operating activities</FONT>&nbsp; </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT> </TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>(10.2</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT>&nbsp; </TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT> </TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>(15.4</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT>&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%"><FONT face=serif size=2>Net cash used in
      investing activities</FONT>&nbsp; </TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>(39.5</FONT> </TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT>&nbsp;
</TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>(39.5</FONT> </TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT>&nbsp;
  </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%" bgColor=#c0c0c0><FONT face=serif size=2>Net cash provided by financing activities</FONT>&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>1.0</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>6.2</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%"><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif>Net decrease
      in cash and cash equivalents</FONT></FONT>&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face=serif size=2>$</FONT> </TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%"><FONT face=serif size=2>(48.7</FONT> </TD>
    <TD style="BORDER-BOTTOM: #ffffff 2pt solid" noWrap align=left width="1%"><FONT face=serif size=2>)</FONT>&nbsp; </TD>
    <TD noWrap align=right width="2%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face=serif size=2>$</FONT> </TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%"><FONT face=serif size=2>(48.7</FONT> </TD>
    <TD style="BORDER-BOTTOM: #ffffff 2pt solid" noWrap align=left width="1%"><FONT face=serif size=2>)</FONT>&nbsp;
</TD></TR></TABLE></DIV><BR>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>These
revised amounts, as applicable, are reflected in the Company&#146;s financial
statements included in this Quarterly Report on Form 10-Q for the period ended
June 30, 2009, and will be reflected in the Company&#146;s financial statements
included in the Company&#146;s Quarterly Reports on Form 10-Q for the periods ended
September 30, 2009 and March 31, 2010 and the Company&#146;s Annual Report on Form
10-K for the year ended December 31, 2009.</FONT></P>
<P align=justify><B><FONT face=serif size=2>9.</FONT></B><B><FONT face=sans-serif size=2> </FONT></B><B><FONT face=serif size=2>Royalty Agreements
with Novartis Pharma AG </FONT></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In June
2009, the Company entered into two royalty agreements with Novartis Pharma AG
(&#147;Novartis&#148;) that replaced a previous collaboration and license agreement. Under
the first royalty agreement, the Company is entitled to receive royalties on
worldwide sales of Novartis&#146; canakinumab (ACZ885), a fully human
anti-interleukin-IL1&#223; antibody approved to treat CAPS and in development for a
number of other inflammatory diseases. On the basis of the same agreement, the
Company waived its rights to opt-in to the development and commercialization of
canakinumab. Under the second royalty agreement, Novartis is entitled to receive
royalties on worldwide sales of a second-generation interleukin-1 Trap, should
the Company decide to proceed in the development of, and ultimately
commercialize, this Trap. The financial terms of both agreements are identical
in relation to stepped royalties to be paid on the basis of future sales, which
start at 4% and reach 15% when annual sales exceed $1.5 billion. The agreements
do not provide for any upfront or milestone payments or any sharing of
development expenses. </FONT></P>
<P align=center><FONT face=serif size=2>15</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><FONT face=serif size=2>REGENERON PHARMACEUTICALS,
INC.<BR>Notes to Condensed Financial Statements (Unaudited)
<BR></FONT></B><B><I><FONT face=serif size=2>(Unless otherwise noted, dollars in
thousands, except per share data) </FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>The
royalty agreements replace a 2003 collaboration and license agreement under
which the Company had the right to opt in to the development and
commercialization of Novartis&#146; interleukin-1 antibody and Novartis had the right
to opt in to the development and commercialization of the Company&#146;s
second-generation interleukin-1 Trap. That collaboration and license agreement
has been terminated.</FONT></P>
<P align=justify><B><FONT face=serif size=2>10.</FONT></B><B><FONT face=sans-serif size=2> </FONT></B><B><FONT face=serif size=2>Legal Matters
</FONT></B><FONT face=serif size=2></FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>From time
to time, the Company is a party to legal proceedings in the course of its
business. The Company does not expect any such current legal proceedings to have
a material adverse effect on the Company&#146;s business or financial condition.
</FONT></P>
<P align=justify><B><FONT face=serif size=2>11.</FONT></B><B><FONT face=sans-serif size=2> </FONT></B><B><FONT face=serif size=2>Future Impact of
Recently Issued Accounting Standards </FONT></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2> In June
2009, the Financial Accounting Standards Board (&#147;FASB&#148;) issued SFAS 168, <I>The
FASB Accounting Standards Codification<SUP> TM</SUP> and the Hierarchy of
Generally Accepted Accounting Principles</I>. When effective, the FASB
Accounting Standards Codification (the &#147;Codification&#148;) will become the single
official source of authoritative, nongovernmental U.S. generally accepted
accounting principles (&#147;GAAP&#148;). The Codification will be effective for interim
and annual periods ending after September 15, 2009. The Company will be required
to report using the Codification commencing with the quarter ended September 30,
2009. Management does not anticipate that reporting under the Codification will
have a material impact on the Company&#146;s financial statements. </FONT></P>
<P align=justify><B><FONT face=serif size=2>12.</FONT></B><B><FONT face=sans-serif size=2> </FONT></B><B><FONT face=serif size=2>Subsequent Events
</FONT></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In
connection with the Company&#146;s license and collaboration agreement with Bayer
HealthCare LLC to globally develop, and commercialize outside the United States,
the Company&#146;s VEGF Trap-Eye for the treatment of eye disease by local
administration, the Company received a $20.0 million milestone payment in July
2009 in connection with the dosing of the first patient in a Phase 3 trial of
VEGF Trap-Eye in Central Retinal Vein Occlusion (&#147;CRVO&#148;).</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>The
Company has evaluated subsequent events through August 4, 2009, the date on
which the financial statements were issued, and has determined that there are no
subsequent events that require adjustments to the financial statements for the
quarter ended June 30, 2009.</FONT></P>
<P align=center><FONT face=serif size=2>16</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><FONT face=serif size=2>ITEM 2. MANAGEMENT&#146;S DISCUSSION AND
ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </FONT></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I><FONT face=serif size=2>The
discussion below contains forward-looking statements that involve risks and
uncertainties relating to future events and the future financial performance of
Regeneron Pharmaceuticals, Inc., and actual events or results may differ
materially. These statements concern, among other things, the possible success
and therapeutic applications of our product candidates and research programs,
anticipated sales of our marketed product, the timing and nature of the clinical
and research programs now underway or planned, and the future sources and uses
of capital and our financial needs. These statements are made by us based on
management's current beliefs and judgment. In evaluating such statements,
stockholders and potential investors should specifically consider the various
factors identified under the caption &#147;Risk Factors&#148; which could cause actual
results to differ materially from those indicated by such forward-looking
statements. We do not undertake any obligation to update publicly any
forward-looking statement, whether as a result of new information, future
events, or otherwise, except as required by law.</FONT></I></P>
<P align=justify><B><FONT face=serif size=2>Overview </FONT></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Regeneron
Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, develops,
and commercializes pharmaceutical products for the treatment of serious medical
conditions. We currently have one marketed product: ARCALYST<SUP>&#174;</SUP>
(rilonacept) Injection for Subcutaneous Use, which is available for prescription
in the United States for the treatment of Cryopyrin-Associated Periodic
Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS) and
Muckle-Wells Syndrome (MWS) in adults and children 12 and older. We also have
six clinical development programs, including three late-stage clinical programs.
Our late stage programs are aflibercept (VEGF Trap), which is being developed in
oncology in collaboration with the sanofi-aventis Group, VEGF Trap-Eye, which is
being developed in eye diseases using intraocular delivery in collaboration with
Bayer HealthCare LLC, and ARCALYST, which is being developed for the treatment
of gout. Our earlier stage clinical programs are REGN88, an antibody to the
interleukin-6 receptor (IL-6R), which is being developed in rheumatoid
arthritis, REGN421, an antibody to Delta-like ligand-4 (Dll4), which is being
developed in oncology, and REGN475, an antibody to Nerve Growth Factor (NGF),
which is being developed for the treatment of pain. All three of these
antibodies are being developed in collaboration with sanofi-aventis. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We expect
that our next generation of product candidates will be based on our proprietary
technologies for developing human monoclonal antibodies. Our antibody program is
being conducted primarily in collaboration with sanofi-aventis. Our preclinical
research programs are in the areas of oncology and angiogenesis, ophthalmology,
metabolic and related diseases, muscle diseases and disorders, inflammation and
immune diseases, bone and cartilage, pain, and cardiovascular diseases.
</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Our core
business strategy is to maintain a strong foundation in basic scientific
research and discovery-enabling technology and combine that foundation with our
clinical development and manufacturing capabilities to build a successful,
integrated biopharmaceutical company. However, developing and commercializing
new medicines entails significant risk and expense. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We
believe that our ability to develop product candidates is enhanced by the
application of our <I>VelociSuite</I><SUP>TM</SUP> technology platforms. Our
discovery platforms are designed to identify specific genes of therapeutic
interest for a particular disease or cell type and validate targets through
high-throughput production of mammalian models. Our human monoclonal antibody
technology (<I>VelocImmune<SUP>&#174;</SUP></I>) and cell line expression
technologies (<I>VelociMab<SUP>TM</SUP></I>) may then be utilized to design and
produce new product candidates directed against the disease target. Our first
three antibody product candidates currently in clinical trials were developed
using <I>VelocImmune</I>. Over the course of the next several years, we plan to
advance an average of two to three new antibody product candidates into clinical
development each year. We continue to invest in the development of enabling
technologies to assist in our efforts to identify, develop, and commercialize
new product candidates. </FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>17</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><U><FONT face=serif size=2>Commercial
Product:</FONT></U></B><B><FONT face=serif size=2> </FONT></B></P>
<P align=justify><FONT face=serif size=2><B><I>ARCALYST<SUP>&#174;</SUP> (rilonacept)
&#150; Cryopyrin-Associated Periodic Syndromes (CAPS)</I></B></FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In
February 2008, we received marketing approval from the U.S. Food and Drug
Administration (FDA) for ARCALYST<SUP>&#174;</SUP> (rilonacept) Injection for
Subcutaneous Use for the treatment of Cryopyrin-Associated Periodic Syndromes
(CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS) and
Muckle-Wells Syndrome (MWS) in adults and children 12 and older. We shipped $5.4
million and $9.8 million of ARCALYST to our distributors in the second quarter
and first half of 2009, respectively, compared to $1.6 million and $2.4 million
in the same periods of 2008. ARCALYST is a protein-based product designed to
bind the interleukin-1 (called IL-1) cytokine and prevent its interaction with
cell surface receptors. ARCALYST is approved in the United States for patients
with CAPS, a group of rare, inherited, auto-inflammatory conditions
characterized by life-long, recurrent symptoms of rash, fever/chills, joint
pain, eye redness/pain, and fatigue. Intermittent, disruptive exacerbations or
flares can be triggered at any time by exposure to cooling temperatures, stress,
exercise, or other unknown stimuli. CAPS is caused by a range of mutations in
the gene NLRP3 (formerly known as <I>CIAS1</I>) which encodes a protein named
cryopyrin. In addition to FCAS and MWS, CAPS includes Neonatal Onset Multisystem
Inflammatory Disease (NOMID). ARCALYST has not been studied for the treatment of
NOMID.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We expect
to ship $15-20 million of ARCALYST to our U.S. distributors in 2009, compared to
$10.7 million in 2008. In July 2009, the Committee for Medicinal Products for
Human Use (CHMP) of the European Medicines Agency (EMEA) issued a positive
opinion for the marketing authorization in the European Union of rilonacept for
the treatment of CAPS with severe symptoms, including FCAS and MWS, in adults
and children aged 12 years and older. The positive opinion recommends the
granting of a marketing authorization for rilonacept under exceptional
circumstances. Such authorizations are permissible for products for which a
company can demonstrate that comprehensive data cannot be provided, for example
because of the rarity of the condition. Each year, we will need to provide the
EMEA with any new information that may become available for review. Regeneron owns worldwide rights to ARCALYST.</FONT></P>
<P align=justify><B><U><FONT face=serif size=2>Clinical
Programs:</FONT></U></B><B><FONT face=serif size=2> </FONT></B></P>
<P align=justify><B><I><FONT face=serif size=2>1. Aflibercept (VEGF Trap) &#150;
Oncology </FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Aflibercept is a protein-based product candidate designed to bind all
forms of Vascular Endothelial Growth Factor-A (called VEGF-A, also known as
Vascular Permeability Factor or VPF), VEGF-B and the related Placental Growth
Factor (called PlGF), and prevent their interaction with cell surface receptors.
VEGF-A (and to a less validated degree, VEGF-B and PlGF) is required for the
growth of new blood vessels (a process known as angiogenesis) that are needed
for tumors to grow and is a potent regulator of vascular permeability and
leakage.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Aflibercept is being developed globally in cancer indications in
collaboration with sanofi-aventis. We and sanofi-aventis are enrolling patients
in four Phase 3 trials that are evaluating combinations of aflibercept with
standard chemotherapy regimens for the treatment of cancer. One trial is
evaluating aflibercept as a 2<SUP>nd</SUP> line treatment for metastatic
colorectal cancer (called VELOUR) in combination with FOLFIRI (folinic acid
(leucovorin), 5-fluorouracil, and irinotecan). A second trial is evaluating
aflibercept as a 1<SUP>st</SUP> line treatment for metastatic pancreatic cancer
in combination with gemcitabine (VANILLA). A third trial is evaluating
aflibercept as a 2<SUP>nd</SUP> line treatment for metastatic non-small cell
lung cancer in combination with docetaxel (VITAL). The fourth trial is
evaluating aflibercept as a 1<SUP>st</SUP> line treatment for metastatic
androgen-independent prostate cancer in combination with docetaxel/prednisone
(VENICE). All four trials are studying the current standard of chemotherapy care
for the cancer being studied with and without aflibercept. At the end of the
second quarter of 2009, each of the four Phase 3 trials was more than 60%
enrolled, and initial data from the Phase 3 program are expected in 2010. In
addition, a Phase 2 study of aflibercept in 1<Sup>st</Sup> line metastatic colorectal
cancer in combination with folinic acid (leucovorin), 5-fluorouracil, and
oxaliplatin (AFFIRM) began recruiting patients in January 2009. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In June
2009, we and sanofi-aventis reported results from a Phase 2 single-agent study
of aflibercept in advanced ovarian cancer (AOC) patients with symptomatic
malignant ascites (SMA), a cancer-associated condition characterized by an
abnormal build-up of fluid in the abdominal cavity. Patients treated with
aflibercept in this randomized, placebo-controlled study experienced a
statistically significant improvement in the primary study endpoint, mean time
to first repeat paracentesis (removal of fluid from the abdominal cavity),
versus placebo control. Mean time to first repeat paracentesis following a
baseline procedure was 55 days with aflibercept as compared to 23 days for
patients receiving placebo (<I>p</I>=0.0019). There was a similar incidence of
deaths in both treatment groups (no statistically significant difference; hazard
ratio 1.02). In this late-stage patient population with advanced ovarian cancer
who were heavily pre-treated (median of four prior courses of chemotherapy),
four fatal events were assessed by the investigators as aflibercept treatment
related, including one case each of intestinal perforation, dyspnea, pneumonia,
and cause unknown. The types and frequencies of adverse events reported with
aflibercept in this study were generally consistent with those reported in
clinical studies with other anti-VEGF therapies in advanced ovarian cancer
patients. As it is difficult, based on this study, to definitively assess the
overall clinical benefit that might be derived from aflibercept treatment of
patients with SMA in a clinical practice setting, we and sanofi-aventis have
decided not to submit these Phase 2 data for accelerated approval in
SMA.</FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>18</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In
addition, multiple exploratory studies are being conducted in conjunction with
the National Cancer Institute (NCI) Cancer Therapy Evaluation Program (CTEP)
evaluating aflibercept as a single agent or in combination with chemotherapy
regimens in a variety of cancer indications. </FONT></P>
<P align=justify><B><FONT face=serif size=2>Aflibercept Collaboration with the
sanofi-aventis Group </FONT></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We and
sanofi-aventis U.S. (successor to Aventis Pharmaceuticals, Inc.) collaborate on
the development and commercialization of aflibercept globally. Under the terms
of our September 2003 collaboration agreement, as amended, we and sanofi-aventis
will share co-promotion rights and profits on sales, if any, of aflibercept
outside of Japan for disease indications included in our collaboration. In
Japan, we are entitled to a royalty of approximately 35% on annual sales of
aflibercept, subject to certain potential adjustments. We may also receive up to
$400 million in milestone payments upon receipt of specified marketing
approvals, including up to $360 million in milestone payments related to receipt
of marketing approvals for up to eight aflibercept oncology and other
indications in the United States or the European Union and up to $40 million
related to receipt of marketing approvals for up to five oncology indications in
Japan. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Under the
aflibercept collaboration agreement, as amended, agreed upon worldwide
development expenses incurred by both companies during the term of the agreement
will be funded by sanofi-aventis. If the collaboration becomes profitable, we
will be obligated to reimburse sanofi-aventis for 50% of aflibercept development
expenses in accordance with a formula based on the amount of development
expenses and our share of the collaboration profits and Japan royalties, or at a
faster rate at our option.</FONT></P>
<P align=justify><B><I><FONT face=serif size=2>2. VEGF Trap-Eye &#150; Ophthalmologic
Diseases </FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>VEGF
Trap-Eye is a specially purified and formulated form of VEGF Trap for use in
intraocular applications. We and Bayer HealthCare are testing VEGF Trap-Eye in a
Phase 3 program in patients with the neovascular form of age-related macular
degeneration (wet AMD). We and Bayer HealthCare also initiated a Phase 2 study
of VEGF Trap-Eye in patients with diabetic macular edema (DME) in late 2008. Wet
AMD and diabetic retinopathy (which includes DME) are two of the leading causes
of adult blindness in the developed world. In both conditions, severe visual
loss is caused by a combination of retinal edema and neovascular proliferation.
We and Bayer HealthCare also initiated a Phase 3 program in Central Retinal Vein
Occlusion (CRVO) in July 2009. In connection with the dosing of the first
patient in a Phase 3 study in CRVO, we received a $20.0 million milestone
payment from Bayer HealthCare.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>The Phase
3 trials in wet AMD, known as VIEW 1 and VIEW 2 (<U>V</U>EGF Trap:
<U>I</U>nvestigation of <U>E</U>fficacy and Safety in <U>W</U>et age-related
macular degeneration), are comparing VEGF Trap-Eye and Lucentis<SUP>&#174;</SUP> (ranibizumab injection),
marketed by Genentech, Inc., an anti-angiogenic agent approved for use in wet AMD. VIEW 1 is being conducted in
North America and VIEW 2 is being conducted in Europe, Asia Pacific, Japan, and
Latin America. The VIEW 1 and VIEW 2 trials are both evaluating VEGF Trap-Eye
doses of 0.5 milligrams (mg) and 2.0 mg at dosing intervals of four weeks and
2.0 mg at a dosing interval of eight weeks (after three monthly doses) compared
with Lucentis dosed according to its U.S. label, which specifies doses of 0.5
mg administered every four weeks over the first year. As-needed dosing (PRN)
with both agents will be evaluated in the second year of the studies. We and
Bayer Healthcare expect to complete enrollment of the VIEW 1 and VIEW 2 trials
in 2009 and initial data are expected in late 2010. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We and
Bayer HealthCare have conducted a Phase 2 study in wet AMD which demonstrated
that patients treated with VEGF Trap-Eye achieved durable improvements in visual
acuity and retinal thickness for up to one year. Study results were reported at
the 2008 annual meeting of the Retina Society. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In this
double-masked Phase 2 trial, known as CLEAR-IT 2, 157 patients were initially
treated for three months with VEGF Trap-Eye: two groups received monthly doses of
0.5 or 2.0 mg (at weeks 0, 4, 8, and 12) and three groups received quarterly
doses of 0.5, 2.0, or 4.0 mg (at baseline and week 12). Following the initial
three-month fixed-dosing phase, patients continued to receive VEGF Trap-Eye at the
same dose on a PRN dosing schedule through one year, based upon the physician
assessment of the need for re-treatment in accordance with pre-specified
criteria.</FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>19</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Patients
receiving monthly doses of VEGF Trap-Eye of either 2.0 or 0.5 mg for 12 weeks
followed by PRN dosing achieved mean improvements in visual acuity versus
baseline of 9.0 letters (p&lt;0.0001 versus baseline) and 5.4 letters
(p&lt;0.085 versus baseline), respectively, at the end of one year. The
proportion of patients with vision of 20/40 or better (part of the legal minimum
requirement for an unrestricted driver's license in the U.S.) increased from 23%
at baseline to 45% at week 52 in patients initially treated with 2.0 mg monthly
and from 16% at baseline to 47% at week 52 in patients initially treated with
0.5 mg monthly. Patients receiving monthly doses of VEGF Trap-Eye of either 2.0
or 0.5 mg also achieved mean decreases in retinal thickness versus baseline of
143 microns (p&lt;0.0001 versus baseline) and 125 microns (p&lt;0.0001 versus
baseline) at week 52, respectively.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>After
week 12 to week 52 in the PRN dosing period, patients initially dosed on a 2.0
mg monthly schedule received, on average, only 1.6 additional injections and
those initially dosed on a 0.5 mg monthly schedule received, on average, 2.5
additional injections.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>While PRN
dosing following a fixed quarterly dosing regimen (with dosing at baseline and
week 12) also yielded improvements in visual acuity and retinal thickness versus
baseline at week 52, the results generally were not as robust as those obtained
with initial fixed monthly dosing.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>All
patients who completed the one year CLEAR-IT 2 study were eligible to
participate in an extension stage of the study. Eighteen-month results of the
extension stage were presented on May 4, 2009 at the 2009 Association for
Research in Vision and Ophthalmology (ARVO) meeting. After receiving VEGF
Trap-Eye for one year, the 117 patients who elected to enter the extension stage
were dosed on a 2.0 mg PRN basis, irrespective of the dose at which they were
treated earlier in the study. On a combined basis, for these 117 patients, the
mean gain in visual acuity was 7.3 letters (<I>p</I>&lt;0.0001 versus baseline)
at the three-month primary endpoint of the original Phase 2 study, 8.4 letters
(<I>p</I>&lt;0.0001 versus baseline) at one year, and 7.1 letters
(<I>p</I>&lt;0.0001 versus baseline) at month six of the extension stage. Thus,
after 18 months of dosing with VEGF Trap-Eye in the Phase 2 study, patients
continued to maintain a highly significant improvement in visual acuity versus
baseline, while receiving, on average, only 3.5 injections over the 15-month PRN
dosing phase that extended from month three to month 18.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Among all
the patients in the Phase 2 wet AMD study, VEGF Trap-Eye was generally well
tolerated and there were no drug-related serious adverse events. There was one
reported case of culture-negative endophthalmitis/uveitis in the study eye and
two arterial thrombotic events; these were deemed not to be drug-related. Three
deaths were reported&#151;one patient with pancreatic cancer, one patient with
squamous cell carcinoma of the lung, and one patient with pulmonary hypertension
(a pre-existing condition). The most common adverse events were those typically
associated with intravitreal injections and included conjunctival hemorrhage at
the injection site and transient increased intraocular pressure following an
injection.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>The DME
study, known as the DA VINCI study, is a double-masked, randomized, controlled
trial that is evaluating four different VEGF Trap-Eye regimens versus laser
treatment. The study completed enrollment of approximately 200 patients in the
U.S., Canada, European Union, and Australia in July 2009. The patients in the
study will be treated for 52 weeks followed by six additional months of safety
evaluation. The primary efficacy endpoint is the change in best corrected visual
acuity (BCVA) from baseline to week 24. </FONT></P>
<P align=justify><B><FONT face=serif size=2>Collaboration with Bayer HealthCare
</FONT></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In
October 2006, we entered into a collaboration agreement with Bayer HealthCare
for the global development and commercialization outside the United States of
VEGF Trap-Eye. Under the agreement, we and Bayer HealthCare will collaborate on,
and share the costs of, the development of VEGF Trap-Eye through an integrated
global plan that encompasses wet AMD, DME, and CRVO. Bayer HealthCare will
market VEGF Trap-Eye outside the United States, where the companies will share
equally in profits from any future sales of VEGF Trap-Eye. If VEGF Trap-Eye is
granted marketing authorization in a major market country outside the United
States, we will be obligated to reimburse Bayer HealthCare for 50% of the
development costs that it has incurred under the agreement from our share of the
collaboration profits. Within the United States, we retain exclusive
commercialization rights to VEGF Trap-Eye and are entitled to all profits from
any such sales. We received an up-front payment of $75.0 million from Bayer
HealthCare. In 2007, we received a $20.0 million milestone payment from Bayer
HealthCare following dosing of the first patient in a Phase 3 study of VEGF
Trap-Eye in wet AMD. In July 2009, we received a $20.0 million milestone payment
from Bayer HealthCare following dosing of the first patient in a Phase 3 study
of VEGF Trap-Eye in CRVO. We can earn up to $70 million in additional
development and regulatory milestones related to the development of VEGF
Trap-Eye and marketing approvals in major market countries outside the United
States. We can also earn up to $135 million in sales milestones if total annual
sales of VEGF Trap-Eye outside the United States achieve certain specified
levels starting at $200 million.</FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>20</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><I><FONT face=serif size=2>3.
ARCALYST</FONT></I></B><B><I><SUP><FONT face=serif size=2>&#174;</FONT></SUP></I></B><B><I><FONT face=serif size=2> (rilonacept) &#150;
Inflammatory Diseases</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We are
evaluating ARCALYST in gout, a disease in which, as in CAPS, IL-1 may play an
important role in pain and inflammation. In September 2008, we announced the
results of a Phase 2 study which evaluated the efficacy and safety of ARCALYST
versus placebo in the prevention of gout flares induced by the initiation of
urate-lowering drug therapy that is used to control gout. In this 83-patient,
double-blind, placebo-controlled study, the mean number of flares per patient
over the first 12 weeks of urate-lowering therapy was 0.79 with placebo and 0.15
with ARCALYST (p=0.0011), an 81% reduction. This was the primary endpoint of the
study. All secondary endpoints also were met with statistical significance. In
the first 12 weeks of treatment, 45.2% of patients treated with placebo
experienced a gout flare and, of those, 47.4% had more than one flare. Among
patients treated with ARCALYST, only 14.6% experienced a gout flare (p=0.0037
versus placebo) and none had more than one flare. Injection-site reaction was
the most commonly reported adverse event with ARCALYST and no serious
drug-related adverse events were reported.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Results
from this study after the first 16 weeks of urate-lowering therapy were reported
at the annual meeting of the European League Against Rheumatism (EULAR) in June
2009. Through 16 weeks, the mean number of flares per patient was 0.93 with
placebo and 0.22 with ARCALYST (p=0.0036). In the first 16 weeks of treatment,
47.6% of patients treated with placebo experienced a gout flare and, of those,
55.0% had more than one flare. Among patients treated with ARCALYST, 22.0%
experienced a gout flare (p=0.0209 versus placebo) and none had more than one
flare. Adverse events after 16 weeks of treatment were similar to those reported
after 12 weeks with the most frequently reported categories being infection and
musculoskeletal complaints. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Gout is
characterized by high blood levels of uric acid, a bodily waste product normally
excreted by the kidneys. The uric acid can form crystals in the joints of the
toes, ankles, knees, wrists, fingers, and elbows. Chronic treatment with uric
acid-lowering medicines, such as allopurinol, is prescribed to eliminate the
uric acid crystals and prevent reformation. During the first months of
allopurinol therapy, while uric acid blood levels are being reduced, the break
up of the uric acid crystals can result in stimulation of inflammatory
mediators, including IL-1, resulting in acute flares of joint pain and
inflammation. These painful flares generally persist for at least five days.
</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>During
the first quarter of 2009, we initiated a Phase 3 clinical development program
with ARCALYST for the treatment of gout. The program includes four clinical
trials, three of which are currently enrolling patients. Two Phase 3 clinical
trials (called PRE-SURGE 1 and PRE-SURGE 2) are evaluating ARCALYST versus
placebo for the prevention of gout flares in patients initiating urate-lowering
drug therapy. A third Phase 3 trial in acute gout (SURGE) is evaluating
treatment with ARCALYST alone versus ARCALYST in combination with a
non-steroidal anti-inflammatory drug (NSAID) versus an NSAID alone. The Phase 3
clinical development program also includes a separate placebo-controlled safety
study (RE-SURGE). We expect to report initial data from the Phase 3 program in
2010. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In June
2009, we announced that we had entered into two royalty agreements with Novartis
Pharma AG that replaced a previous collaboration and license agreement. Under
the first royalty agreement, we are entitled to receive royalties on worldwide
sales of Novartis&#146; canakinumab (ACZ885), a fully human anti-interleukin-IL1&#223;
antibody approved to treat cryopyrin-associated periodic syndrome (CAPS) and in
development for a number of other inflammatory diseases. On the basis of the
same agreement, we waived our rights to opt-in to the development and
commercialization of canakinumab. Under the second royalty agreement, Novartis
is entitled to receive royalties on worldwide sales of a second-generation
interleukin-1 Trap, should we decide to proceed in the development of this Trap.
The financial terms of both agreements are identical in relation to stepped
royalties, to be paid on the basis of future sales, which start at 4% and reach
15%, when annual sales exceed $1.5 billion. The agreements do not provide for
any upfront or milestone payments or any sharing of development
expenses.</FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>21</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>The
royalty agreements replace a 2003 collaboration and license agreement under
which we had the right to opt in to the development and commercialization of
Novartis&#146; interleukin-1 antibody and Novartis had the right to opt in to the
development and commercialization of our second-generation interleukin-1 Trap.
That collaboration and license agreement has been terminated. </FONT></P>
<P align=justify><B><I><FONT face=serif size=2>4. Monoclonal Antibodies
</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We and
sanofi-aventis are collaborating on the discovery, development, and
commercialization of fully human monoclonal antibodies generated using our
<I>VelocImmune<SUP>&#174;</SUP></I> technology. The first therapeutic antibodies to
enter clinical development under the collaboration are REGN88, REGN475, and
REGN421. REGN88, an antibody to the interleukin-6 receptor (IL-6R), is being
evaluated in rheumatoid arthritis. REGN475, an antibody to Nerve Growth Factor
(NGF) that binds NGF selectively without cross-reacting with other members of
the neurotrophin family (such as neurotrophin-3, neurotrophin-4, and BDNF), is
being developed for the treatment of pain. REGN421, an antibody to Delta-like
ligand-4 (Dll4), is being studied in patients with advanced malignancies. Over
the course of the next several years, we and sanofi-aventis plan to advance an
average of two to three new fully human monoclonal antibodies into clinical
development each year. </FONT></P>
<P align=justify><B><U><FONT face=serif size=2>Research and Development
Technologies:</FONT></U></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>One way
that a cell communicates with other cells is by releasing specific signaling
proteins, either locally or into the bloodstream. These proteins have distinct
functions, and are classified into different &#147;families&#148; of molecules, such as
peptide hormones, growth factors, and cytokines. All of these secreted (or
signaling) proteins travel to and are recognized by another set of proteins,
called &#147;receptors,&#148; which reside on the surface of responding cells. These
secreted proteins impact many critical cellular and biological processes,
causing diverse effects ranging from the regulation of growth of particular cell
types, to inflammation mediated by white blood cells. Secreted proteins can at
times be overactive and thus result in a variety of diseases. In these disease
settings, blocking the action of specific secreted proteins can have clinical
benefit.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2> Our
scientists have developed two different technologies to design protein
therapeutics to block the action of specific secreted proteins. The first
technology, termed the &#147;Trap&#148; technology, was used to generate our first
approved product, ARCALYST<SUP>&#174;</SUP> (rilonacept), as well as aflibercept and
VEGF Trap-Eye, all of which are in Phase 3 clinical trials. These novel &#147;Traps&#148;
are composed of fusions between two distinct receptor components and the
constant region of an antibody molecule called the &#147;Fc region&#148;, resulting in
high affinity product candidates. </FONT><I><FONT face=serif size=2>VelociSuite</FONT></I><FONT face=serif size=2> is our second technology
platform and it is used for discovering, developing, and producing fully human
monoclonal antibodies.</FONT></P>
<P align=justify><FONT face=serif size=2><B><I>VelociSuite<SUP>TM</SUP></I></B></FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2><I>VelociSuite</I> consists of <I>VelocImmune<SUP>&#174;</SUP>,
VelociGene<SUP>&#174;</SUP>, VelociMouse<SUP>&#174;</SUP>, and VelociMab<SUP>TM</SUP>.</I>
The <I>VelocImmune</I> mouse platform is utilized to produce fully human
monoclonal antibodies. <I>VelocImmune</I> was generated by exploiting our
<I>VelociGene</I> technology (see below), in a process in which six megabases of
mouse immune gene loci were replaced, or &#147;humanized,&#148; with corresponding human
immune gene loci. <I>VelocImmune</I> mice can be used to generate efficiently
fully human monoclonal antibodies to targets of therapeutic interest.
<I>VelocImmune</I> and our entire <I>VelociSuite</I> offer the potential to
increase the speed and efficiency through which human monoclonal antibody
therapeutics may be discovered and validated, thereby improving the overall
efficiency of our early stage drug development activities. We are utilizing the
<I>VelocImmune</I> technology to produce our next generation of drug candidates
for preclinical and clinical development.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Our
<I>VelociGene</I> platform allows custom and precise manipulation of very large
sequences of DNA to produce highly customized alterations of a specified target
gene, or genes, and accelerates the production of knock-out and transgenic
expression models without using either positive/negative selection or isogenic
DNA. In producing knock-out models, a color or fluorescent marker may be
substituted in place of the actual gene sequence, allowing for high-resolution
visualization of precisely where the gene is active in the body, during normal
body functioning, as well as in disease processes. For the optimization of
pre-clinical development and toxicology programs, <I>VelociGene</I> offers the
opportunity to humanize targets by replacing the mouse gene with the human
homolog. Thus, <I>VelociGene</I> allows scientists to rapidly identify the
physical and biological effects of deleting or over-expressing the target gene,
as well as to characterize and test potential therapeutic molecules.</FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>22</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2>The </FONT><I><FONT size=2>VelociMouse<SUP>&#174;</SUP></FONT></I><FONT size=2> technology platform allows for the
direct and immediate generation of genetically altered mice from embryonic stem
cells (ES cells), thereby avoiding the lengthy process involved in generating
and breeding knockout mice from chimeras. Mice generated through this method are
normal and healthy and exhibit a 100% germ-line transmission. Furthermore, the
VelociMice are suitable for direct phenotyping or other studies. We have also
developed our </FONT><I><FONT size=2>VelociMab</FONT></I><FONT size=2>&#153; platform
for the rapid screening of antibodies and rapid generation of expression cell
lines for our Traps and our </FONT><I><FONT size=2>VelocImmune<SUP>&#174;</SUP></FONT></I><FONT size=2> human monoclonal antibodies.</FONT></P>
<P align=justify><B><FONT size=2>Antibody Collaboration with sanofi-aventis
</FONT></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2>In November 2007, we
and sanofi-aventis entered into a global, strategic collaboration to discover,
develop, and commercialize fully human monoclonal antibodies. The collaboration
is governed by a Discovery and Preclinical Development Agreement and a License
and Collaboration Agreement. We received a non-refundable, up-front payment of
$85.0 million from sanofi-aventis under the discovery agreement. In addition,
sanofi-aventis is funding research at Regeneron to identify and validate
potential drug discovery targets and develop fully human monoclonal antibodies
against these targets. Sanofi-aventis funded approximately $75 million of
research from the collaboration&#146;s inception through December 31, 2008 and will
fund up to $100 million per year in 2009 through 2012. Sanofi-aventis also has
an option to extend the discovery program for up to an additional three years
for further antibody development and preclinical activities. We will lead the
design and conduct of research activities, including target identification and
validation, antibody development, research and preclinical activities through
filing of an Investigational New Drug Application, toxicology studies, and
manufacture of preclinical and clinical supplies. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2>For each drug
candidate identified under the discovery agreement, sanofi-aventis has the
option to license rights to the candidate under the license agreement. If it
elects to do so, sanofi-aventis will co-develop the drug candidate with us
through product approval. Development costs will be shared between the
companies, with sanofi-aventis generally funding drug candidate development
costs up front. We are generally responsible for reimbursing sanofi-aventis for
half of the total development costs for all collaboration products from our
share of profits from commercialization of collaboration products to the extent
they are sufficient for this purpose. Sanofi-aventis will lead commercialization
activities for products developed under the license agreement, subject to our
right to co-promote such products. The parties will equally share profits and
losses from sales within the United States. The parties will share profits
outside the United States on a sliding scale based on sales starting at 65%
(sanofi-aventis)/35% (us) and ending at 55% (sanofi-aventis)/45% (us), and will
share losses outside the United States at 55% (sanofi-aventis)/45% (us). In
addition to profit sharing, we are entitled to receive up to $250 million in
sales milestone payments, with milestone payments commencing after aggregate
annual sales outside the United States exceed $1.0 billion on a rolling 12-month
basis. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2>In August 2008, we
entered into an agreement with sanofi-aventis to use our </FONT><I><FONT size=2>VelociGene</FONT></I><I><FONT size=2><SUP>&#174;</SUP></FONT></I><FONT size=2>
platform to supply sanofi-aventis with genetically modified mammalian models of
gene function and disease. Sanofi-aventis will pay us a minimum of $21.5 million
for the term of the agreement, which extends through December 2012, for
knock-out and transgenic models of gene function for target genes identified by
sanofi-aventis. Sanofi-aventis will use these models for its internal research
programs that are outside of the scope of our antibody collaboration.
</FONT></P>
<P align=justify><B><FONT size=2>License Agreement with AstraZeneca
</FONT></B><FONT size=2></FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2>In February 2007, we
entered into a non-exclusive license agreement with AstraZeneca UK Limited that
allows AstraZeneca to utilize our </FONT><I><FONT size=2>VelocImmune</FONT></I><FONT size=2> technology in its internal research
programs to discover human monoclonal antibodies. Under the terms of the
agreement, AstraZeneca made $20.0 million annual, non-refundable payments to us
in the first quarter of 2007, 2008, and 2009. AstraZeneca is required to make up
to three additional annual payments of $20.0 million, subject to its ability to
terminate the agreement after making the next additional payment. We are entitled to
receive a mid-single-digit royalty on any future sales of antibody products
discovered by AstraZeneca using our </FONT><I><FONT size=2>VelocImmune</FONT></I><FONT size=2> technology.</FONT><B><FONT size=2>
</FONT></B></P>
<P align=center><FONT size=2>23</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><FONT size=2>License Agreement with Astellas
</FONT></B><FONT size=2></FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2>In March 2007, we
entered into a non-exclusive license agreement with Astellas Pharma Inc. that
allows Astellas to utilize our </FONT><I><FONT size=2>VelocImmune</FONT></I><FONT size=2> technology in its internal research
programs to discover human monoclonal antibodies. Under the terms of the
agreement, Astellas made $20.0 million annual, non-refundable payments to us in
the second quarter of 2007, 2008, and 2009. Astellas is required to make up to
three additional annual payments of $20.0 million, subject to its ability to
terminate the agreement after making the next additional payment. We are entitled to
receive a mid-single-digit royalty on any future sales of antibody products
discovered by Astellas using our </FONT><I><FONT size=2>VelocImmune</FONT></I><FONT size=2> technology.</FONT></P>
<P align=justify><B><FONT size=2>Academic </FONT></B><EM><B><FONT size=2>VelocImmune</FONT></B><FONT size=2><SUP>&#174;</SUP></FONT></EM><B><FONT size=2> Investigators&#146; Program</FONT></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2>In September 2008,
we entered into an agreement that will provide researchers at Columbia
University Medical Center with access to our </FONT><I><FONT size=2>VelocImmune</FONT></I><FONT size=2> technology platform. In March 2009,
we entered into a similar agreement with The University of Texas Southwestern
Medical Center at Dallas. Under the agreements, scientists at these academic
institutions will use </FONT><I><FONT size=2>VelocImmune</FONT></I><FONT size=2>
mice to generate antibodies against their research targets and will conduct
research to discover potential human therapeutics based on the antibodies. We
have an exclusive option to license the antibodies for development and
commercialization as therapeutic or diagnostic products and will pay to the
appropriate institution a low single-digit royalty on ensuing product sales.
</FONT></P>
<P align=justify><B><FONT size=2>National Institutes of Health
Grant</FONT></B><FONT size=2> </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2>In September 2006,
we were awarded a five-year grant from the National Institutes of Health (NIH)
as part of the NIH&#146;s Knockout Mouse Project. The goal of the Knockout Mouse
Project is to build a comprehensive and broadly available resource of knockout
mice to accelerate the understanding of gene function and human diseases. We are
using our </FONT><I><FONT size=2>VelociGene</FONT></I><I><FONT size=2><SUP>&#174;</SUP></FONT></I><FONT size=2> technology to take aim at 3,500 of
the most difficult genes to target and which are not currently the focus of
other large-scale knockout mouse programs. We also agreed to grant a limited
license to a consortium of research institutions, the other major participants
in the Knockout Mouse Project, to use components of our </FONT><I><FONT size=2>VelociGene</FONT></I><FONT size=2> technology in the Knockout Mouse
Project. We are generating a collection of targeting vectors and targeted mouse
ES cells which can be used to produce knockout mice. These materials are
available to academic researchers without charge. We will receive a fee for each
targeted ES cell line or targeting construct made by us or the research
consortium and transferred to commercial entities. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2>Under the NIH grant,
as amended in September 2008, we are entitled to receive a minimum of $24.5
million over the five-year period beginning September 2006, including $1.5
million to optimize our existing C57BL/6 ES cell line and its proprietary growth
medium, both of which are being supplied to the research consortium for its use
in the Knockout Mouse Project. We have the right to use, for any purpose, all
materials generated by us and the research consortium.</FONT></P>
<P align=justify><B><U><FONT size=2>Research Programs</FONT></U></B><B><FONT size=2>: </FONT></B></P>
<P align=justify><B><I><FONT size=2>Oncology and Angiogenesis
</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2>In many clinical
settings, positively or negatively regulating blood vessel growth could have
important therapeutic benefits, as could the repair of damaged and leaky
vessels. VEGF was the first growth factor shown to be specific for blood
vessels, by virtue of having its receptor specifically expressed on blood vessel
cells. In 1994, we discovered a second family of angiogenic growth factors,
termed angiopoietins, and we have received patents covering members of this
family. Angiopoietins include naturally occurring positive and negative
regulators of angiogenesis, as described in numerous scientific manuscripts
published by our scientists and their collaborators. Angiopoietins are being
evaluated in preclinical research by us and our academic collaborators. Our
preclinical studies have revealed that VEGF and angiopoietins normally function
in a coordinated and collaborative manner during blood vessel growth.
Manipulation of both VEGF and angiopoietins seems to be of value in either
promoting or blocking vessel growth. We have research programs focusing on
several targets in the areas of oncology and angiogenesis. </FONT></P>
<P align=center><FONT size=2>24</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><FONT size=2><FONT size=3>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT size=2>Tumors depend on the
growth of new blood vessels (a process called &#147;angiogenesis&#148;) to support their
continued growth. Therapies that block tumor angiogenesis, specifically those
that block VEGF, the key initiator of tumor </FONT>angiogenesis, recently have
been validated in human cancer patients. However, anti-VEGF approaches do not
work in all patients, and many tumors can become resistant to such
therapies.</FONT><I><FONT size=2> </FONT></I><FONT size=2></FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2>In the December 21,
2006 issue of the journal </FONT><I><FONT size=2>Nature,</FONT></I><FONT size=2>
we reported data from a preclinical study demonstrating that blocking an
important cell signaling molecule, known as Delta-like ligand 4 (Dll4),
inhibited the growth of experimental tumors by interfering with their ability to
produce a functional blood supply. The inhibition of tumor growth was seen in a
variety of tumor types, including those that were resistant to blockade of VEGF,
suggesting a novel anti-angiogenesis therapeutic approach. A fully human monoclonal antibody
to Dll4 that was discovered using our </FONT><EM><FONT size=2>VelocImmune</FONT><FONT size=2><SUP>&#174;</SUP></FONT><FONT size=2>
</FONT></EM><FONT size=2>technology is being studied in a Phase 1 clinical trial in patients with advanced malignancies.</FONT></P>
<P align=justify><B><I><FONT size=2>Metabolic and Related Diseases
</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2>Food intake and
metabolism are regulated by complex interactions between diverse neural and
hormonal signals that serve to maintain an optimal balance between energy
intake, storage, and utilization. The hypothalamus, a small area at the base of
the brain, is critically involved in integrating peripheral signals which
reflect nutritional status and neural outputs which regulate appetite, food
seeking behaviors, and energy expenditure. Metabolic disorders, such as type 2
diabetes, reflect a dysregulation in the systems which ordinarily tightly couple
energy intake to energy expenditure. Our preclinical research program in this
area encompasses the study of peripheral (hormonal) regulators of food intake
and metabolism in health and disease. We have identified several targets in
these therapeutic areas and are evaluating lead monoclonal antibodies in
relevant preclinical models. </FONT></P>
<P align=justify><B><I><FONT size=2>Muscle Diseases and Disorders
</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2>Muscle atrophy
occurs in many neuromuscular diseases and also when muscle is unused, as often
occurs during prolonged hospital stays and during convalescence. Currently,
physicians have few options to treat subjects with muscle atrophy or other
muscle conditions which afflict millions of people globally. Thus, a treatment
that has beneficial effects on skeletal muscle could have significant clinical
benefit. Our muscle research program is currently focused on conducting
</FONT><I><FONT size=2>in vivo</FONT></I><FONT size=2> and </FONT><I><FONT size=2>in vitro</FONT></I><FONT size=2> experiments with the objective of
demonstrating and further understanding the molecular pathways involved in
muscle atrophy and hypertrophy, and discovering therapeutic candidates that can
modulate these pathways. We have several molecules in late stage research and
are evaluating them for possible further development. </FONT></P>
<P align=justify><B><I><FONT size=2>Other Therapeutic Areas </FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2>We also have
research programs focusing on ophthalmology, inflammatory and immune diseases,
bone and cartilage, pain, and cardiovascular diseases. </FONT></P>
<P align=justify><B><FONT size=2>General </FONT></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Developing and
commercializing new medicines entails significant risk and expense. Since
inception we have not generated any significant sales or profits from the
commercialization of ARCALYST<SUP>&#174;</SUP> (rilonacept) or any of our other product candidates. Before
significant revenues from the commercialization of ARCALYST or our other product
candidates can be realized, we (or our collaborators) must overcome a number of
hurdles which include successfully completing research and development and
obtaining regulatory approval from the FDA and regulatory authorities in other
countries. In addition, the biotechnology and pharmaceutical industries are
rapidly evolving and highly competitive, and new developments may render our
products and technologies uncompetitive or obsolete.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2>From inception on
January 8, 1988 through June 30, 2009, we had a cumulative loss of $903.6
million. In the absence of significant revenues from the commercialization of
ARCALYST or our other product candidates or other sources, the amount, timing,
nature, and source of which cannot be predicted, our losses will continue as we
conduct our research and development activities. We expect to incur substantial
losses over the next several years as we continue the clinical development of
VEGF Trap-Eye and ARCALYST in other indications; advance new product candidates
into clinical development from our existing research programs utilizing our
technology for discovering fully human monoclonal antibodies; continue our
research and development programs; and commercialize additional product
candidates that receive regulatory approval, if any. Also, our activities may
expand over time and require additional resources, and we expect our operating
losses to be substantial over at least the next several years. Our losses may
fluctuate from quarter to quarter and will depend on, among other factors, the
progress of our research and development efforts, the timing of certain
expenses, and the amount and timing of payments that we receive from
collaborators.</FONT></P>
<P align=center><FONT size=2>25</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2>The planning,
execution, and results of our clinical programs are significant factors that can
affect our operating and financial results. In our clinical programs, key events
to date in 2009 and plans over the next 12 months are as follows: </FONT></P>
<TABLE style="BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD vAlign=top noWrap align=left width="4%">&nbsp; </TD>
    <TD vAlign=top noWrap align=left width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD vAlign=top noWrap align=left width="48%">&nbsp; </TD>
    <TD vAlign=top noWrap align=left width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD vAlign=top noWrap align=left width="45%"><B><FONT size=2>2009-10
      Plans</FONT></B>&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD vAlign=top noWrap align=left width="4%"><B><U><FONT size=2>Clinical
      Program</FONT></U></B>&nbsp; </TD>
    <TD vAlign=top noWrap align=left width="1%">&nbsp;</TD>
    <TD vAlign=top noWrap align=left width="48%"><B><U><FONT size=2>2009
      Events to Date</FONT></U></B>&nbsp; </TD>
    <TD vAlign=top noWrap align=left width="1%"></TD>
    <TD vAlign=top noWrap align=left width="45%"><B><U><FONT size=2>(next 12
      months)</FONT></U></B>&nbsp; </TD></TR>
  <TR>
    <TD vAlign=top noWrap align=left width="4%" bgColor=#c0c0c0><FONT size=2>ARCALYST<SUP>&#174;&nbsp;<BR></SUP>&nbsp;&nbsp;&nbsp;&nbsp; (rilonacept;
      also&nbsp;<BR>&nbsp;&nbsp;&nbsp;&nbsp; known as
      IL-1&nbsp;<BR>&nbsp;&nbsp;&nbsp;&nbsp; Trap)</FONT></TD>
    <TD vAlign=top align=left width="1%" bgColor=#c0c0c0></TD>
    <TD vAlign=top align=left width="48%" bgColor=#c0c0c0>
      <UL style="FONT-SIZE: 10pt; MARGIN-BOTTOM: 10pt; MARGIN-LEFT: 16px">
        <LI><FONT size=2>Initiated patient enrollment in the Phase 3 program
        evaluating ARCALYST in the prevention of gout flares associated with the
        initiation of urate-lowering drug therapy and in the treatment of acute
        gout attacks</FONT></LI></UL></TD>
    <TD vAlign=top align=left width="1%" bgColor=#c0c0c0></TD>
    <TD vAlign=top align=left width="45%" bgColor=#c0c0c0>
      <UL style="FONT-SIZE: 10pt; MARGIN-BOTTOM: 10pt; MARGIN-LEFT: 16px">
        <LI><FONT size=2>Continue enrollment in the Phase 3 program in gout
        </FONT>
        <LI><FONT size=2><FONT face=sans-serif></FONT><FONT face=serif>Report
        initial data from Phase 3 gout program</FONT></FONT></LI></UL></TD></TR>
  <TR>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top noWrap align=left width="4%" bgColor=#ffffff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="1%" bgColor=#ffffff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="48%" bgColor=#ffffff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="1%" bgColor=#ffffff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="45%" bgColor=#ffffff></TD></TR>
  <TR>
    <TD vAlign=top noWrap align=left width="4%" bgColor=#ffffff><FONT size=2>Aflibercept&nbsp;<BR>&nbsp;&nbsp;&nbsp;&nbsp; (VEGF Trap
      &#150;<BR>&nbsp;&nbsp;&nbsp;&nbsp; Oncology)</FONT></TD>
    <TD vAlign=top align=left width="1%" bgColor=#ffffff></TD>
    <TD vAlign=top align=left width="48%" bgColor=#ffffff>
      <UL style="FONT-SIZE: 10pt; MARGIN-BOTTOM: 10pt; MARGIN-LEFT: 16px">
        <LI><FONT size=2>Initiated a Phase 2 1<sup>st</sup> line study in metastatic
        colorectal cancer in combination with chemotherapy</FONT>
        <LI><FONT size=2><FONT face=sans-serif></FONT><FONT face=serif>Achieved
        more than 60% enrollment in each of the Phase 3 studies </FONT></FONT>
        <LI><FONT size=2><FONT face=sans-serif></FONT><FONT face=serif>Reported
        results of a Phase 2 single-agent study in symptomatic malignant ascites
        (SMA)</FONT></FONT></LI></UL></TD>
    <TD vAlign=top align=left width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD vAlign=top align=left width="45%" bgColor=#ffffff>
      <UL style="FONT-SIZE: 10pt; MARGIN-BOTTOM: 10pt; MARGIN-LEFT: 16px">
        <LI><FONT size=2>Continue enrollment of the four Phase 3
        studies</FONT></LI></UL></TD></TR>
  <TR>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top noWrap align=left width="4%" bgColor=#ffffff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="1%" bgColor=#ffffff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="48%" bgColor=#ffffff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="1%" bgColor=#ffffff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="45%" bgColor=#ffffff></TD></TR>
  <TR>
    <TD vAlign=top noWrap align=left width="4%" bgColor=#c0c0c0><FONT size=2>VEGF Trap-Eye&nbsp;<BR>&nbsp;&nbsp;&nbsp;&nbsp;
      (intravitreal&nbsp;<BR>&nbsp;&nbsp;&nbsp;&nbsp; injection)</FONT></TD>
    <TD vAlign=top align=left width="1%" bgColor=#c0c0c0></TD>
    <TD vAlign=top align=left width="48%" bgColor=#c0c0c0>
      <UL style="FONT-SIZE: 10pt; MARGIN-BOTTOM: 10pt; MARGIN-LEFT: 16px">
        <LI><FONT size=2>Completed enrollment of patients in the Phase 2 DME
        trial </FONT>
        <LI><FONT size=2><FONT face=sans-serif></FONT><FONT face=serif>Initiated
        a Phase 3 CRVO Program</FONT></FONT></LI></UL></TD>
    <TD vAlign=top align=left width="1%" bgColor=#c0c0c0></TD>
    <TD vAlign=top align=left width="45%" bgColor=#c0c0c0>
      <UL style="FONT-SIZE: 10pt; MARGIN-BOTTOM: 10pt; MARGIN-LEFT: 16px">
        <LI><FONT size=2>Complete enrollment in VIEW 1 and VIEW 2 trials </FONT>
        <LI><FONT size=2><FONT face=sans-serif></FONT><FONT face=serif>Continue
        enrollment in Phase 3 CRVO Program </FONT></FONT>
        <LI><FONT size=2><FONT face=sans-serif></FONT><FONT face=serif>Report
        data from Phase 2 DME trial</FONT></FONT></LI></UL></TD></TR>
  <TR>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top noWrap align=left width="4%" bgColor=#ffffff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="1%" bgColor=#ffffff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="48%" bgColor=#ffffff>&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="1%" bgColor=#ffffff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="45%" bgColor=#ffffff></TD></TR>
  <TR>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top noWrap align=left width="4%" bgColor=#ffffff>
      <P align=justify><FONT face=serif size=2>Monoclonal&nbsp;<BR>&nbsp;&nbsp;&nbsp;&nbsp; </FONT><FONT face=serif size=2>Antibodies</FONT></P></TD>
    <TD vAlign=top align=left width="1%" bgColor=#ffffff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="48%" bgColor=#ffffff>
      <UL style="FONT-SIZE: 10pt; MARGIN-BOTTOM: 10pt; MARGIN-LEFT: 16px">
        <LI><FONT size=2>Initiated a Phase 1 trial for REGN475 (anti-NGF) in
        healthy volunteers </FONT>
        <LI><FONT size=2><FONT face=sans-serif></FONT><FONT face=serif>Initiated
        a Phase 1 trial for REGN421(anti-Dll4) in
    oncology</FONT></FONT></LI></UL></TD>
    <TD vAlign=top align=left width="1%" bgColor=#ffffff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="45%" bgColor=#ffffff>
      <UL style="FONT-SIZE: 10pt; MARGIN-BOTTOM: 10pt; MARGIN-LEFT: 16px">
        <LI><FONT size=2>Report data from a Phase 1 trial of REGN88 (anti-IL-6R)
        in rheumatoid arthritis </FONT>
        <LI><FONT size=2><FONT face=sans-serif></FONT><FONT face=serif>Initiate
        multiple Phase 2 trials for REGN475 in pain indications </FONT></FONT>
        <LI><FONT size=2><FONT face=sans-serif></FONT>Advance additional
        antibody candidate(s) into clinical
  development</FONT></LI></UL></TD></TR></TABLE><BR>
<P align=justify><B><FONT size=2>Results of Operations</FONT></B></P>
<P align=justify><B><I><FONT size=2>Three Months Ended June 30, 2009 and 2008
</FONT></I></B></P>
<P align=justify><I><FONT size=2>Net Loss: </FONT></I></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2>Regeneron reported a
net loss of $14.9 million, or $0.19 per share (basic and diluted), for the
second quarter of 2009 compared to a net loss of $18.7 million, or $0.24 per
share (basic and diluted), for the second quarter of 2008. The decrease in our
net loss was principally due to higher contract research and development revenue
in connection with our antibody collaboration with sanofi-aventis and net
product sales of ARCALYST for the treatment of CAPS, partially offset by higher research and
development expenses, as detailed below.</FONT></P>
<P align=center><FONT size=2>26</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><I><FONT size=2>Revenues: </FONT></I></P>
<P align=justify><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Revenues for
the three months ended June 30, 2009 and 2008 consist of the following:
</FONT></P>
<DIV align=center>
<TABLE style="BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="80%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="95%"><FONT size=+0><B><I><FONT size=2>(In
      millions)</FONT></I></B>&nbsp; </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="2%" colSpan=2><FONT size=+0><B><FONT size=2>2009</FONT></B> </FONT></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="2%" colSpan=2><FONT size=+0><B><FONT size=2>2008</FONT></B> </FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="95%" bgColor=#c0c0c0><FONT size=+0><FONT size=2>Contract research &amp; development revenue</FONT> </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT size=+0>&nbsp;
      </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT size=+0>&nbsp;
      </FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="95%"><FONT size=+0>&nbsp; &nbsp; &nbsp;<FONT size=2>Sanofi-aventis</FONT> </FONT></TD>
    <TD noWrap align=left width="1%"><FONT size=+0><FONT size=2>$</FONT>
      </FONT></TD>
    <TD noWrap align=right width="1%"><FONT size=+0><FONT size=2>60.7</FONT>
      </FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT size=+0><FONT size=2>$</FONT>
      </FONT></TD>
    <TD noWrap align=right width="1%"><FONT size=+0><FONT size=2>38.6</FONT>
      </FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="95%" bgColor=#c0c0c0><FONT size=+0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2>Bayer HealthCare</FONT>
      </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT size=+0><FONT size=2>12.8</FONT> </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT size=+0><FONT size=2>10.2</FONT> </FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="95%"><FONT size=+0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2>Other</FONT> </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%"><FONT size=+0><FONT size=2>2.0</FONT> </FONT></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%"><FONT size=+0><FONT size=2>1.9</FONT> </FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="95%" bgColor=#c0c0c0><FONT size=+0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2>Total contract research &amp; development revenue</FONT> </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT size=+0><FONT size=2>75.5</FONT> </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT size=+0><FONT size=2>50.7</FONT> </FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="95%"><FONT size=+0><FONT size=2>Technology
      licensing revenue</FONT> </FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT size=+0><FONT size=2>10.0</FONT>
      </FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT size=+0><FONT size=2>10.0</FONT>
      </FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="95%" bgColor=#c0c0c0><FONT size=+0><FONT size=2>Net product sales</FONT> </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%" bgColor=#c0c0c0><FONT size=+0><FONT size=2>4.5</FONT> </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0><FONT size=+0>&nbsp; </FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="95%"><FONT size=+0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2>Total revenue</FONT> </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT size=+0><FONT size=2>$</FONT> </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="1%"><FONT size=+0><FONT size=2>90.0</FONT> </FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT size=+0><FONT size=2>$</FONT> </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="1%"><FONT size=+0><FONT size=2>60.7</FONT>
</FONT></TD></TR></TABLE></DIV><BR>
<P align=justify><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The contract
research and development revenue we earn from sanofi-aventis, as detailed below,
consists primarily of reimbursement for research and development expenses and
partly of the recognition of revenue related to non-refundable up-front payments
of $105.0 million related to the aflibercept collaboration and $85.0 million
related to the antibody collaboration. </FONT></P>
<TABLE style="BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="47%"><FONT size=+0><B><FONT size=2>Sanofi-aventis Contract Research
      &amp; Development Revenue</FONT></B></FONT>&nbsp;</TD>
    <TD noWrap align=left width="47%">&nbsp;</TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</TD>
    <TD noWrap align=center width="5%" colSpan=5><FONT size=+0><B><FONT size=2>Three months ended</FONT></B> </FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="94%" colSpan=2><FONT size=+0><B><I><FONT size=2>(In millions)</FONT></I></B>&nbsp; </FONT></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=5><FONT size=+0><B><FONT size=2>June 30,</FONT></B> </FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="94%" bgColor=#c0c0c0 colSpan=2><FONT size=+0><FONT size=2>Aflibercept:</FONT> </FONT></TD>
    <TD noWrap align=center width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="2%" bgColor=#c0c0c0 colSpan=2><FONT size=+0><B><FONT size=2>2009</FONT></B>
      </FONT></TD>
    <TD noWrap align=center width="1%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="2%" bgColor=#c0c0c0 colSpan=2><FONT size=+0><B><FONT size=2>2008</FONT></B>
      </FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="94%" colSpan=2><FONT size=+0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2>Regeneron expense
      reimbursement</FONT> </FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT size=+0><FONT size=2>$</FONT>
      </FONT></TD>
    <TD noWrap align=right width="1%"><FONT size=+0><FONT size=2>9.2</FONT>
      </FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT size=+0><FONT size=2>$</FONT>
      </FONT></TD>
    <TD noWrap align=right width="1%"><FONT size=+0><FONT size=2>10.3</FONT>
      </FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="94%" bgColor=#c0c0c0 colSpan=2><FONT size=+0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2>Recognition of deferred
      revenue related to up-front payments</FONT> </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%" bgColor=#c0c0c0><FONT size=+0><FONT size=2>2.5</FONT> </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%" bgColor=#c0c0c0><FONT size=+0><FONT size=2>2.1</FONT> </FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="94%" colSpan=2><FONT size=+0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2>Total aflibercept</FONT> </FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%"><FONT size=+0><FONT size=2>11.7</FONT> </FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%"><FONT size=+0><FONT size=2>12.4</FONT> </FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="94%" bgColor=#c0c0c0 colSpan=2><FONT size=+0><FONT size=2>Antibody:</FONT> </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT size=+0>&nbsp;
      </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="94%" colSpan=2><FONT size=+0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2>Regeneron expense
      reimbursement</FONT> </FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT size=+0><FONT size=2>45.7</FONT>
      </FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT size=+0><FONT size=2>23.6</FONT>
      </FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="94%" bgColor=#c0c0c0 colSpan=2><FONT size=+0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2>Recognition of deferred
      revenue related to up-front payment</FONT> </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT size=+0><FONT size=2>2.6</FONT> </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT size=+0><FONT size=2>2.6</FONT> </FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="94%" colSpan=2><FONT size=+0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2>Recognition of revenue
      related to </FONT><I><FONT size=2>VelociGene</FONT></I><I><FONT size=2><SUP>&#174;</SUP> </FONT></I><FONT size=2>agreement</FONT> </FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%"><FONT size=+0><FONT size=2>0.7</FONT> </FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><FONT size=+0>&nbsp; </FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="94%" bgColor=#c0c0c0 colSpan=2><FONT size=+0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2>Total antibody</FONT> </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%" bgColor=#c0c0c0><FONT size=+0><FONT size=2>49.0</FONT> </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%" bgColor=#c0c0c0><FONT size=+0><FONT size=2>26.2</FONT> </FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="94%" colSpan=2><FONT size=+0><FONT size=2>Total sanofi-aventis contract research &amp; development
      revenue</FONT> </FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT size=+0><FONT size=2>$</FONT> </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="1%"><FONT size=+0><FONT size=2>60.7</FONT> </FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT size=+0><FONT size=2>$</FONT> </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="1%"><FONT size=+0><FONT size=2>38.6</FONT>
</FONT></TD></TR></TABLE><BR>
<P align=justify><FONT size=2><FONT size=3>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Sanofi-aventis&#146; reimbursement of
Regeneron&#146;s aflibercept expenses decreased in the second quarter of 2009,
compared to the same period in 2008, primarily due to lower costs related to
internal research activities and manufacturing aflibercept clinical supplies.
Recognition of deferred revenue related to sanofi-aventis&#146; up-front aflibercept
payments increased in the second quarter of 2009 compared to the same period in
2008 due to shortening the estimated performance period over which this deferred
revenue is being recognized, effective in the fourth quarter of 2008. As of June
30, 2009, $47.5 million of the original $105.0 million of up-front payments
related to aflibercept was deferred and will be recognized as revenue in future
periods.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2>In the second
quarter of 2009, sanofi-aventis&#146; reimbursement of Regeneron&#146;s antibody expenses
consisted of $28.3 million under the discovery agreement and $17.4 million of
development costs under the license agreement, compared to $17.3 million and
$6.3 million, respectively, in the second quarter of 2008. The higher
reimbursement amounts in the second quarter of 2009 compared to the same period
in 2008 were due to an increase in our research activities conducted under the
discovery agreement and increases in our development activities for REGN88,
REGN421, and REGN475 under the license agreement. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2>Recognition of
deferred revenue under the antibody collaboration related to sanofi-aventis&#146;
$85.0 million up-front payment. As of June 30, 2009, $68.4 million of this
up-front payment was deferred and will be recognized as revenue in future
periods. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>As described above,
in August 2008, we entered into a separate <I>VelociGene</I>
agreement with sanofi-aventis. For the three months ended June 30, 2009, we
recognized $0.7 million of revenue related to this agreement.</FONT></P>
<P align=center><FONT size=2>27</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2>The contract
research and development revenue we earn from Bayer HealthCare, as detailed
below, consists partly of cost sharing of Regeneron VEGF Trap-Eye development
expenses and partly of recognition of revenue related to a non-refundable $75.0
million up-front payment and $20.0 million non-substantive milestone payment.
</FONT></P>
<TABLE style="BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="94%" colSpan=2>&nbsp; </TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=center width="5%" colSpan=5><B><FONT size=2>Three months
      ended</FONT></B> </TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="30%"><B><FONT size=2>Bayer HealthCare Contract Research &amp;
      Development Revenue</FONT></B> </TD>
    <TD noWrap align=left width="64%">&nbsp;</TD>
    <TD noWrap align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=5><B><FONT size=2>June 30,</FONT></B> </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="94%" colSpan=2><B><I><FONT size=2>(In
      millions)</FONT></I></B>&nbsp; </TD>
    <TD noWrap align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="2%" colSpan=2><B><FONT size=2>2009</FONT></B> </TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="2%" colSpan=2><B><FONT size=2>2008</FONT></B> </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="94%" bgColor=#c0c0c0 colSpan=2><FONT size=2>Cost-sharing of Regeneron VEGF Trap-Eye development expenses</FONT>
    </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT size=2>$</FONT> </TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT size=2>10.4</FONT>
    </TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT size=2>$</FONT> </TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT size=2>6.9</FONT>
    </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="94%" colSpan=2><FONT size=2>Recognition of
      deferred revenue related to up-front and milestone payments</FONT> </TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%"><FONT size=2>2.4</FONT> </TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%"><FONT size=2>3.3</FONT> </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="94%" bgColor=#c0c0c0 colSpan=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2>Total Bayer
      HealthCare contract research &amp; development revenue</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT size=2>$</FONT> </TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="1%" bgColor=#c0c0c0><FONT size=2>12.8</FONT> </TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT size=2>$</FONT> </TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="1%" bgColor=#c0c0c0><FONT size=2>10.2</FONT> </TD></TR></TABLE><BR>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2>In the second
quarter of 2009, cost-sharing of Regeneron VEGF Trap-Eye development expenses
increased, compared to the same period in 2008, primarily due to higher clinical
development costs in connection with our VIEW 1 trial in wet AMD and Phase 2
trial in DME, and start-up costs related to our Phase 3 trial in CRVO.
Recognition of deferred revenue related to Bayer&#146;s up-front and milestone
payments decreased in the second quarter of 2009 compared to the same period in
2008 due to an extension of the estimated performance period over which this
deferred revenue is being recognized, effective in the fourth quarter of 2008.
As of June 30, 2009, $61.8 million of the up-front licensing and milestone
payments was deferred and will be recognized as revenue in future
periods.</FONT></P>
<P align=justify><FONT size=2><FONT size=3>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Other contract research and
development revenue in the second quarter of 2009 and 2008 includes $1.5 million
and $1.4 million, respectively, in connection with our five-year grant from the
NIH, which we were awarded in September 2006 as part of the NIH&#146;s Knockout Mouse
Project. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2>In connection with
our </FONT><I><FONT size=2>VelocImmune</FONT></I><I><FONT size=2><SUP>&#174;</SUP></FONT></I><FONT size=2> license agreements with AstraZeneca
and Astellas, each of the $20.0 million annual, non-refundable payments are
deferred upon receipt and recognized as revenue ratably over approximately the
ensuing year of each agreement. In the second quarter of both 2009 and 2008, we
recognized $10.0 million of technology licensing revenue related to these
agreements. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2>For the three months
ended June 30, 2009, we recognized as revenue $4.5 million of
ARCALYST</FONT><FONT size=2><SUP><EM>&#174;</EM></SUP></FONT><FONT size=2>
(rilonacept) net product sales for which both the right of return no longer
exists and rebates can be reasonably estimated. At June 30, 2009, deferred
revenue related to ARCALYST net product sales totaled $4.9 million. </FONT></P>
<P align=justify><I><FONT size=2>Expenses:</FONT></I><FONT size=2> </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2>Total operating
expenses increased to $106.3 million in the second quarter of 2009 from $80.3
million in the same period of 2008. Our average headcount increased to 966 in
the second quarter of 2009 from 771 in the same period of 2008, principally as a
result of our expanding research and development activities that are primarily
attributable to the sanofi-aventis antibody collaboration.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2>Operating expenses
in the second quarter of 2009 and 2008 include a total of $7.4 million and $8.2
million, respectively, of non-cash compensation expense related to employee
stock option and restricted stock awards (Non-cash Compensation Expense), as
detailed below: </FONT></P>
<DIV align=center>
<TABLE style="BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="95%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" colSpan=2><FONT size=+0>&nbsp;
</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="10%" colSpan=8><FONT size=+0><B><FONT size=2>For the three months ended June
      30, 2009</FONT></B> </FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=center width="89%" colSpan=2><FONT size=+0></FONT></TD>
    <TD align=center width="2%" colSpan=2><STRONG><FONT size=2>Expenses
      before</FONT></STRONG> </TD>
    <TD align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD align=center width="1%">&nbsp;</TD>
    <TD align=center width="1%">&nbsp;</TD>
    <TD align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD align=center width="1%">&nbsp;</TD>
    <TD align=center width="3%">&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" colSpan=2><FONT size=+0>&nbsp;
</FONT></TD>
    <TD noWrap align=center width="2%" colSpan=2><FONT size=+0><B><FONT size=2>inclusion of Non-cash</FONT></B> </FONT></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="2%" colSpan=2><FONT size=+0><B><FONT size=2>Non-cash</FONT></B> </FONT></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="3%"><FONT size=+0>&nbsp; </FONT></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><FONT size=+0><B><FONT size=2>Expenses</FONT></B> </FONT></TD>
    <TD noWrap align=left width="88%">&nbsp;</TD>
    <TD noWrap align=center width="2%" colSpan=2><FONT size=+0><B><FONT size=2>Compensation</FONT></B> </FONT></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="2%" colSpan=2><FONT size=+0><B><FONT size=2>Compensation</FONT></B> </FONT></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="4%" colSpan=2><FONT size=+0><B><FONT size=2>Expenses as</FONT></B> </FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" bgColor=#ffffff colSpan=2><FONT size=+0><B><I><FONT size=2>(In millions)</FONT></I></B>&nbsp; </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="2%" bgColor=#ffffff colSpan=2><FONT size=+0><B><FONT size=2>Expense</FONT></B>
      </FONT></TD>
    <TD noWrap align=center width="1%" bgColor=#ffffff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="2%" bgColor=#ffffff colSpan=2><FONT size=+0><B><FONT size=2>Expense</FONT></B>
      </FONT></TD>
    <TD noWrap align=center width="1%" bgColor=#ffffff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" bgColor=#ffffff colSpan=2><FONT size=+0><B><FONT size=2>Reported</FONT></B> </FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" bgColor=#c0c0c0 colSpan=2><FONT size=+0><FONT size=2>Research and development</FONT> </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT size=2>$</FONT> </FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT size=+0><FONT size=2>89.5</FONT> </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT size=2>$</FONT> </FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT size=+0><FONT size=2>4.7</FONT> </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT size=2>$</FONT> </FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT size=2>94.2</FONT> </FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" bgColor=#ffffff colSpan=2><FONT size=+0><FONT size=2>Selling, general, and administrative</FONT>
</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff><FONT size=+0><FONT size=2>9.0</FONT> </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff><FONT size=+0><FONT size=2>2.7</FONT> </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="3%" bgColor=#ffffff><FONT size=+0><FONT size=2>11.7</FONT> </FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" bgColor=#c0c0c0 colSpan=2><FONT size=+0><FONT size=2>Cost of goods sold</FONT> </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%" bgColor=#c0c0c0><FONT size=+0><FONT size=2>0.4</FONT> </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0><FONT size=+0>&nbsp; </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT size=2>0.4</FONT> </FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" bgColor=#ffffff colSpan=2><FONT size=+0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2>Total operating
      expenses</FONT> </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#ffffff><FONT size=+0><FONT size=2>$</FONT> </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="1%" bgColor=#ffffff><FONT size=+0><FONT size=2>98.9</FONT> </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#ffffff><FONT size=+0><FONT size=2>$</FONT> </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="1%" bgColor=#ffffff><FONT size=+0><FONT size=2>7.4</FONT> </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#ffffff><FONT size=+0><FONT size=2>$</FONT> </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%" bgColor=#ffffff><FONT size=+0><FONT size=2>106.3</FONT>
  </FONT></TD></TR></TABLE></DIV><BR>
<P align=center><FONT size=2>28</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE><BR>
<DIV align=center>
<TABLE style="BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="90%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="91%" colSpan=2></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="8%" colSpan=8><B><FONT size=2>For the three months ended June 30,
      2008</FONT></B> </TD></TR>
  <TR vAlign=bottom>
    <TD align=center width="91%" colSpan=2></TD>
    <TD align=center width="2%" colSpan=2><STRONG><FONT size=2>Expenses
      before</FONT></STRONG> </TD>
    <TD align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD align=center width="1%">&nbsp;</TD>
    <TD align=center width="1%">&nbsp;</TD>
    <TD align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD align=center width="1%">&nbsp;</TD>
    <TD align=center width="1%">&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="91%" colSpan=2></TD>
    <TD noWrap align=center width="2%" colSpan=2><B><FONT size=2>inclusion of
      Non-cash</FONT></B> </TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="2%" colSpan=2><B><FONT size=2>Non-cash</FONT></B> </TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="4%"><B><FONT size=2>Expenses</FONT></B> </TD>
    <TD noWrap align=left width="87%">&nbsp;</TD>
    <TD noWrap align=center width="2%" colSpan=2><B><FONT size=2>Compensation</FONT></B> </TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="2%" colSpan=2><B><FONT size=2>Compensation</FONT></B> </TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="2%" colSpan=2><B><FONT size=2>Expenses
      as</FONT></B> </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="91%" colSpan=2><B><I><FONT size=2>(In
      millions)</FONT></I></B> </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="2%" colSpan=2><B><FONT size=2>Expense</FONT></B> </TD>
    <TD noWrap align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="2%" colSpan=2><B><FONT size=2>Expense</FONT></B> </TD>
    <TD noWrap align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="2%" colSpan=2><B><FONT size=2>Reported</FONT></B> </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="91%" bgColor=#c0c0c0 colSpan=2><FONT size=2>Research and development</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT size=2>$</FONT> </TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT size=2>61.9</FONT>
    </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT size=2>$</FONT> </TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT size=2>4.9</FONT>
    </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT size=2>$</FONT> </TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT size=2>66.8</FONT>
    </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="91%" colSpan=2><FONT size=2>Selling, general,
      and administrative</FONT> </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%"><FONT size=2>10.2</FONT> </TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%"><FONT size=2>3.3</FONT> </TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%"><FONT size=2>13.5</FONT> </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="91%" bgColor=#c0c0c0 colSpan=2><FONT size=2><FONT size=3>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Total operating
      expenses</FONT> </TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT size=2>$</FONT> </TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="1%" bgColor=#c0c0c0><FONT size=2>72.1</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT size=2>$</FONT> </TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="1%" bgColor=#c0c0c0><FONT size=2>8.2</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT size=2>$</FONT> </TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="1%" bgColor=#c0c0c0><FONT size=2>80.3</FONT> </TD></TR></TABLE></DIV><BR>
<P align=justify><I><FONT size=2>Research and Development Expenses:
</FONT></I></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2>Research and
development expenses increased to $94.2 million in the second quarter of 2009
from $66.8 million in the same period of 2008. The following table summarizes
the major categories of our research and development expenses for the three
months ended June 30, 2009 and 2008: </FONT></P>
<DIV align=center>
<TABLE style="BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="90%" border=0>

  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="5%"><FONT size=+0><B><FONT size=2>Research and Development Expenses</FONT></B> </FONT></TD>
    <TD noWrap align=left width="84%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=5><FONT size=+0><STRONG><FONT size=2>For the three months ended June
      30,</FONT></STRONG> </FONT></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    &nbsp;&nbsp;</TD>
    <TD noWrap align=center width="4%" colSpan=3><FONT size=+0><B><FONT size=2>Increase</FONT></B>
    </FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" colSpan=2><FONT size=+0><B><I><FONT size=2>(In
      millions)</FONT></I></B>&nbsp; </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="2%" colSpan=2><FONT size=+0><B><FONT size=2>2009</FONT></B> </FONT></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="2%" colSpan=2><FONT size=+0><B><FONT size=2>2008</FONT></B> </FONT></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=3><FONT size=+0><B><FONT size=2>(Decrease)</FONT></B> </FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" bgColor=#c0c0c0 colSpan=2><FONT size=+0><FONT size=2>Payroll and
      benefits (1)</FONT> </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT size=2>$</FONT>
      </FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT size=+0><FONT size=2>23.6</FONT>
      </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT size=2>$</FONT>
      </FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT size=+0><FONT size=2>19.7</FONT>
      </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT size=2>$</FONT>
      </FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT size=+0><FONT size=2>3.9</FONT>
      </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT size=+0>&nbsp; </FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" colSpan=2><FONT size=+0><FONT size=2>Clinical trial expenses</FONT>
      </FONT></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=right width="1%"><FONT size=+0><FONT size=2>30.2</FONT> </FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT size=+0><FONT size=2>11.9</FONT> </FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT size=+0><FONT size=2>18.3</FONT> </FONT></TD>
    <TD noWrap align=left width="1%"><FONT size=+0>&nbsp; </FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" bgColor=#c0c0c0 colSpan=2><FONT size=+0><FONT size=2>Clinical
      manufacturing costs (2)</FONT> </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT size=+0><FONT size=2>13.8</FONT>
      </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT size=+0><FONT size=2>11.9</FONT>
      </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT size=+0><FONT size=2>1.9</FONT>
      </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT size=+0>&nbsp; </FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" colSpan=2><FONT size=+0><FONT size=2>Research and preclinical
      development costs</FONT> </FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT size=+0><FONT size=2>9.9</FONT> </FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=right width="1%"><FONT size=+0><FONT size=2>7.4</FONT> </FONT></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT size=+0><FONT size=2>2.5</FONT> </FONT></TD>
    <TD noWrap align=left width="1%"><FONT size=+0>&nbsp; </FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" bgColor=#c0c0c0 colSpan=2><FONT size=+0><FONT size=2>Occupancy and
      other operating costs</FONT> </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT size=+0><FONT size=2>8.9</FONT>
      </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT size=+0><FONT size=2>7.1</FONT>
      </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT size=+0><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      1.8</FONT> </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" colSpan=2><FONT size=+0><FONT size=2>Cost-sharing of Bayer
      HealthCare VEGF</FONT> </FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%">&nbsp; </TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%">&nbsp; </TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="2%">&nbsp;</TD>
    <TD noWrap align=left width="1%">&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" bgColor=#c0c0c0 colSpan=2><FONT size=+0><FONT size=2><FONT size=3>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Trap-Eye development expenses
      (3)</FONT> </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%" bgColor=#c0c0c0><FONT size=+0><FONT size=2>7.8</FONT> </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%" bgColor=#c0c0c0><FONT size=+0><FONT size=2>8.8</FONT> </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#c0c0c0><FONT size=+0><FONT size=2>(1.0</FONT> </FONT></TD>
    <TD style="PADDING-BOTTOM: 1pt" noWrap align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT size=2>)</FONT> </FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" colSpan=2><FONT size=+0><FONT size=2><FONT size=3>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Total research and
      development</FONT> </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT size=+0><FONT size=2>$</FONT> </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="1%"><FONT size=+0><FONT size=2>94.2</FONT> </FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT size=+0><FONT size=2>$</FONT> </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="1%"><FONT size=+0><FONT size=2>66.8</FONT> </FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT size=+0><FONT size=2>$</FONT> </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%"><FONT size=+0><FONT size=2>27.4</FONT> </FONT></TD>
    <TD noWrap align=left width="1%"><FONT size=+0>&nbsp;
</FONT></TD></TR></TABLE>

</DIV><BR>
<DIV align=center>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD vAlign=top noWrap >&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD vAlign=top noWrap><FONT size=2>(1)</FONT></TD>
    <TD vAlign=top noWrap>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD vAlign=top align=left width="100%">
      <P align=justify><FONT size=2>Includes $4.0 million and $4.2 million of
      Non-cash Compensation Expense for the three months ended June 30, 2009 and
      2008, respectively.</FONT></P></TD></TR>
  <TR>
    <TD vAlign=top noWrap ></TD>
    <TD vAlign=top noWrap><FONT size=2>(2)</FONT></TD>
    <TD vAlign=top noWrap></TD>
    <TD vAlign=top align=left width="100%">
      <P align=justify><FONT size=2>Represents the full cost of manufacturing
      drug for use in research, preclinical development, and clinical trials,
      including related payroll and benefits, Non-cash Compensation Expense,
      manufacturing materials and supplies, depreciation, and occupancy costs of
      our Rensselaer manufacturing facility. Includes $0.7 million of Non-cash
      Compensation Expense for both the three months ended June 30, 2009 and
      2008.</FONT></P></TD></TR>
  <TR>
    <TD vAlign=top noWrap ></TD>
    <TD vAlign=top noWrap><FONT size=2>(3)</FONT></TD>
    <TD vAlign=top noWrap></TD>
    <TD vAlign=top align=left width="100%">
      <P align=justify><FONT size=2>Under our collaboration with Bayer
      HealthCare, in periods when Bayer HealthCare incurs VEGF Trap-Eye
      development expenses, we also recognize, as additional research and
      development expense, the portion of Bayer HealthCare&#146;s VEGF Trap-Eye
      development expenses that we are obligated to reimburse. Bayer HealthCare
      provides us with estimated VEGF Trap-Eye development expenses for the most
      recent interim fiscal quarter. Bayer HealthCare&#146;s estimate is reconciled
      to its actual expenses for such quarter in the subsequent interim quarter
      and our portion of its VEGF Trap-Eye development expenses that we are
      obligated to reimburse is adjusted
accordingly.</FONT></P></TD></TR></TABLE></DIV>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2>Payroll and benefits
increased principally due to the increase in employee headcount, as described
above. Clinical trial expenses increased due primarily to higher costs related
to our clinical development programs for (i) VEGF Trap-Eye, including our VIEW 1
trial in wet AMD, Phase 2 trial in DME, and recently initiated Phase 3 trial in
CRVO, (ii) ARCALYST, related to our Phase 3 clinical development program in
gout, and (iii) monoclonal antibodies, primarily related to REGN88 in rheumatoid
arthritis. Clinical manufacturing costs increased due to higher costs related to
manufacturing clinical supplies of ARCALYST and monoclonal antibodies, including
REGN88. Research and preclinical development costs increased primarily due to
higher costs associated with our antibody programs. Occupancy and other
operating costs increased principally in connection with our higher headcount
and expanded research and development activities. Cost-sharing of Bayer
HealthCare&#146;s VEGF Trap-Eye development expenses decreased primarily due to lower
costs in connection with the VIEW 2 trial in wet AMD, which is being conducted
by Bayer HealthCare.</FONT></P>
<P align=center><FONT size=2>29</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><FONT size=2><FONT size=3>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>We budget our research and
development costs by expense category, rather than by project. We also prepare
estimates of research and development costs for projects in clinical
development, which include direct costs and allocations of certain costs such as
indirect labor, Non-cash Compensation Expense, and manufacturing and other costs
related to activities that benefit multiple projects, and, under our
collaboration with Bayer HealthCare, the portion of Bayer HealthCare&#146;s VEGF
Trap-Eye development expenses that we are obligated to reimburse. Our estimates
of research and development costs for clinical development programs are shown
below: </FONT></P>
<TABLE style="BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="4%"><FONT size=+0><B><FONT size=2>Project Costs</FONT></B> </FONT></TD>
    <TD noWrap align=left width="85%">&nbsp;</TD>
    <TD noWrap align=center width="11%" colSpan=9><FONT size=+0></FONT><FONT size=+0></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" colSpan=2><FONT size=+0></FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=5><FONT size=+0><STRONG><FONT size=2>For the three months ended
      June 30,</FONT></STRONG> </FONT></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=center width="5%" colSpan=3><FONT size=+0><B><FONT size=2>Increase</FONT></B></FONT><FONT size=+0> </FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" colSpan=2><FONT size=+0><B><I><FONT size=2>(In millions)</FONT></I></B> </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="2%" colSpan=2><FONT size=+0><B><FONT size=2>2009</FONT></B> </FONT></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="2%" colSpan=2><FONT size=+0><B><FONT size=2>2008</FONT></B> </FONT></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=3><FONT size=+0><B><FONT size=2>(Decrease)</FONT></B> </FONT><FONT size=+0></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" bgColor=#c0c0c0 colSpan=2><FONT size=+0><FONT size=2>ARCALYST</FONT><FONT size=2><SUP>&#174;</SUP> </FONT><FONT size=2>(rilonacept)</FONT> </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT size=2>$</FONT> </FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT size=+0><FONT size=2>15.7</FONT> </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT size=2>$</FONT> </FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT size=+0><FONT size=2>7.2</FONT> </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT size=2>$</FONT> </FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT size=2>8.5</FONT> </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT size=+0>&nbsp;
      </FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" colSpan=2><FONT size=+0><FONT size=2>Aflibercept</FONT> </FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT size=+0><FONT size=2>7.4</FONT>
      </FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT size=+0><FONT size=2>8.8</FONT>
      </FONT></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT size=+0><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (1.4</FONT>
      </FONT></TD>
    <TD noWrap align=left width="1%"><FONT size=+0><FONT size=2>)</FONT>
      </FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" bgColor=#c0c0c0 colSpan=2><FONT size=+0><FONT size=2>VEGF Trap-Eye</FONT> </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT size=+0><FONT size=2>27.0</FONT> </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT size=+0><FONT size=2>22.2</FONT> </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT size=2>4.8</FONT> </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT size=+0>&nbsp;
      </FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" colSpan=2><FONT size=+0><FONT size=2>REGN88</FONT> </FONT></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=right width="1%"><FONT size=+0><FONT size=2>8.5</FONT>
      </FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=right width="1%"><FONT size=+0><FONT size=2>5.5</FONT>
      </FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT size=+0><FONT size=2>3.0</FONT>
      </FONT></TD>
    <TD noWrap align=left width="1%"><FONT size=+0>&nbsp; </FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" bgColor=#c0c0c0 colSpan=2><FONT size=+0><FONT size=2>REGN421 and REGN475</FONT> </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT size=+0><FONT size=2>5.1</FONT> </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT size=+0></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT size=2>5.1</FONT> </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" colSpan=2><FONT size=+0><FONT size=2>Other research programs &amp; unallocated costs<FONT size=3>
      </FONT></FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%"><FONT size=+0><FONT size=2>30.5</FONT> </FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%"><FONT size=+0><FONT size=2>23.1</FONT> </FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT size=+0><FONT size=2>7.4</FONT> </FONT></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" bgColor=#c0c0c0 colSpan=2><FONT size=+0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2>Total research and
      development expenses</FONT>&nbsp; </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT size=2>$</FONT> </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="1%" bgColor=#c0c0c0><FONT size=+0><FONT size=2>94.2</FONT> </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT size=2>$</FONT> </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="1%" bgColor=#c0c0c0><FONT size=+0><FONT size=2>66.8</FONT> </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT size=2>$</FONT> </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%" bgColor=#c0c0c0><FONT size=+0><FONT size=2>27.4</FONT> </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT size=+0>&nbsp;
      </FONT></TD></TR></TABLE>
<BR>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2>Drug development and
approval in the United States is a multi-step process regulated by the FDA. The
process begins with discovery and preclinical evaluation, leading up to the
submission of an IND to the FDA which, if successful, allows the opportunity for
study in humans, or clinical study, of the potential new drug. Clinical
development typically involves three phases of study: Phase 1, 2, and 3. The
most significant costs in clinical development are in Phase 3 clinical trials,
as they tend to be the longest and largest studies in the drug development
process. Following successful completion of Phase 3 clinical trials for a
biological product, a biologics license application (or BLA) must be submitted
to, and accepted by, the FDA, and the FDA must approve the BLA prior to
commercialization of the drug. It is not uncommon for the FDA to request
additional data following its review of a BLA, which can significantly increase
the drug development timeline and expenses. We may elect either on our own, or
at the request of the FDA, to conduct further studies that are referred to as
Phase 3B and 4 studies. Phase 3B studies are initiated and either completed or
substantially completed while the BLA is under FDA review. These studies are
conducted under an IND. Phase 4 studies, also referred to as post-marketing
studies, are studies that are initiated and conducted after the FDA has approved
a product for marketing. In addition, as discovery research, preclinical
development, and clinical programs progress, opportunities to expand development
of drug candidates into new disease indications can emerge. We may elect to add
such new disease indications to our development efforts (with the approval of
our collaborator for joint development programs), thereby extending the period
in which we will be developing a product. For example, we, and our collaborators
where applicable, continue to explore further development of ARCALYST,
aflibercept, and VEGF Trap-Eye in different disease indications. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2>There are numerous
uncertainties associated with drug development, including uncertainties related
to safety and efficacy data from each phase of drug development, uncertainties
related to the enrollment and performance of clinical trials, changes in
regulatory requirements, changes in the competitive landscape affecting a
product candidate, and other risks and uncertainties described in Part II, Item 1A, &#147;Risk
Factors&#148; under &#147;Risks Related to ARCALYST</FONT><FONT size=2><SUP>&#174;</SUP></FONT><FONT size=2> (rilonacept) and the Development of Our
Product Candidates,&#148; &#147;Regulatory and Litigation Risks,&#148; and &#147;Risks Related to
Commercialization of Products.&#148; The lengthy process of seeking FDA approvals,
and subsequent compliance with applicable statutes and regulations, require the
expenditure of substantial resources. Any failure by us to obtain, or delay in
obtaining, regulatory approvals could materially adversely affect our
business.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2>For these reasons
and due to the variability in the costs necessary to develop a product and the
uncertainties related to future indications to be studied, the estimated cost
and scope of the projects, and our ultimate ability to obtain governmental
approval for commercialization, accurate and meaningful estimates of the total
cost to bring our product candidates to market are not available. Similarly, we
are currently unable to reasonably estimate if our product candidates will
generate material product revenues and net cash inflows. In the first quarter of
2008, we received FDA approval for ARCALYST for the treatment of CAPS,
a group of rare, inherited auto-inflammatory diseases. These rare diseases
affect a very small group of people. As a result, we can not predict whether the
commercialization of ARCALYST in CAPS will result in a significant net cash
benefit to us.&nbsp;</FONT><I><FONT size=2>&nbsp;</FONT></I></P>
<P align=center><FONT size=2>30</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><EM><FONT size=2>Selling, General, and Administrative
Expenses:</FONT></EM></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Selling, general,
and administrative expenses decreased to $11.7 million in the second quarter of
2009 from $13.5 million in the same period of 2008 due to (i) lower selling
expenses related to ARCALYST<SUP>&#174;</SUP> (rilonacept), (ii) a decrease in recruitment costs for
administrative headcount, (iii) lower market research costs related to various
programs, (iv) lower patent-related costs, and (v) lower professional fees
related to various corporate matters. These decreases were partially offset by
higher compensation expense due primarily to increases in administrative
headcount to support our expanded research and development activities.
</FONT></P>
<P align=justify><I><FONT size=2>Cost of Goods Sold: </FONT></I></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In the third quarter
of 2008, we began recognizing revenue and cost of goods sold from product sales
of ARCALYST. We began capitalizing inventory costs associated with commercial
supplies of ARCALYST subsequent to receipt of marketing approval from the FDA in
February 2008. Costs for manufacturing supplies of ARCALYST prior to receipt of
FDA approval were recognized as research and development expenses in the period
that the costs were incurred. Therefore, these costs are not being included in
cost of goods sold when revenue is recognized from the sale of those supplies of
ARCALYST. Cost of goods sold for the second quarter of 2009 was $0.4 million and
consisted primarily of royalty and other period costs related to ARCALYST
commercial supplies. </FONT></P>
<P align=justify><B><I><FONT size=2>Other Income and Expense:
</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Investment income
decreased to $1.3 million in the second quarter of 2009 from $4.5 million in the
comparable quarter of 2008. The decrease in investment income was due to lower
yields on, and lower balances of, cash and marketable securities in the first
quarter of 2009 compared to the same quarter of 2008. Interest expense was $2.7
million in the second quarter of 2008 and related to $200.0 million of formerly
outstanding 5.5% Convertible Senior Subordinated Notes which we either
repurchased or repaid in full during 2008. In the second quarter of 2008, we
repurchased $81.3 million in principal amount of these convertible notes for
$82.1 million. In connection with the repurchases, we recognized a $0.9 million
loss on early extinguishment of debt, representing the premium paid on the notes
plus related unamortized debt issuance costs.</FONT></P>
<P align=justify><B><I><FONT size=2>Six Months Ended June 30, 2009 and 2008
</FONT></I></B></P>
<P align=justify><I><FONT size=2>Net Loss: </FONT></I></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2>Regeneron reported a
net loss of $30.3 million, or $0.38 per share (basic and diluted), for the first
half of 2009 compared to a net loss of $30.5 million, or $0.39 per share (basic
and diluted), for the same period of 2008. The decrease in our net loss was
principally due to higher contract research and development revenue in
connection with our antibody collaboration with sanofi-aventis and increased net
product sales of ARCALYST for the treatment of CAPS, partially offset by higher research and
development expenses, as detailed below. </FONT></P>
<P align=justify><I><FONT size=2>Revenues: </FONT></I></P>
<P align=justify><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Revenues for
the six months ended June 30, 2009 and 2008 consist of the following:
</FONT></P>
<DIV align=center>
<TABLE style="BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="80%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="94%"><FONT size=+0><B><I><FONT size=2>(In
      millions)</FONT></I></B>&nbsp; </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="2%" colSpan=2><FONT size=+0><B><FONT size=2>2009</FONT></B> </FONT></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="2%" colSpan=2><FONT size=+0><B><FONT size=2>2008</FONT></B> </FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="94%" bgColor=#c0c0c0><FONT size=+0><FONT size=2>Contract research &amp; development revenue</FONT> </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT size=+0>&nbsp;
      </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT size=+0>&nbsp;
      </FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="94%"><FONT size=+0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2>Sanofi-aventis</FONT>
      </FONT></TD>
    <TD noWrap align=left width="1%"><FONT size=+0><FONT size=2>$</FONT>
      </FONT></TD>
    <TD noWrap align=right width="1%"><FONT size=+0><FONT size=2>110.4</FONT>
      </FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT size=+0><FONT size=2>$</FONT>
      </FONT></TD>
    <TD noWrap align=right width="1%"><FONT size=+0><FONT size=2>74.3</FONT>
      </FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="94%" bgColor=#c0c0c0><FONT size=+0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2>Bayer HealthCare</FONT>
      </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT size=+0><FONT size=2>22.8</FONT> </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT size=+0><FONT size=2>19.2</FONT> </FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="94%"><FONT size=+0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2>Other</FONT> </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%"><FONT size=+0><FONT size=2>3.4</FONT> </FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%"><FONT size=+0><FONT size=2>3.5</FONT> </FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="94%" bgColor=#c0c0c0><FONT size=+0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2>Total contract research &amp; development revenue</FONT> </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT size=+0><FONT size=2>136.6</FONT> </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT size=+0><FONT size=2>97.0</FONT> </FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="94%"><FONT size=+0><FONT size=2>Technology
      licensing revenue</FONT> </FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT size=+0><FONT size=2>20.0</FONT>
      </FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=right width="1%"><FONT size=+0><FONT size=2>20.0</FONT>
      </FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="94%" bgColor=#c0c0c0><FONT size=+0><FONT size=2>Net product sales</FONT> </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%" bgColor=#c0c0c0><FONT size=+0><FONT size=2>8.4</FONT> </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0><FONT size=+0>&nbsp; </FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="94%"><FONT size=+0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2>Total revenue</FONT> </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT size=+0><FONT size=2>$</FONT> </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="1%"><FONT size=+0><FONT size=2>165.0</FONT> </FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT size=+0><FONT size=2>$</FONT> </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="1%"><FONT size=+0><FONT size=2>117.0</FONT>
</FONT></TD></TR></TABLE></DIV><BR>
<P align=justify><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The contract
and research development revenue we earn from sanofi-aventis, as detailed below,
consists primarily of reimbursement for research and development expenses and
partly of the recognition of revenue related to non-refundable up-front payments
of $105.0 million related to the aflibercept collaboration and $85.0 million
related to the antibody collaboration. </FONT></P>
<P align=center><FONT size=2>31</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE><BR>
<TABLE style="BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD noWrap align=left width="10%" ></TD>
    <TD noWrap align=left width="84%" ></TD>
    <TD noWrap align=center width="6%"  colSpan=5><STRONG><FONT size=2>Six months ended</FONT></STRONG> </TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="10%"><B><FONT size=2>Sanofi-aventis Contract Research &amp;
      Development Revenue</FONT></B> </TD>
    <TD noWrap align=left width="84%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="6%" colSpan=5><STRONG><FONT size=2>June 30,</FONT></STRONG> </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="94%" colSpan=2><B><I><FONT size=2>(In
      millions)</FONT></I></B>&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="2%" colSpan=2>&nbsp;<STRONG><FONT size=2>2009</FONT></STRONG> </TD>
    <TD noWrap align=center width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="3%"  colSpan=2>&nbsp; <STRONG><FONT size=2>2008</FONT></STRONG>&nbsp;&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="94%" bgColor=#c0c0c0 colSpan=2><FONT size=2>Aflibercept:</FONT> </TD>
    <TD noWrap align=center width="2%" bgColor=#c0c0c0 colSpan=2></TD>
    <TD noWrap align=center width="1%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=center width="3%" bgColor=#c0c0c0 colSpan=2></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="94%" bgColor=#ffffff colSpan=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2>Regeneron expense
      reimbursement</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff><FONT size=2>$</FONT> </TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff><FONT size=2>14.6</FONT>
    </TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff><FONT size=2>$</FONT> </TD>
    <TD noWrap align=right width="2%" bgColor=#ffffff><FONT size=2>22.0</FONT>
    </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="94%" bgColor=#c0c0c0 colSpan=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2>Recognition of
      deferred revenue related to up-front payments</FONT> </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%" bgColor=#c0c0c0><FONT size=2>5.0</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#c0c0c0><FONT size=2>4.2</FONT> </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="94%" bgColor=#ffffff colSpan=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2>Total aflibercept</FONT> </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%" bgColor=#ffffff><FONT size=2>19.6</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#ffffff><FONT size=2>26.2</FONT> </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="94%" bgColor=#c0c0c0 colSpan=2><FONT size=2>Antibody:</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp; </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="94%" bgColor=#ffffff colSpan=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2>Regeneron expense
      reimbursement</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff><FONT size=2>84.1</FONT>
    </TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="2%" bgColor=#ffffff><FONT size=2>42.9</FONT>
    </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="94%" bgColor=#c0c0c0 colSpan=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2>Recognition of
      deferred revenue related to up-front payment</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT size=2>5.3</FONT>
    </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT size=2>5.2</FONT>
    </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="94%" bgColor=#ffffff colSpan=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2>Recognition of
      revenue related to </FONT><I><FONT size=2>VelociGene</FONT></I><I><FONT size=2><SUP>&#174;</SUP> </FONT></I><FONT size=2>agreement</FONT> </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%" bgColor=#ffffff><FONT size=2>1.4</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="2%" bgColor=#ffffff>&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="94%" bgColor=#c0c0c0 colSpan=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2>Total antibody</FONT> </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%" bgColor=#c0c0c0><FONT size=2>90.8</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#c0c0c0><FONT size=2>48.1</FONT> </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="94%" bgColor=#ffffff colSpan=2><FONT size=2>Total sanofi-aventis contract research &amp; development
      revenue</FONT> </TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#ffffff><FONT size=2>$</FONT> </TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="1%" bgColor=#ffffff><FONT size=2>110.4</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#ffffff><FONT size=2>$</FONT> </TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%" bgColor=#ffffff><FONT size=2>74.3</FONT> </TD></TR></TABLE><BR>
<P align=justify><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Sanofi-aventis&#146; reimbursement of Regeneron&#146;s aflibercept expenses decreased in
the first half of 2009, compared to the same period in 2008, primarily due to
lower costs related to internal research activities and manufacturing
aflibercept clinical supplies. Recognition of deferred revenue related to
sanofi-aventis&#146; up-front aflibercept payments increased in the first half of
2009 compared to the same period in 2008 due to shortening the estimated
performance period over which this deferred revenue is being recognized,
effective in the fourth quarter of 2008.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2>In the first half of
2009, sanofi-aventis&#146; reimbursement of Regeneron&#146;s antibody expenses consisted
of $51.0 million under the discovery agreement and $33.1 million of development
costs under the license agreement, compared to $32.4 million and $10.5 million,
respectively, in the first half of 2008. The higher reimbursement amounts in the
first half of 2009 compared to the same period in 2008 were due to an increase
in our research activities conducted under the discovery agreement and increases
in our development activities for REGN88, REGN421, and REGN475 under the license
agreement. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2>As described above,
in August 2008, we entered into a separate </FONT><I><FONT size=2>VelociGene</FONT></I><I><FONT size=2><SUP>&#174;</SUP></FONT></I><FONT size=2>
agreement with sanofi-aventis. For the six months ended June 30, 2009, we
recognized $1.4 million of revenue related to this agreement. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2>The contract
research and development revenue we earn from Bayer HealthCare, as detailed
below, consists partly of cost sharing of Regeneron VEGF Trap-Eye development
expenses and partly of recognition of revenue related to a non-refundable $75.0
million up-front payment and $20.0 million non-substantive milestone payment.
</FONT></P>
<TABLE style="BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="95%" colSpan=2><FONT size=+0>&nbsp;
</FONT></TD>
    <TD noWrap align=center width="5%" colSpan=5><FONT size=+0><B><FONT size=2>Six months ended</FONT></B> </FONT></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="30%"><FONT size=+0><B><FONT size=2>Bayer HealthCare Contract
      Research &amp; Development Revenue</FONT></B> </FONT></TD>
    <TD noWrap align=left width="65%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=5><FONT size=+0><B><FONT size=2>June 30,</FONT></B> </FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="95%" colSpan=2><FONT size=+0><B><I><FONT size=2>(In millions)</FONT></I></B>&nbsp; </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="2%" colSpan=2><FONT size=+0><B><FONT size=2>2009</FONT></B> </FONT></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="2%" colSpan=2><FONT size=+0><B><FONT size=2>2008</FONT></B> </FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="95%" bgColor=#c0c0c0 colSpan=2><FONT size=+0><FONT size=2>Cost-sharing of Regeneron VEGF Trap-Eye development
      expenses</FONT> </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT size=2>$</FONT> </FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT size=+0><FONT size=2>17.9</FONT> </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT size=2>$</FONT> </FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT size=+0><FONT size=2>12.6</FONT> </FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="95%" colSpan=2><FONT size=+0><FONT size=2>Recognition of deferred revenue related to up-front and milestone
      payments</FONT> </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%"><FONT size=+0><FONT size=2>4.9</FONT> </FONT></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%"><FONT size=+0><FONT size=2>6.6</FONT> </FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="95%" bgColor=#c0c0c0 colSpan=2><FONT size=+0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2>Total Bayer HealthCare
      contract research &amp; development revenue</FONT> </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT size=2>$</FONT> </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="1%" bgColor=#c0c0c0><FONT size=+0><FONT size=2>22.8</FONT> </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT size=2>$</FONT> </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="1%" bgColor=#c0c0c0><FONT size=+0><FONT size=2>19.2</FONT>
  </FONT></TD></TR></TABLE><BR>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2>In the first half of
2009, cost-sharing of Regeneron VEGF Trap-Eye development expenses increased,
compared to the same period in 2008, primarily due to higher clinical
development costs in connection with our VIEW 1 trial in wet AMD and Phase 2
trial in DME, and start-up costs related to our Phase 3 trial in CRVO.
Recognition of deferred revenue related to Bayer&#146;s up-front and milestone
payments decreased in the first half of 2009 compared to the same period in 2008
due to an extension of the estimated performance period over which this deferred
revenue is being recognized, effective in the fourth quarter of 2008.</FONT></P>
<P align=justify><FONT size=2><FONT size=3>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Other contract research and
development revenue in the first half of 2009 and 2008 includes $3.0 million and
$2.5 million, respectively, in connection with our five-year grant from the NIH,
which we were awarded in September 2006 as part of the NIH&#146;s Knockout Mouse
Project. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2>In connection with
our </FONT><I><FONT size=2>VelocImmune</FONT></I><I><FONT size=2><SUP>&#174;</SUP></FONT></I><FONT size=2> license agreements with AstraZeneca
and Astellas, each of the $20.0 million annual, non-refundable payments are
deferred upon receipt and recognized as revenue ratably over approximately the
ensuing year of each agreement. In the first half of both 2009 and 2008, we
recognized $20.0 million of technology licensing revenue related to these
agreements. </FONT></P>
<P align=center><FONT size=2>32</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>For the
six months ended June 30, 2009, we recognized as revenue $8.4 million of
ARCALYST<SUP>&#174;</SUP> (rilonacept) net product sales for which both the right of
return no longer exists and rebates can be reasonably estimated.</FONT></P>
<P align=justify><I><FONT face=serif size=2>Expenses:</FONT></I><FONT face=serif size=2> </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Total
operating expenses increased to $198.4 million in the first half of 2009 from
$152.8 million in the same period of 2008. Our average headcount increased to
952 in the first half of 2009 from 742 in the same period of 2008
principally as a result of our expanding research and development activities
that are primarily attributable to the sanofi-aventis antibody
collaboration.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Operating
expenses for the first six months of 2009 and 2008 include a total of $15.1
million and $16.5 million, respectively, of Non-cash
Compensation Expense, as detailed below: </FONT></P>
<DIV align=center>
<TABLE style="FONT-SIZE: 10pt; LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="90%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="81%" colSpan=2></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="18%" colSpan=8><B><FONT face=serif size=2>For the six months ended June 30,
      2009</FONT></B></TD></TR>
  <TR>
    <TD noWrap align=left width="81%" colSpan=2></TD>
    <TD noWrap align=center width="6%" colSpan=2><STRONG>Expenses
      before</STRONG> </TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="4%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="4%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="81%" colSpan=2></TD>
    <TD noWrap align=center width="6%" colSpan=2><B><FONT face=serif size=2>inclusion of Non-cash</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%" colSpan=2><B><FONT face=serif size=2>Non-cash</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="4%"></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><B><FONT face=serif size=2>Expenses</FONT></B></TD>
    <TD noWrap align=left width="80%">&nbsp;</TD>
    <TD noWrap align=center width="6%" colSpan=2><B><FONT face=serif size=2>Compensation</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%" colSpan=2><B><FONT face=serif size=2>Compensation</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%" colSpan=2><B><FONT face=serif size=2>Expenses as</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="81%" colSpan=2><B><I><FONT face=serif size=2>(In millions)</FONT></I></B></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="6%" colSpan=2><B><FONT face=serif size=2>Expense</FONT></B></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=2><B><FONT face=serif size=2>Expense</FONT></B></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=2><B><FONT face=serif size=2>Reported</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="81%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>Research and development</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT> </TD>
    <TD noWrap align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>165.1</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT> </TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>9.4</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT> </TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>174.5</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="81%" colSpan=2><FONT face=serif size=2>Selling, general, and administrative</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="5%"><FONT face=serif size=2>17.4</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>5.7</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>23.1</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="81%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>Cost of goods sold</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>0.8</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>0.8</FONT> </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="81%" colSpan=2><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total operating
    expenses</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face=serif size=2>$</FONT> </TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="5%"><FONT face=serif size=2>183.3</FONT> </TD>
    <TD noWrap align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face=serif size=2>$</FONT> </TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="4%"><FONT face=serif size=2>15.1</FONT> </TD>
    <TD noWrap align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face=serif size=2>$</FONT> </TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="4%"><FONT face=serif size=2>198.4</FONT>
</TD></TR></TABLE></DIV><BR>
<DIV align=center>
<TABLE style="FONT-SIZE: 10pt; LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="90%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="81%" colSpan=2></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="18%" colSpan=8><B><FONT face=serif size=2>For the six months ended June 30,
      2008</FONT></B></TD></TR>
  <TR>
    <TD noWrap align=left width="81%" colSpan=2></TD>
    <TD noWrap align=center width="6%" colSpan=2><STRONG>Expenses
      before</STRONG> </TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="4%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="4%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="81%" colSpan=2></TD>
    <TD noWrap align=center width="6%" colSpan=2><B><FONT face=serif size=2>inclusion of Non-cash</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%" colSpan=2><B><FONT face=serif size=2>Non-cash</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="4%"></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><B><FONT face=serif size=2>Expenses</FONT></B></TD>
    <TD noWrap align=left width="80%">&nbsp;</TD>
    <TD noWrap align=center width="6%" colSpan=2><B><FONT face=serif size=2>Compensation</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%" colSpan=2><B><FONT face=serif size=2>Compensation</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%" colSpan=2><B><FONT face=serif size=2>Expenses as</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="81%" colSpan=2><B><I><FONT face=serif size=2>(In millions)</FONT></I></B></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="6%" colSpan=2><B><FONT face=serif size=2>Expense</FONT></B></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=2><B><FONT face=serif size=2>Expense</FONT></B></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=2><B><FONT face=serif size=2>Reported</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="81%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>Research and development</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT> </TD>
    <TD noWrap align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>118.5</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT> </TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>9.8</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT> </TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>128.3</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="81%" colSpan=2><FONT face=serif size=2>Selling, general, and administrative</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="5%"><FONT face=serif size=2>17.8</FONT> </TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%"><FONT face=serif size=2>6.7</FONT> </TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%"><FONT face=serif size=2>24.5</FONT> </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="81%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total operating
      expenses</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT> </TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>136.3</FONT> </TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT> </TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>16.5</FONT> </TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT> </TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>152.8</FONT>
</TD></TR></TABLE></DIV><BR>
<P align=justify><I><FONT face=serif size=2>Research and Development Expenses:
</FONT></I></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Research
and development expenses increased to $174.5 million in the first half of 2009
from $128.3 million in the same period of 2008. The following table summarizes
the major categories of our research and development expenses for the six months
ended June 30, 2009 and 2008: </FONT></P>
<DIV align=center>
<TABLE style="FONT-SIZE: 10pt; LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="90%" border=0>

  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><B><FONT face=serif size=2>Research and Development
      Expenses</FONT></B></TD>
    <TD noWrap align=left width="83%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="9%" colSpan=5><B><FONT face=serif size=2>For the six months ended June 30,</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="6%" colSpan=3><B><FONT face=serif size=2>Increase</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="84%" colSpan=2><B><I><FONT face=serif size=2>(In millions)</FONT></I></B></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=2><B><FONT face=serif size=2>2009</FONT></B></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=2><B><FONT face=serif size=2>2008</FONT></B></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="6%" colSpan=3><B><FONT face=serif size=2>(Decrease)</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="84%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>Payroll and benefits (1)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT> </TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>46.5</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT> </TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>38.9</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT> </TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>7.6</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="84%" colSpan=2><FONT face=serif size=2>Clinical trial expenses</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>49.5</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>20.5</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>29.0</FONT> </TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="84%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>Clinical manufacturing costs (2)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>27.9</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>26.5</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>1.4</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="84%" colSpan=2><FONT face=serif size=2>Research and preclinical development costs</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>18.4</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>12.9</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>5.5</FONT> </TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="84%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>Occupancy and other operating costs</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>17.4</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>14.1</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>3.3</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="84%" colSpan=2><FONT face=serif size=2>Cost-sharing of Bayer HealthCare VEGF</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="84%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Trap-Eye
      development expenses (3)</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>14.8</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>15.4</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>(0.6</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="84%" colSpan=2><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total research and
      development</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face=serif size=2>$</FONT> </TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%"><FONT face=serif size=2>174.5</FONT> </TD>
    <TD noWrap align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face=serif size=2>$</FONT> </TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%"><FONT face=serif size=2>128.3</FONT> </TD>
    <TD noWrap align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face=serif size=2>$</FONT> </TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="4%"><FONT face=serif size=2>46.2</FONT> </TD>
    <TD noWrap align=left width="1%">&nbsp; </TD></TR></TABLE>
</DIV><BR>
<P align=center><FONT face=serif size=2>33</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE><BR>
<TABLE style="TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 border=0>

  <TR>
    <TD vAlign=top noWrap>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD vAlign=top noWrap><FONT face=serif size=2>(1)</FONT></TD>
    <TD vAlign=top noWrap>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD vAlign=top width="100%"><FONT face=serif size=2>Includes $8.0 million
      and $8.4 million of Non-cash Compensation Expense for the six months ended
      June 30, 2009 and 2008, respectively.</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap></TD>
    <TD vAlign=top width="100%" colSpan=3></TD></TR>
  <TR>
    <TD vAlign=top noWrap></TD>
    <TD vAlign=top noWrap><FONT face=serif size=2>(2)</FONT></TD>
    <TD vAlign=top noWrap></TD>
    <TD vAlign=top width="100%"><FONT face=serif size=2>Represents the full
      cost of manufacturing drug for use in research, preclinical development,
      and clinical trials, including related payroll and benefits, Non-cash
      Compensation Expense, manufacturing materials and supplies, depreciation,
      and occupancy costs of our Rensselaer manufacturing facility. Includes
      $1.4 million of Non-cash Compensation Expense for both the six months
      ended June 30, 2009 and 2008.</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap></TD>
    <TD vAlign=top width="100%" colSpan=3></TD></TR>
  <TR>
    <TD vAlign=top noWrap></TD>
    <TD vAlign=top noWrap><FONT face=serif size=2>(3)</FONT></TD>
    <TD vAlign=top noWrap></TD>
    <TD vAlign=top width="100%"><FONT face=serif size=2>Under our
      collaboration with Bayer HealthCare, in periods when Bayer HealthCare
      incurs VEGF Trap-Eye development expenses, we also recognize, as
      additional research and development expense, the portion of Bayer
      HealthCare&#146;s VEGF Trap-Eye development expenses that we are obligated to
      reimburse. Bayer HealthCare provides us with estimated VEGF Trap-Eye
      development expenses for the most recent interim fiscal quarter. Bayer
      HealthCare&#146;s estimate is reconciled to its actual expenses for such
      quarter in the subsequent interim quarter and our portion of its VEGF
      Trap-Eye development expenses that we are obligated to reimburse is
      adjusted accordingly.</FONT></TD></TR></TABLE>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Payroll
and benefits increased principally due to the increase in employee headcount, as
described above. Clinical trial expenses increased due primarily to higher costs
related to our clinical development programs for (i) VEGF Trap-Eye, including
our VIEW 1 trial in wet AMD, Phase 2 trial in DME, and Phase 3 trial in CRVO,
(ii) ARCALYST, related to our Phase 3 clinical development program in gout, and
(iii) monoclonal antibodies, primarily related to REGN88 in rheumatoid
arthritis. Clinical manufacturing costs increased due to higher costs related to
manufacturing clinical supplies of ARCALYST and monoclonal antibodies, including
REGN88, partially offset by lower costs related to manufacturing aflibercept
clinical supplies. Research and preclinical development costs increased
primarily due to higher costs associated with our antibody programs. Occupancy
and other operating costs increased principally in connection with our higher
headcount and expanded research and development activities. Cost-sharing of
Bayer HealthCare&#146;s VEGF Trap-Eye development expenses slightly decreased
primarily due to lower costs in connection with the VIEW 2 trial in wet AMD,
which is being conducted by Bayer HealthCare.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We budget
our research and development costs by expense category, rather than by project.
We also prepare estimates of research and development costs for projects in
clinical development, which include direct costs and allocations of certain
costs such as indirect labor, Non-cash Compensation Expense, and manufacturing
and other costs related to activities that benefit multiple projects, and, under
our collaboration with Bayer HealthCare, the portion of Bayer HealthCare&#146;s VEGF
Trap-Eye development expenses that we are obligated to reimburse. Our estimates
of research and development costs for clinical development programs (including
ARCALYST for the treatment of CAPS prior to receipt of marketing approval from
the FDA in February 2008) are shown below: </FONT></P>
<DIV align=center>
<TABLE style="FONT-SIZE: 10pt; LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="90%" border=0>

  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><B><FONT face=serif size=2>Project Costs</FONT></B></TD>
    <TD noWrap align=left width="81%"></TD>
    <TD noWrap align=center width="18%" colSpan=9></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="82%" colSpan=2>&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="11%" colSpan=5>&nbsp;<B><FONT face=serif size=2>For the six months ended
      June 30,</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="6%" colSpan=3><B><FONT face=serif size=2>Increase</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="82%" colSpan=2><B><I><FONT face=serif size=2>(In millions)</FONT></I></B>&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=2><B><FONT face=serif size=2>2009</FONT></B></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=2><B><FONT face=serif size=2>2008</FONT></B></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="6%" colSpan=3><B><FONT face=serif size=2>(Decrease)</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="82%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>ARCALYST<SUP>&#174; </SUP>(rilonacept)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>33.6</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>15.2</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>18.4</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="82%" colSpan=2><FONT face=serif size=2>Aflibercept</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>11.7</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>18.9</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>(7.2</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="82%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>VEGF Trap-Eye</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>47.8</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>38.8</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>9.0</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="82%" colSpan=2><FONT face=serif size=2>REGN88</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>17.5</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>9.3</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>8.2</FONT></TD>
    <TD noWrap align=left width="1%">&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="82%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>REGN421 and REGN475</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>10.0</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0>&nbsp; </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>10.0</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="82%" colSpan=2><FONT face=serif size=2>Other
      research programs &amp; unallocated costs</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%"><FONT face=serif size=2>53.9</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%"><FONT face=serif size=2>46.1</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%"><FONT face=serif size=2>7.8</FONT></TD>
    <TD noWrap align=left width="1%">&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="82%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total research and
      development expenses</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>174.5</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>128.3</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>46.2</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;
</TD></TR></TABLE>
</DIV><BR>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>For the
reasons described above under &#147;Research and Development Expenses&#148; for the three
months ended June 30, 2009 and 2008, and due to the variability in the costs
necessary to develop a product and the uncertainties related to future
indications to be studied, the estimated cost and scope of the projects, and our
ultimate ability to obtain governmental approval for commercialization, accurate
and meaningful estimates of the total cost to bring our product candidates to
market are not available. Similarly, we are currently unable to reasonably
estimate if our product candidates will generate material product revenues and
net cash inflows. In the first quarter of 2008, we received FDA approval for
ARCALYST for the treatment of CAPS, a group of rare,
inherited auto-inflammatory diseases. These rare diseases affect a very small
group of people. As a result, we can not predict whether the commercialization
of ARCALYST in CAPS will result in a significant net cash benefit to us.
</FONT><I><FONT face=serif size=2></FONT></I></P>
<P align=center><FONT face=serif size=2>34</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><I><FONT face=serif size=2>Selling, General, and Administrative
Expenses: </FONT></I></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Selling,
general, and administrative expenses decreased to $23.1 million in the first
half of 2009 from $24.5 million in the same period of 2008 due to (i) lower
selling expenses related to ARCALYST<SUP>&#174;</SUP> (rilonacept), (ii) a decrease in recruitment costs for
administrative headcount, (iii) lower market research costs related to various
programs, and (iv) lower legal and other professional fees related to various
corporate matters. These decreases were partially offset by higher compensation
expense due primarily to increases in administrative headcount to support our
expanded research and development activities. </FONT></P>
<P align=justify><I><FONT face=serif size=2>Cost of Goods Sold: </FONT></I></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In the
third quarter of 2008, we began recognizing revenue and cost of goods sold from
product sales of ARCALYST. We began capitalizing inventory costs associated with
commercial supplies of ARCALYST subsequent to receipt of marketing approval from
the FDA in February 2008. Costs for manufacturing supplies of ARCALYST prior to
receipt of FDA approval were recognized as research and development expenses in
the period that the costs were incurred. Therefore, these costs are not included
in cost of goods sold when revenue is recognized from the sale of those supplies
of ARCALYST. Cost of goods sold for the first half of 2009 was $0.8 million and
consisted primarily of royalty and other period costs related to ARCALYST
commercial supplies. </FONT></P>
<P align=justify><B><I><FONT face=serif size=2>Other Income and Expense:
</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Investment income decreased to $3.1 million in the first half of 2009
from $11.8 million in the comparable period of 2008. The decrease in investment
income was due to lower yields on, and lower balances of, cash and marketable
securities in the first half of 2009 compared to the same period in 2008.
Interest expense was $5.7 million in the first half of 2008 and related to
$200.0 million of formerly outstanding 5.5% Convertible Senior Subordinated
Notes which we either repurchased or repaid in full during 2008. In the second
quarter of 2008, we repurchased $81.3 million in principal amount of these
convertible notes for $82.1 million. In connection with the repurchases, we
recognized a $0.9 million loss on early extinguishment of debt, representing the
premium paid on the notes plus related unamortized debt issuance
costs.</FONT></P>
<P align=justify><B><FONT face=serif size=2>Revision of Previously Issued
Financial Statements</FONT></B><FONT face=serif size=2> </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>The
application of Emerging Issues Task Force Statement No. 97-10, </FONT><I><FONT face=serif size=2>The Effect of Lessee Involvement in Asset
Construction</FONT></I><FONT face=serif size=2> (EITF 97-10), under certain
conditions, can result in the capitalization on a lessee&#146;s books of a lessor&#146;s
costs of constructing facilities to be leased to the lessee. Recently, we became
aware that certain of these conditions were applicable to our December 2006
lease, as amended, of new laboratory and office facilities being constructed in
Tarrytown, New York by our landlord. As a result, pursuant to EITF 97-10, we are
deemed, in substance, to be the owner of the landlord&#146;s buildings during the
construction phase and the landlord&#146;s costs of constructing these new facilities
are required to be capitalized on our books as a non-cash transaction during the
facilities&#146; construction, offset by a corresponding lease obligation on our
balance sheet. In addition, the land element of the lease should have been
accounted for as an operating lease; therefore, adjustments to non-cash rent
expense previously recognized pursuant to SFAS 13, </FONT><I><FONT face=serif size=2>Accounting for Leases,</FONT></I><FONT face=serif size=2> in connection
with these new facilities are also required. Construction of these new
facilities is not yet completed and actual lease payments will not commence
until August 2009.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We have
revised our previously issued financial statements to capitalize the landlord&#146;s
costs of constructing their new Tarrytown facilities which we are leasing and to
adjust our previously recognized rent expense in connection with these
facilities, as described above. These revisions primarily resulted in an
increase to property, plant, and equipment and a corresponding increase in
facility lease obligation (a long-term liability) at each balance sheet date. We
also revised our statements of operations and statements of cash flows to
reflect rent expense in connection with only the land element of our lease, with
a corresponding adjustment to other long-term liabilities. In addition, we have
revised our statement of cash flows for the quarter ended March 31, 2009 to
reclassify, from an operating activity to a financing activity, a $5.2 million
reimbursement received from our landlord for tenant improvement costs we
incurred. Under EITF 97-10, such payments that we receive from our landlord are
deemed to be a financing obligation.</FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>35</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>The above
described revisions consisted entirely of non-cash adjustments. They had no
impact on our business operations, existing capital resources, or our ability to
fund our operating needs, including the preclinical and clinical development of
our product candidates. The revisions also had no impact on our previously
reported net increases or decreases in cash and cash equivalents in any period
and, except for the quarter ended March 31, 2009 (as described above), had no
impact on our previously reported net cash flows from operating activities,
investing activities and financing activities. In addition, these revisions had
no impact on our previously reported current assets, current liabilities, and
operating revenues. Therefore, after considering both qualitative and
quantitative factors, we believe that the judgment of a reasonable person
relying on our previously issued financial statements would not have been
changed or influenced by the above described revisions to those financial
statements, which result from applying EITF 97-10.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>For
comparative purposes, the impact of the above described revisions to our balance
sheets as of the dates set forth below is as follows: </FONT></P>
<P align=justify><B><FONT face=serif size=2>Balance Sheet Impact at December 31,
2007 and 2008, and March 31, 2009<BR></FONT></B><B><I><FONT face=serif size=2>(in millions)</FONT></I></B><B><FONT face=serif size=2> </FONT></B></P>
<DIV align=center>
<TABLE style="FONT-SIZE: 10pt; LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="90%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="81%"></TD>
    <TD noWrap align=center width="6%" colSpan=3><B><FONT face=serif size=2>December 31,</FONT></B> </TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="6%" colSpan=3><B><FONT face=serif size=2>December 31,</FONT></B> </TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%" colSpan=3><B><FONT face=serif size=2>March 31,</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="81%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="6%" colSpan=3><B><FONT face=serif size=2>2007</FONT></B></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="6%" colSpan=3><B><FONT face=serif size=2>2008</FONT></B></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=3><B><FONT face=serif size=2>2009</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="81%" bgColor=#c0c0c0><B><FONT style="BORDER-BOTTOM: black 1pt solid" face=serif size=2>As originally
      reported</FONT></B>&nbsp; </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="81%" bgColor=#ffffff><FONT face=serif size=2>Property, plant, and equipment, net</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="4%" bgColor=#ffffff><FONT face=serif size=2>58.3</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="4%" bgColor=#ffffff><FONT face=serif size=2>87.9</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#ffffff><FONT face=serif size=2>109.8</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="81%" bgColor=#c0c0c0><FONT face=serif size=2>Total assets</FONT>&nbsp; </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>936.3</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>670.0</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>681.4</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD></TR>
  <TR>
    <TD width="100%" bgColor=#ffffff colSpan=12>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="81%" bgColor=#c0c0c0><FONT face=serif size=2>Other long-term liabilities</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>5.1</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>13.2</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="81%" bgColor=#ffffff><FONT face=serif size=2>Total liabilities</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="4%" bgColor=#ffffff><FONT face=serif size=2>476.0</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="4%" bgColor=#ffffff><FONT face=serif size=2>251.2</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="3%" bgColor=#ffffff><FONT face=serif size=2>271.1</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD></TR>
  <TR>
    <TD width="100%" bgColor=#ffffff colSpan=12>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="81%" bgColor=#c0c0c0><FONT face=serif size=2>Accumulated deficit</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>(793.2</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>(875.9</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>(893.4</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="81%" bgColor=#ffffff><FONT face=serif size=2>Total stockholders&#146; equity</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="4%" bgColor=#ffffff><FONT face=serif size=2>460.3</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="4%" bgColor=#ffffff><FONT face=serif size=2>418.8</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="3%" bgColor=#ffffff><FONT face=serif size=2>410.3</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="81%" bgColor=#c0c0c0><FONT face=serif size=2>Total liabilities and stockholders&#146; equity</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>936.3</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>670.0</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>681.4</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR>
    <TD width="100%" colSpan=12>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="81%" bgColor=#c0c0c0><B><FONT style="BORDER-BOTTOM: black 1pt solid" face=serif size=2>As
      revised</FONT></B></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="81%" bgColor=#ffffff><FONT face=serif size=2>Property, plant, and equipment, net</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="4%" bgColor=#ffffff><FONT face=serif size=2>79.9</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="4%" bgColor=#ffffff><FONT face=serif size=2>142.0</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#ffffff><FONT face=serif size=2>164.6</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="81%" bgColor=#c0c0c0><FONT face=serif size=2>Total assets</FONT>&nbsp; </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>957.9</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>724.2</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>736.2</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR>
    <TD width="100%" colSpan=12>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="81%" bgColor=#c0c0c0><FONT face=serif size=2>Facility lease obligation</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>22.5</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>56.0</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>62.0</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="81%"><FONT face=serif size=2>Other long-term
      liabilities</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>0.6</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>1.2</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="81%" bgColor=#c0c0c0><FONT face=serif size=2>Total liabilities</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>498.5</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>302.7</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>321.1</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR>
    <TD width="100%" colSpan=12>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="81%" bgColor=#c0c0c0><FONT face=serif size=2>Accumulated deficit</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>(794.1</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>(873.3</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>(888.7</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="81%"><FONT face=serif size=2>Total
      stockholders&#146; equity</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>459.4</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>421.5</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>415.1</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="81%" bgColor=#c0c0c0><FONT face=serif size=2>Total liabilities and stockholders&#146; equity</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>957.9</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>724.2</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>736.2</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;
</TD></TR></TABLE></DIV><BR>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>For
comparative purposes, the impact of the above described revisions to our
statements of operations and statement of cash flows for the period(s) set forth
below is as follows: </FONT></P>
<P align=justify><B><FONT face=serif size=2>Statements of Operations Impact for
the three, six, and nine month periods ended March 31, June 30 and September 30,
2008, the years ended December 31, 2007 and 2008, and the three months ended
March 31, 2009<BR></FONT></B><B><I><FONT face=serif size=2>(in millions, except
per share data)</FONT></I></B><B><FONT face=serif size=2> </FONT></B></P>
<TABLE style="FONT-SIZE: 10pt; LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="63%"></TD>
    <TD noWrap align=center width="5%" colSpan=3><STRONG>March 31,</STRONG></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%" colSpan=3><STRONG>June 30,</STRONG></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="7%" colSpan=3><B><FONT face=serif>September 30,</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="11%" colSpan=7><STRONG>December 31,</STRONG></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%" colSpan=3><STRONG>March 31,</STRONG></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="63%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=3><B><FONT face=serif>2008</FONT></B></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=3><B><FONT face=serif>2008</FONT></B></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="7%" colSpan=3><B><FONT face=serif>2008</FONT></B></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=3><B><FONT face=serif>2007</FONT></B></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=3><B><FONT face=serif>2008</FONT></B></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=3><B><FONT face=serif>2009</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="63%" bgColor=#c0c0c0><B><FONT style="BORDER-BOTTOM: #000000 1pt solid" face=serif>As originally
      reported</FONT></B>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="5%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="63%" bgColor=#ffffff><FONT face=serif>Research and development
      expenses</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff><FONT face=serif>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#ffffff><FONT face=serif>61.3</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff><FONT face=serif>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#ffffff><FONT face=serif>127.8</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff><FONT face=serif>$</FONT></TD>
    <TD noWrap align=right width="5%" bgColor=#ffffff>&nbsp; &nbsp; &nbsp; &nbsp; <FONT face=serif>201.7</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff><FONT face=serif>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#ffffff><FONT face=serif>201.6</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff><FONT face=serif>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#ffffff><FONT face=serif>278.0</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff><FONT face=serif>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#ffffff><FONT face=serif>82.1</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="63%" bgColor=#c0c0c0>Selling, general, and <FONT face=serif>administrative expenses</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif>11.0</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif>24.5</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="5%" bgColor=#c0c0c0><FONT face=serif>35.9</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif>37.9</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif>49.3</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif>11.7</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="63%" bgColor=#ffffff><FONT face=serif>Total expenses</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="3%" bgColor=#ffffff><FONT face=serif>72.3</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="3%" bgColor=#ffffff><FONT face=serif>152.3</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="5%" bgColor=#ffffff>&nbsp; &nbsp; &nbsp;
      &nbsp;&nbsp;&nbsp;&nbsp; &nbsp;<FONT face=serif>237.9</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="3%" bgColor=#ffffff><FONT face=serif>239.5</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="3%" bgColor=#ffffff><FONT face=serif>328.3</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="3%" bgColor=#ffffff><FONT face=serif>94.2</FONT>&nbsp; </TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="63%" bgColor=#c0c0c0><FONT face=serif>Net loss</FONT>&nbsp;
</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif>(11.6</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif>)</FONT>&nbsp; </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif>(30.1</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif>)</FONT>&nbsp; </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="5%" bgColor=#c0c0c0><FONT face=serif>(51.2</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif>)</FONT>&nbsp; </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif>(105.6</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif>)</FONT>&nbsp; </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif>(82.7</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif>)</FONT>&nbsp; </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif>(17.5</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>)&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="63%" bgColor=#ffffff>Net loss per share, basic <FONT face=serif>and diluted</FONT>&nbsp; </TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff><FONT face=serif>$</FONT> </TD>
    <TD noWrap align=right width="3%" bgColor=#ffffff><FONT face=serif>(0.15</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff><FONT face=serif>)</FONT>&nbsp; </TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff><FONT face=serif>$</FONT> </TD>
    <TD noWrap align=right width="3%" bgColor=#ffffff><FONT face=serif>(0.38</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff><FONT face=serif>)</FONT>&nbsp; </TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff><FONT face=serif>$</FONT> </TD>
    <TD noWrap align=right width="5%" bgColor=#ffffff><FONT face=serif>(0.65</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff><FONT face=serif>)</FONT>&nbsp; </TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff><FONT face=serif>$</FONT> </TD>
    <TD noWrap align=right width="3%" bgColor=#ffffff><FONT face=serif>(1.59</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff><FONT face=serif>)</FONT>&nbsp; </TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff><FONT face=serif>$</FONT> </TD>
    <TD noWrap align=right width="3%" bgColor=#ffffff><FONT face=serif>(1.05</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff><FONT face=serif>)</FONT>&nbsp; </TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff><FONT face=serif>$</FONT> </TD>
    <TD noWrap align=right width="3%" bgColor=#ffffff><FONT face=serif>(0.22</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff>)&nbsp;
</TD></TR></TABLE><BR>
<P align=center><FONT face=serif size=2>36</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE><BR>
<TABLE style="FONT-SIZE: 10pt; LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="65%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="3%"><B><FONT face=serif size=2></FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="3%"><B><FONT face=serif size=2></FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%" colSpan=3><B><FONT face=serif size=2></FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="9%" colSpan=5><B><FONT face=serif size=2></FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="3%"><B><FONT face=serif size=2></FONT></B></TD>
    <TD noWrap align=center width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="65%"></TD>
    <TD noWrap align=center width="5%" colSpan=3><STRONG>March 31,</STRONG></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%" colSpan=3><STRONG>June 30,</STRONG></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%" colSpan=3><B><FONT face=serif size=2>September 30,</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="11%" colSpan=7><STRONG>December 31,</STRONG></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%" colSpan=3><STRONG>March 31,</STRONG></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="65%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=3><B><FONT face=serif size=2>2008</FONT></B></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=3><B><FONT face=serif size=2>2008</FONT></B></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=3><B><FONT face=serif size=2>2008</FONT></B></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=3><B><FONT face=serif size=2>2007</FONT></B></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=3><B><FONT face=serif size=2>2008</FONT></B></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=3><B><FONT face=serif size=2>2009</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="65%" bgColor=#c0c0c0><B><FONT style="BORDER-BOTTOM: #000000 1pt solid" face=serif size=2>As
      revised</FONT></B>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="65%" bgColor=#ffffff><FONT face=serif size=2>Research and
      development expenses</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#ffffff><FONT face=serif size=2>61.5</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#ffffff><FONT face=serif size=2>128.2</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#ffffff><FONT face=serif size=2>200.3</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#ffffff><FONT face=serif size=2>202.5</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#ffffff><FONT face=serif size=2>274.9</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#ffffff><FONT face=serif size=2>80.3</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="65%" bgColor=#c0c0c0>Selling, general, and <FONT face=serif size=2>administrative expenses</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>11.1</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>24.6</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>35.7</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>37.9</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>48.9</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>11.4</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="65%" bgColor=#ffffff><FONT face=serif size=2>Total
      expenses</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="3%" bgColor=#ffffff><FONT face=serif size=2>72.5</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="3%" bgColor=#ffffff><FONT face=serif size=2>152.8</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="3%" bgColor=#ffffff><FONT face=serif size=2>236.3</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="3%" bgColor=#ffffff><FONT face=serif size=2>240.4</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="3%" bgColor=#ffffff><FONT face=serif size=2>324.7</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="3%" bgColor=#ffffff><FONT face=serif size=2>92.1</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="65%" bgColor=#c0c0c0><FONT face=serif size=2>Net
loss</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>(11.8</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>(30.5</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>(49.6</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>(106.5</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>(79.1</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>(15.4</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="65%" bgColor=#ffffff>Net loss per share, basic <FONT face=serif size=2>and diluted</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#ffffff><FONT face=serif size=2>(0.15</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#ffffff><FONT face=serif size=2>(0.39</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#ffffff><FONT face=serif size=2>(0.63</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#ffffff><FONT face=serif size=2>(1.61</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#ffffff><FONT face=serif size=2>(1.00</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#ffffff><FONT face=serif size=2>(0.19</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff><FONT face=serif size=2>)</FONT></TD></TR></TABLE><BR>
<P align=justify><B><FONT face=serif size=2>Statement of Cash Flows Impact for
the three months ended March 31, 2009 <BR></FONT></B><B><I><FONT face=serif size=2>(in millions)</FONT></I></B><B><FONT face=serif size=2> </FONT></B></P>
<DIV align=center>
<TABLE style="FONT-SIZE: 10pt; LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="80%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="88%"></TD>
    <TD noWrap align=center width="6%" colSpan=3><B><FONT face=serif size=2>As
      Originally</FONT></B> </TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="3%"></TD>
    <TD noWrap align=center width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="6%" colSpan=3><B><FONT face=serif size=2>Reported</FONT></B></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=3><B><FONT face=serif size=2>As Revised</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%" bgColor=#c0c0c0><FONT face=serif size=2>Net cash used in operating activities</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>(10.2</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>(15.4</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%"><FONT face=serif size=2>Net cash used in
      investing activities</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>(39.5</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>(39.5</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%" bgColor=#c0c0c0><FONT face=serif size=2>Net cash provided by financing activities</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>1.0</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>6.2</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%"><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Net decrease in cash and cash
      equivalents</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="4%"><FONT face=serif size=2>(48.7</FONT></TD>
    <TD style="BORDER-BOTTOM: #ffffff 2pt solid" noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%"><FONT face=serif size=2>(48.7</FONT></TD>
    <TD style="BORDER-BOTTOM: #ffffff 2pt solid" noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD></TR></TABLE></DIV><BR>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>These
revised amounts, as applicable, are reflected in this Quarterly Report on Form
10-Q for the period ended June 30, 2009, and will be included in our Quarterly
Reports on Form 10-Q for the periods ended September 30, 2009 and March 31, 2010
and our Annual Report on Form 10-K for the year ended December 31,
2009.</FONT></P>
<P align=justify><B><FONT face=serif size=2>Liquidity and Capital
Resources</FONT></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Since our
inception in 1988, we have financed our operations primarily through offerings
of our equity securities, a private placement of convertible debt (which was
repurchased or repaid in 2008), purchases of our equity securities by our
collaborators, including sanofi-aventis, revenue earned under our past and
present research and development agreements, including our agreements with
sanofi-aventis and Bayer HealthCare, our past contract manufacturing agreements,
and our technology licensing agreements, ARCALYST product revenue, and
investment income.</FONT></P>
<P align=justify><B><I><FONT face=serif size=2>Six months ended June 30, 2009
and 2008 </FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>At June
30, 2009, we had $466.4 million in cash, cash equivalents, restricted cash, and
marketable securities compared with $527.5 million at December 31, 2008. In
February 2009, we received a $20.0 million annual, non-refundable payment in
connection with our non-exclusive license agreement with AstraZeneca. In May
2009, we received a $20.0 million annual, non-refundable payment in connection
with our non-exclusive license agreement with Astellas.</FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>37</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><I><FONT face=serif size=2>Cash Used in Operations:
</FONT></I></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Net cash
used in operations was $16.0 million in the first six months of 2009 compared to
$11.7 million in the first six months of 2008. Our net losses of $30.3 million
in the first half of 2009 and $30.5 million in the first half of 2008 included
$15.1 million and $16.5 million, respectively, of Non-cash Compensation
Expense.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>At June
30, 2009, accounts receivable increased by $24.8 million, compared to
end-of-year 2008, primarily due to a higher receivable balance related to our
antibody collaboration with sanofi-aventis. Also, our deferred revenue balances
at June 30, 2009 increased by $5.9 million, compared to end-of-year 2008,
primarily due to the receipt of the $20.0 million payments from AstraZeneca and
Astellas, as described above, which were deferred and are being recognized
ratably over the ensuing year. This increase was partially offset by amortization
of previously received deferred payments under our collaborations with
sanofi-aventis and Bayer HealthCare. At June 30, 2009, accounts payable, accrued
expenses, and other liabilities increased by $13.0 million compared to
end-of-year 2008. The increase was due primarily to higher liabilities for
clinical trial and payroll-related costs, partially offset by a $9.8 million
cost-sharing payment which was due to Bayer HealthCare at December 31, 2008 in
connection with the companies&#146; VEGF Trap-Eye collaboration; no cost-sharing
payment was due to Bayer HealthCare at June 30, 2009.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>At June
30, 2008, accounts receivable increased by $14.5 million, compared to
end-of-year 2007, primarily due to higher receivable balances related to our
collaborations with sanofi-aventis. Also, our deferred revenue balances at June
30, 2008 increased by $6.5 million, compared to end-of-year 2007, primarily due
to the receipt of $20.0 million payments from AstraZeneca in February 2008 and
Astellas in June 2008, which were deferred and recognized ratably over the
ensuing year. This increase was partially offset by amortization of previously
received deferred payments under our collaborations with sanofi-aventis and
Bayer HealthCare.</FONT></P>
<P align=justify><I><FONT face=serif size=2>Cash Provided by (Used in) Investing
Activities: </FONT></I></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Net cash
provided by investing activities was $32.8 million in the first six months of
2009 compared to net cash used in investing activities of $116.6 million in the
same period of 2008, due primarily to a decrease in purchases of marketable
securities net of sales or maturities. In the first half of 2009, sales or
maturities of marketable securities exceeded purchases by $85.4 million, whereas
in the first half of 2008, purchases of marketable securities exceeded sales or
maturities by $106.8 million. In addition, cash used for capital expenditures
totaled $52.7 million in the first six months of 2009, primarily for tenant
improvements and related costs in connection with our new leased facilities in
Tarrytown. </FONT></P>
<P align=justify><I><FONT face=serif size=2>Cash Provided by (Used in) Financing
Activities: </FONT></I></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Net cash
provided by financing activities was $6.9 million in the first six months of
2009 compared to net cash used in financing activities of $78.5 million in the
same period in 2008. In the first half of 2009, we received a $5.2 million
reimbursement of tenant improvements from our landlord in connection with our
new Tarrytown facilities, which we are deemed to own in accordance with the
provisions of EITF 97-10. In the second quarter of 2008, the Company repurchased
$81.3 million in principal amount of our convertible senior subordinated notes
for $82.1 million. In addition, proceeds from issuances of Common Stock in
connection with exercises of employee stock options were $1.7 million and $3.7
million in the first half of 2009 and 2008, respectively.</FONT></P>
<P align=justify><B><I><FONT face=serif size=2>Fair Value of Marketable
Securities: </FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>At June
30, 2009 and December 31, 2008, we held marketable securities whose aggregate
fair value totaled $193.3 million and $278.0 million, respectively. The
composition of our portfolio of marketable securities on these dates was as
follows: </FONT></P>
<TABLE style="FONT-SIZE: 10pt; LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="80%" colSpan=2></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="10%" colSpan=5><B><FONT face=serif size=2>June 30, 2009</FONT></B></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="9%" colSpan=5><B><FONT face=serif size=2>December 31, 2008</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><B><FONT face=serif size=2>Investment type</FONT></B></TD>
    <TD noWrap align=left width="79%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=2><B><FONT face=serif size=2>Fair Value</FONT></B></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=2><B><FONT face=serif size=2>Percent</FONT></B></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=2>&nbsp; <B><FONT face=serif size=2>Fair Value</FONT></B></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=2><B><FONT face=serif size=2>Percent</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>U.S. Treasury securities</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>75.9</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>39</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>%</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>113.9</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>41</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>%</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%" colSpan=2><FONT face=serif size=2>U.S.
      government agency securities</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>30.1</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>16</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>%</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>58.3</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>21</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>%</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>U.S. government-guaranteed corporate bonds</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>48.7</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>25</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>%</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>29.8</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>11</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>%</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%" colSpan=2><FONT face=serif size=2>U.S.
      government guaranteed collateralized mortgage obligations</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>7.5</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>4</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>%</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>17.4</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>6</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>%</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>Corporate bonds</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>20.3</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>11</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>%</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>37.1</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>13</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>%</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%" colSpan=2><FONT face=serif size=2>Mortgage-backed securities</FONT>&nbsp; &nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>5.3</FONT> </TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>3</FONT> </TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>%</FONT>&nbsp;
</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>10.0</FONT> </TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face=serif size=2>4</FONT> </TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>%</FONT>&nbsp;
  </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>Other asset-backed securities</FONT>&nbsp; </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>0.5</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp; </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>7.8</FONT> </TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>3</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>%</FONT>&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%" colSpan=2><FONT face=serif size=2>Other</FONT>&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%"><FONT face=serif size=2>5.0</FONT> </TD>
    <TD noWrap align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face=serif size=2>2</FONT> </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><FONT face=serif size=2>%</FONT>&nbsp; </TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face=serif size=2>3.7</FONT> </TD>
    <TD noWrap align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face=serif size=2>1</FONT> </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><FONT face=serif size=2>%</FONT>&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total marketable
      securities</FONT>&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>$</FONT> </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>193.3</FONT> </TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>100</FONT> </TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>%</FONT>&nbsp; </TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT size=+0><FONT face=serif size=2>$</FONT> </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>278.0</FONT> </TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>100</FONT> </TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>%</FONT>&nbsp;
</TD></TR></TABLE><BR>
<P align=center><FONT face=serif size=2>38</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In
addition, at June 30, 2009 and December 31, 2008, we had $273.1 million and
$249.5 million, respectively, of cash, cash equivalents, and restricted cash,
primarily held in money market funds that invest in U.S. government securities.
</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>During
the first half of 2009, as marketable securities in our portfolio matured or
paid down, we purchased primarily U.S. Treasury securities, U.S. government
agency obligations and U.S. government-guaranteed debt. This shift toward higher
quality securities, which we initiated in 2008, continues to reduce the risk
profile, as well as the overall yield, of our portfolio. In particular, we
continue to reduce the proportion of asset-backed securities and corporate bonds
in our portfolio.</FONT><B><FONT face=serif size=2> </FONT></B></P>
<P align=justify><B><I><FONT face=serif size=2>Capital
Expenditures:</FONT></I></B><B><I><FONT face=serif size=2> </FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Our cash
expenditures for property, plant, and equipment totaled $52.7 million and $9.8
million for the first half of 2009 and 2008, respectively. During the remainder
of 2009, we expect to incur approximately $50 to $60 million in capital
expenditures, primarily in connection with expanding our Rensselaer, New York
manufacturing facilities and tenant improvements at our new leased Tarrytown
facilities. In connection with our tenant improvement costs in Tarrytown, up to
approximately $50 million is reimbursable at our option from our landlord under
the terms of our lease.</FONT></P>
<P align=justify><B><I><FONT face=serif size=2>Amendment to Lease &#150; Tarrytown,
New York Facilities: </FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We
currently lease approximately 248,000 square feet of laboratory and office
facilities in Tarrytown, New York. In December 2006, we entered into a new lease
agreement (as amended in October 2007 and September 2008) to lease approximately
348,000 square feet of laboratory and office space at our current Tarrytown
location, including approximately 230,000 square feet in new facilities that are
currently under construction and expected to be completed in mid-2009. The term
of the lease commenced effective June 2008 and will expire in June 2024. In
April 2009, we amended the lease agreement to increase the amount of space we
will lease to approximately 389,500 square feet. As amended, the lease contains
early termination options on approximately 159,500 square feet of space. Other
terms and conditions, as previously described in our Annual Report on Form 10-K
for the year ended December 31, 2008, remain unchanged. In connection with the
lease amendment, in April 2009, we terminated a sublease for 16,200 square feet
of space in Tarrytown, New York. </FONT></P>
<P align=justify><B><I><FONT face=serif size=2>Funding Requirements:
</FONT></I></B><B><I><FONT face=serif size=2></FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We expect
to continue to incur substantial funding requirements primarily for research and
development activities (including preclinical and clinical testing). Before
taking into account reimbursements from collaborators, we currently anticipate
that approximately 50-60% of our expenditures for 2009 will be directed toward
the preclinical and clinical development of product candidates, including
ARCALYST<SUP>&#174;</SUP> (rilonacept), aflibercept, VEGF Trap-Eye, and monoclonal
antibodies (including REGN88, REGN421, and REGN475); approximately 20-30% of our
expenditures for 2009 will be applied to our basic research and early
preclinical activities and the remainder of our expenditures for 2009 will be
used for the continued development of our novel technology platforms, capital
expenditures, and general corporate purposes.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We
currently anticipate that in 2009 sales of ARCALYST</FONT><SUP><FONT face=serif size=2> </FONT></SUP><FONT face=serif size=2>for the treatment of CAPS will not
materially enhance or otherwise materially impact our cash flows. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In
connection with the April 2009 amendment to our lease agreement for facilities
in Tarrytown, New York, as described above, our total estimated future minimum
noncancelable lease commitments, previously disclosed in our Annual Report on
Form 10-K for the year ended December 31, 2008, will increase (i) from $9.1
million to $9.4 million for the year ending December 31, 2009, (ii) from $26.8
million to $29.2 million for the two-year period beginning January 1, 2010,
(iii) from $27.2 million to $28.8 million for the two-year period beginning
January 1, 2012, and (iv) from $167.0 million to $182.5 million for the fiscal
years beginning January 1, 2014 and thereafter. </FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>39</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>The
amount we need to fund operations will depend on various factors, including the
status of competitive products, the success of our research and development
programs, the potential future need to expand our professional and support staff
and facilities, the status of patents and other intellectual property rights,
the delay or failure of a clinical trial of any of our potential drug
candidates, and the continuation, extent, and success of our collaborations with
sanofi-aventis and Bayer HealthCare. Clinical trial costs are dependent, among
other things, on the size and duration of trials, fees charged for services
provided by clinical trial investigators and other third parties, the costs for
manufacturing the product candidate for use in the trials, and for supplies,
laboratory tests, and other expenses. The amount of funding that will be
required for our clinical programs depends upon the results of our research and
preclinical programs and early-stage clinical trials, regulatory requirements,
the duration and results of clinical trials underway and of additional clinical
trials that we decide to initiate, and the various factors that affect the cost
of each trial as described above. Currently, we are required to remit royalties
on product sales of ARCALYST<SUP>&#174;</SUP> (rilonacept) for the treatment of CAPS. In the future, if we are
able to successfully develop, market, and sell ARCALYST for other indications or
certain of our product candidates, we may be required to pay royalties or
otherwise share the profits generated on such sales in connection with our
collaboration and licensing agreements. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We expect
that expenses related to the filing, prosecution, defense, and enforcement of
patent and other intellectual property claims will continue to be substantial as
a result of patent filings and prosecutions in the United States and foreign
countries.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We
believe that our existing capital resources, including funding we are entitled
to receive under our collaboration agreements, will enable us to meet operating
needs through at least 2012. However, this is a forward-looking statement based
on our current operating plan, and there may be a change in projected revenues
or expenses that would lead to our capital being consumed significantly before
such time. If there is insufficient capital to fund all of our planned
operations and activities, we would expect to prioritize available capital to
fund selected preclinical and clinical development programs.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Other
than a $1.6 million letter of credit issued to our landlord in connection with
our lease for facilities in Tarrytown, New York, as described above, we have no
off-balance sheet arrangements. In addition, we do not guarantee the obligations
of any other entity. As of June 30, 2009, we had no established banking
arrangements through which we could obtain short-term financing or a line of
credit. In the event we need additional financing for the operation of our
business, we will consider collaborative arrangements and additional public or
private financing, including additional equity financing. Factors influencing
the availability of additional financing include our progress in product
development, investor perception of our prospects, and the general condition of
the financial markets. We may not be able to secure the necessary funding
through new collaborative arrangements or additional public or private
offerings. If we cannot raise adequate funds to satisfy our capital
requirements, we may have to delay, scale-back, or eliminate certain of our
research and development activities or future operations. This could materially
harm our business.</FONT><I><FONT face=serif size=2> </FONT></I></P>
<P align=justify><B><FONT face=serif size=2>Future Impact of Recently Issued
Accounting Standards </FONT></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In June
2009, the Financial Accounting Standards Board (&#147;FASB&#148;) issued FAS 168,
</FONT><I><FONT face=serif size=2>The FASB Accounting Standards
Codification</FONT></I><I><SUP><FONT face=serif size=2> TM</FONT></SUP></I><FONT face=serif size=2> </FONT><I><FONT face=serif size=2>and the Hierarchy of
Generally Accepted Accounting Principles</FONT></I><FONT face=serif size=2>.
When effective, the FASB Accounting Standards Codification (the Codification)
will become the single official source of authoritative, nongovernmental U.S.
generally accepted accounting principles (GAAP). The Codification will be
effective for interim and annual periods ending after September 15, 2009. We
will be required to report using the Codification commencing with the quarter
ended September 30, 2009. We do not anticipate that reporting under the
Codification will have a material impact on our financial statements.
</FONT></P>
<P align=justify><B><FONT face=serif size=2>ITEM 3. QUANTITATIVE AND QUALITATIVE
DISCLOSURE ABOUT MARKET RISK </FONT></B></P>
<P align=justify><I><FONT face=serif size=2>Interest Rate Risk:</FONT></I><FONT face=serif size=2> </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Our
earnings and cash flows are subject to fluctuations due to changes in interest
rates primarily from our investment of available cash balances in investment
grade corporate, asset-backed, and U.S. government securities. We do not believe
we are materially exposed to changes in interest rates. Under our current
policies, we do not use interest rate derivative instruments to manage exposure
to interest rate changes. We estimated that a one percent unfavorable change in
interest rates would result in approximately a $0.8 million and $2.0 million
decrease in the fair value of our investment portfolio at June 30, 2009 and
2008, respectively.</FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>40</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><I><FONT face=serif size=2>Credit Quality Risk:</FONT></I><FONT face=serif size=2> </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We have
an investment policy that includes guidelines on acceptable investment
securities, minimum credit quality, maturity parameters, and concentration and
diversification. Nonetheless, deterioration of the credit quality of an
investment security subsequent to purchase may subject us to the risk of not
being able to recover the full principal value of the security. In 2007, we
recognized a $5.9 million charge related to marketable securities from two
issuers which we considered to be other than temporarily impaired in value. In
2008, an additional $0.7 million impairment charge was recognized related to one
of these securities and a $1.8 million charge was recognized related to another
marketable security which we considered to be other than temporarily impaired in
value. </FONT></P>
<P align=justify><FONT face=serif size=2><FONT size=3>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The current economic environment,
the deterioration in the credit quality of some of the issuers of securities
that we hold, and the recent volatility of securities markets increase the
risk that there could be further declines in the market value of marketable
securities in our investment portfolio and that such declines could result in
charges against income in future periods for other-than-temporary impairments,
and such amounts could be material. </FONT></P>
<P align=justify><B><FONT face=serif size=2>ITEM 4. CONTROLS AND PROCEDURES
</FONT></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Our
management, with the participation of our chief executive officer and chief
financial officer, conducted an evaluation of the effectiveness of our
disclosure controls and procedures (as such term is defined in Rules 13a-15(e)
and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the
&#147;Exchange Act&#148;)), as of the end of the period covered by this report. Based on
this evaluation, our chief executive officer and chief financial officer each
concluded that, as of the end of such period, our disclosure controls and
procedures were effective in ensuring that information required to be disclosed
by us in the reports that we file or submit under the Exchange Act is recorded,
processed, summarized, and reported within the time periods specified in
applicable rules and forms of the Securities and Exchange Commission, and is
accumulated and communicated to our management, including our chief executive
officer and chief financial officer, as appropriate to allow timely decisions
regarding required disclosure. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>There has
been no change in our internal control over financial reporting (as such term is
defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the
quarter ended June 30, 2009 that has materially affected, or is reasonably
likely to materially affect, our internal control over financial
reporting.</FONT><B><I><FONT face=serif size=2> </FONT></I></B></P>
<P align=justify><B><FONT face=serif size=2>PART II. OTHER INFORMATION
</FONT></B></P>
<P align=justify><B><FONT face=serif size=2>ITEM 1. LEGAL
PROCEEDINGS</FONT></B><B><I><FONT face=serif size=2> </FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>From time
to time, we are a party to legal proceedings in the course of our business. We
do not expect any such current legal proceedings to have a material adverse
effect on our business or financial condition.</FONT></P>
<P align=justify><B><FONT face=serif size=2>ITEM 1A. RISK FACTORS
</FONT></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We
operate in an environment that involves a number of significant risks and
uncertainties. We caution you to read the following risk factors, which have
affected, and/or in the future could affect, our business, operating results,
financial condition, and cash flows. The risks described below include
forward-looking statements, and actual events and our actual results may differ
substantially from those discussed in these forward-looking statements.
Additional risks and uncertainties not currently known to us or that we
currently deem immaterial may also impair our business operations. Furthermore,
additional risks and uncertainties are described under other captions in this
report and should be considered by our investors. </FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>41</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><FONT face=serif size=2>Risks Related to Our Financial
Results and Need for Additional Financing </FONT></B></P>
<P align=justify><B><I><FONT face=serif size=2>We have had a history of
operating losses and we may never achieve profitability. If we continue to incur
operating losses, we may be unable to continue our operations.
</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>From
inception on January 8, 1988 through June 30, 2009, we had a cumulative loss of
$903.6 million. If we continue to incur operating losses and fail to become a
profitable company, we may be unable to continue our operations. In the absence
of substantial revenue from the sale of products or other sources, the amount,
timing, nature or source of which cannot be predicted, our losses will continue
as we conduct our research and development activities.</FONT></P>
<P align=justify><B><I><FONT face=serif size=2>We may need additional funding in
the future, which may not be available to us, and which may force us to delay,
reduce or eliminate our product development programs or commercialization
efforts. </FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We will
need to expend substantial resources for research and development, including
costs associated with clinical testing of our product candidates. We believe our
existing capital resources, including funding we are entitled to receive under
our collaboration agreements, will enable us to meet operating needs through at
least 2012; however, one or more of our collaboration agreements may terminate,
our projected revenue may decrease, or our expenses may increase and that would
lead to our capital being consumed significantly before such time. We may
require additional financing in the future and we may not be able to raise such
additional funds. If we are able to obtain additional financing through the sale
of equity or convertible debt securities, such sales may be dilutive to our
shareholders. Debt financing arrangements may require us to pledge certain
assets or enter into covenants that would restrict our business activities or
our ability to incur further indebtedness and may contain other terms that are
not favorable to our shareholders. If we are unable to raise sufficient funds to
complete the development of our product candidates, we may face delay, reduction
or elimination of our research and development programs or preclinical or
clinical trials, in which case our business, financial condition or results of
operations may be materially harmed. </FONT></P>
<P align=justify><B><I><FONT face=serif size=2>The value of our investment
portfolio, which includes cash, cash equivalents, and marketable securities, is
influenced by varying economic and market conditions. A decrease in the value of
an asset in our investment portfolio or a default by the issuer may result in
our inability to recover the principal we invested and/or a recognition of a
loss charged against income. </FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>As of
June 30, 2009, cash, cash equivalents, restricted cash, and marketable
securities totaled $466.4 million and represented 63% of our total assets. We
have invested available cash balances primarily in money market funds and U.S.
Treasury, U.S. government agency, corporate, and to a lesser extent,
asset-backed securities. We consider assets classified as marketable securities
to be &#147;available-for-sale,&#148; as defined by Statement of Financial Accounting
Standards No. (SFAS) 115, </FONT><I><FONT face=serif size=2>Accounting for
Certain Investments in Debt and Equity Securities</FONT></I><FONT face=serif size=2>. Marketable securities totaled $193.3 million at June 30, 2009, are
carried at fair value, and the unrealized gains and losses are included in other
accumulated comprehensive income (loss) as a separate component of stockholders&#146;
equity. If the decline in the value of a security in our investment portfolio is
deemed to be other-than-temporary, we write down the security to its current
fair value and recognize a loss which may be fully charged against income. For
example, during the year ended December 31, 2008, we recorded charges for
other-than-temporary impairments totaling $2.5 million related to two marketable
securities in our investment portfolio. The current economic environment, the
deterioration in the credit quality of some of the issuers of securities that we
hold, and the recent volatility of securities markets increase the risk that we
may not recover the principal we invested and/or there may be further declines
in the market value of securities in our investment portfolio. As a result, we
may incur additional charges against income in future periods for
other-than-temporary impairments or realized losses upon a security&#146;s sale or
maturity, and such amounts may be material. </FONT></P>
<P align=justify><B><FONT face=serif size=2>Risks Related to
ARCALYST<SUP>&#174;</SUP> (rilonacept) and the Development of Our Product Candidates
</FONT></B></P>
<P align=justify><B><I><FONT face=serif size=2>Successful development of any of
our product candidates is highly uncertain. </FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Only a
small minority of all research and development programs ultimately result in
commercially successful drugs. Even if clinical trials demonstrate safety and
effectiveness of any of our product candidates for a specific disease and the
necessary regulatory approvals are obtained, the commercial success of any of
our product candidates will depend upon their acceptance by patients, the
medical community, and third-party payers and on our partners&#146; ability to
successfully manufacture and commercialize our product candidates. Our product
candidates are delivered either by intravenous infusion or by intravitreal or
subcutaneous injections, which are generally less well received by patients than
tablet or capsule delivery. If our products are not successfully commercialized,
we will not be able to recover the significant investment we have made in
developing such products and our business would be severely harmed. </FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>42</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We are
testing aflibcercept, VEGF Trap-Eye, and ARCALYST<SUP>&#174;</SUP> (rilonacept) in a
number of late-stage clinical trials. Clinical trials may not demonstrate
statistically sufficient effectiveness and safety to obtain the requisite
regulatory approvals for these product candidates. In a number of instances, we
have terminated the development of product candidates due to a lack of or modest
effectiveness. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Aflibercept is in Phase 3 clinical trials in combination with standard
chemotherapy regimens for the treatment of 2<SUP>nd</SUP> line metastatic
colorectal cancer, 1<SUP>st</SUP> line metastatic pancreatic cancer,
1<SUP>st</SUP> line androgen independent prostate cancer, and 2<SUP>nd</SUP>
line metastatic non-small cell lung cancer. Aflibercept may not demonstrate the
required safety or efficacy to support an application for approval in any of
these indications. We do not have proof of concept data from early-stage,
double-blind, controlled clinical trials that aflibercept will be safe or
effective in any of these cancer settings. Treatment with another VEGF
inhibitor, Avastin<SUP>&#174;</SUP> (bevacizumab), marketed by Genentech, Inc., in
combination with a chemotherapy regimen did not extend survival in a previous
Phase 3 study in patients with pancreatic cancer.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We are
testing VEGF Trap-Eye in Phase 3 trials for the treatment of wet AMD. Although
we reported positive Phase 2 trial results with VEGF Trap-Eye in this indication
based on a limited number of patients, the results from the larger Phase 3
trials may not demonstrate that VEGF Trap-Eye is safe and effective or compares
favorably to Lucentis<SUP>&#174;</SUP> (ranibizumab injection),
marketed by Genentech, Inc. A number of other potential new drugs and biologics which showed promising
results in initial clinical trials subsequently failed to establish sufficient
safety and efficacy data to obtain necessary regulatory approvals. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>ARCALYST
is in Phase 3 clinical trials for two different gout indications &#150; the
prevention of gout flares in patients initiating urate-lowering drug therapy and
acute gout. We do not have proof of concept data from Phase 2 clinical trials
that ARCALYST will be safe or effective in the acute gout setting. Although we
reported positive Phase 2 proof of concept data from a small number of patients
initiating urate-lowering drug therapy, there is a risk that the results of the
larger Phase 3 trials of ARCALYST in patients initiating urate-lowering drug
therapy will differ from the previously reported Phase 2 trial. A number of
potential new drugs and biologics which showed promising results in initial
clinical trials subsequently failed to establish sufficient safety and efficacy
data to obtain necessary regulatory approvals. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We are
studying our antibody candidates in a wide variety of indications in early stage
clinical trials. Many of these trials are exploratory studies designed to
identify what diseases and uses, if any, are best suited for these product
candidates. These early stage product candidates may not demonstrate the
requisite efficacy and/or safety profile to support continued development for
some or all of the indications that are being, or are planned to be,
studied.</FONT></P>
<P align=justify><B><I><FONT face=serif size=2>Clinical trials required for our
product candidates are expensive and time-consuming, and their outcome is highly
uncertain. If any of our drug trials are delayed or yield unfavorable results,
we will have to delay or may be unable to obtain regulatory approval for our
product candidates. </FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We must
conduct extensive testing of our product candidates before we can obtain
regulatory approval to market and sell them. We need to conduct both preclinical
animal testing and human clinical trials. Conducting these trials is a lengthy,
time-consuming, and expensive process. These tests and trials may not achieve
favorable results for many reasons, including, among others, failure of the
product candidate to demonstrate safety or efficacy, the development of serious
or life-threatening adverse events (or side effects) caused by or connected with
exposure to the product candidate, difficulty in enrolling and maintaining
subjects in the clinical trial, lack of sufficient supplies of the product
candidate or comparator drug, and the failure of clinical investigators, trial
monitors and other consultants, or trial subjects to comply with the trial plan
or protocol. A clinical trial may fail because it did not include a sufficient
number of patients to detect the endpoint being measured or reach statistical
significance. A clinical trial may also fail because the dose(s) of the
investigational drug included in the trial were either too low or too high to
determine the optimal effect of the investigational drug in the disease
setting.</FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>43</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We will
need to reevaluate any drug candidate that does not test favorably and either
conduct new trials, which are expensive and time consuming, or abandon the drug
development program. Even if we obtain positive results from preclinical or
clinical trials, we may not achieve the same success in future trials. Many
companies in the biopharmaceutical industry, including Regeneron, have suffered
significant setbacks in clinical trials, even after promising results have been
obtained in earlier trials. The failure of clinical trials to demonstrate safety
and effectiveness for the desired indication(s) could harm the development of
our product candidate(s), and our business, financial condition, and results of
operations may be materially harmed.</FONT></P>
<P align=justify><B><I><FONT face=serif size=2>Serious complications or side
effects have occurred, and may continue to occur, in connection with the use of
our approved product and in clinical trials of some of our product candidates
which could cause our regulatory approval to be revoked or otherwise negatively
affected or lead to delay or discontinuation of development of our product
candidates which could severely harm our business.</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>During
the conduct of clinical trials, patients report changes in their health,
including illnesses, injuries, and discomforts, to their study doctor. Often, it
is not possible to determine whether or not the drug candidate being studied
caused these conditions. Various illnesses, injuries, and discomforts have been
reported from time-to-time during clinical trials of our product candidates. It
is possible as we test our drug candidates in larger, longer, and more extensive
clinical programs, illnesses, injuries, and discomforts that were observed in
earlier trials, as well as conditions that did not occur or went undetected in
smaller previous trials, will be reported by patients. Many times, side effects
are only detectable after investigational drugs are tested in large scale, Phase
3 clinical trials or, in some cases, after they are made available to patients
after approval. If additional clinical experience indicates that any of our
product candidates has many side effects or causes serious or life-threatening
side effects, the development of the product candidate may fail or be delayed,
which would severely harm our business.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Aflibercept (VEGF Trap) is being studied for the potential treatment of
certain types of cancer and our VEGF Trap-Eye candidate is being studied in
diseases of the eye. There are many potential safety concerns associated with
significant blockade of vascular endothelial growth factor, or VEGF, that may
limit our ability to successfully develop aflibercept and VEGF Trap-Eye. These
serious and potentially life-threatening risks, based on clinical and
preclinical experience of VEGF inhibitors, include bleeding, intestinal
perforation, hypertension, proteinuria, heart attack, and stroke. In addition,
patients given infusions of any protein, including VEGF Trap delivered through
intravenous administration, may develop severe hypersensitivity reactions or
infusion reactions. Other VEGF blockers have reported side effects that became
evident only after large scale trials or after marketing approval and large
number of patients were treated. These and other complications or side effects
could harm the development of aflibercept for the treatment of cancer or VEGF
Trap-Eye for the treatment of diseases of the eye. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We have
tested ARCALYST in only a small number of patients. As more patients begin to
use our product and as we test it in new disease settings, new risks and side
effects associated with ARCALYST may be discovered, and risks previously viewed
as inconsequential could be determined to be significant. Like cytokine
antagonists such as Kineret<SUP>&#174;</SUP> (anakinra), marketed by Biovitrum, Enbrel<SUP>&#174;</SUP>
(etanercept), marketed by Amgen Inc. and Wyeth Pharmaceuticals, Inc., and Remicade<SUP>&#174;</SUP> (infliximab), marketed by Centocor Ortho Biotech, Inc.,
ARCALYST affects the immune defense system of the body by blocking some of its functions.
Therefore, ARCALYST may interfere with the body&#146;s ability to fight infections.
Treatment with Kineret, a medication that works through the inhibition
of IL-1, has been associated with an increased risk of serious infections, and
serious, life threatening infections have been reported in patients taking
ARCALYST. These or other complications or side effects could cause regulatory
authorities to revoke approvals of ARCALYST. Alternatively, we may be required
to conduct additional clinical trials, make changes in the labeling of our
product, or limit or abandon our efforts to develop ARCALYST in new disease
settings. These side effects may also result in a reduction, or even the
elimination, of sales of ARCALYST in approved indications.</FONT></P>
<P align=justify><B><I><FONT face=serif size=2>ARCALYST<SUP>&#174;</SUP> (rilonacept)
and our product candidates in development are recombinant proteins that could
cause an immune response, resulting in the creation of harmful or neutralizing
antibodies against the therapeutic protein.</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In
addition to the safety, efficacy, manufacturing, and regulatory hurdles faced by
our product candidates, the administration of recombinant proteins frequently
causes an immune response, resulting in the creation of antibodies against the
therapeutic protein. The antibodies can have no effect or can totally neutralize
the effectiveness of the protein, or require that higher doses be used to obtain
a therapeutic effect. In some cases, the antibody can cross react with the
patient&#146;s own proteins, resulting in an &#147;auto-immune&#148; type disease. Whether
antibodies will be created can often not be predicted from preclinical or
clinical experiments, and their detection or appearance is often delayed, so
that there can be no assurance that neutralizing antibodies will not be detected
at a later date, in some cases even after pivotal clinical trials have been
completed. Antibodies directed against the receptor domains of rilonacept were
detected in patients with CAPS after treatment with ARCALYST. Nineteen of 55
subjects (35%) who received ARCALYST for at least 6 weeks tested positive for
treatment-emerging binding antibodies on at least one occasion. To date, no side
effects related to antibodies were observed in these subjects and there were no
observed effects on drug efficacy or drug levels. It is possible that as we
continue to test aflibercept and VEGF Trap-Eye with more sensitive assays in
different patient populations and larger clinical trials, we will find that
subjects given aflibercept and VEGF Trap-Eye develop antibodies to these product
candidates, and may also experience side effects related to the antibodies,
which could adversely impact the development of such candidates.</FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>44</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><I><FONT face=serif size=2>We may be unable to formulate or
manufacture our product candidates in a way that is suitable for clinical or
commercial use. </FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Changes
in product formulations and manufacturing processes may be required as product
candidates progress in clinical development and are ultimately commercialized.
If we are unable to develop suitable product formulations or manufacturing
processes to support large scale clinical testing of our product candidates,
including aflibercept, VEGF Trap-Eye, and our antibody candidates, we may be
unable to supply necessary materials for our clinical trials, which would delay
the development of our product candidates. Similarly, if we are unable to supply
sufficient quantities of our product or develop product formulations suitable
for commercial use, we will not be able to successfully commercialize our
product candidates.</FONT></P>
<P align=justify><B><FONT face=serif size=2>Risks Related to Intellectual
Property </FONT></B></P>
<P align=justify><B><I><FONT face=serif size=2>If we cannot protect the
confidentiality of our trade secrets or our patents are insufficient to protect
our proprietary rights, our business and competitive position will be harmed.
</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Our
business requires using sensitive and proprietary technology and other
information that we protect as trade secrets. We seek to prevent improper
disclosure of these trade secrets through confidentiality agreements. If our
trade secrets are improperly exposed, either by our own employees or our
collaborators, it would help our competitors and adversely affect our business.
We will be able to protect our proprietary rights from unauthorized use by third
parties only to the extent that our rights are covered by valid and enforceable
patents or are effectively maintained as trade secrets. The patent position of
biotechnology companies involves complex legal and factual questions and,
therefore, enforceability cannot be predicted with certainty. Our patents may be
challenged, invalidated, or circumvented. Patent applications filed outside the
United States may be challenged by third parties who file an opposition. Such
opposition proceedings are increasingly common in the European Union and are
costly to defend. We have patent applications that are being opposed and it is
likely that we will need to defend additional patent applications in the future.
Our patent rights may not provide us with a proprietary position or competitive
advantages against competitors. Furthermore, even if the outcome is favorable to
us, the enforcement of our intellectual property rights can be extremely
expensive and time consuming. </FONT></P>
<P align=justify><B><I><FONT face=serif size=2>We may be restricted in our
development and/or commercialization activities by, and could be subject to
damage awards if we are found to have infringed, third party patents or other
proprietary rights. </FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Our
commercial success depends significantly on our ability to operate without
infringing the patents and other proprietary rights of third parties. Other
parties may allege that they have blocking patents to our products in clinical
development, either because they claim to hold proprietary rights to the
composition of a product or the way it is manufactured or used. Moreover, other
parties may allege that they have blocking patents to antibody products made
using our <I>VelocImmune</I><SUP>&#174;</SUP> technology, either because of the way
the antibodies are discovered or produced or because of a proprietary position
covering an antibody or the antibody&#146;s target.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We are
aware of patents and pending applications owned by Genentech that claim
certain chimeric VEGF receptor compositions. Although we do not believe that
aflibercept or VEGF Trap-Eye infringes any valid claim in these patents or
patent applications, Genentech could initiate a lawsuit for patent
infringement and assert that its patents are valid and cover aflibercept or VEGF
Trap-Eye. Genentech may be motivated to initiate such a lawsuit at some
point in an effort to impair our ability to develop and sell aflibercept or VEGF
Trap-Eye, which represent potential competitive threats to Genentech&#146;s
VEGF-binding products and product candidates. An adverse determination by a
court in any such potential patent litigation would likely materially harm our
business by requiring us to seek a license, which may not be available, or
resulting in our inability to manufacture, develop, and sell aflibercept or VEGF
Trap-Eye or in a damage award.</FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>45</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We are
aware of patents and pending applications owned by Roche that claim antibodies
to the interleukin-6 receptor and methods of treating rheumatoid arthritis with
such antibodies. We are developing REGN88, an antibody to the interleukin-6
receptor, for the treatment of rheumatoid arthritis. Although we do not believe
that REGN88 infringes any valid claim in these patents or patent applications,
Roche could initiate a lawsuit for patent infringement and assert its patents
are valid and cover REGN88.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We are
aware of a U.S. patent jointly owned by Genentech and City of Hope
relating to the production of recombinant antibodies in host cells. We currently
produce our antibody product candidates using recombinant antibodies from host
cells and may choose to produce additional antibody product candidates in this
manner. Neither ARCALYST<SUP>&#174;</SUP> (rilonacept), aflibercept, nor VEGF Trap-Eye are
recombinant antibodies. If any of our antibody product candidates are produced
in a manner subject to valid claims in the Genentech patent, then we may
need to obtain a license from Genentech should one be available.
Genentech has licensed this patent to several different companies under
confidential license agreements. If we desire a license for any of our antibody
product candidates and are unable to obtain a license on commercially reasonable
terms or at all, we may be restricted in our ability to use Genentech&#146;s
techniques to make recombinant antibodies in or to import them into the United
States. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Further,
we are aware of a number of other third party patent applications that, if
granted, with claims as currently drafted, may cover our current or planned
activities. We cannot assure you that our products and/or actions in
manufacturing and selling our product candidates will not infringe such
patents.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Any
patent holders could sue us for damages and seek to prevent us from
manufacturing, selling, or developing our drug candidates, and a court may find
that we are infringing validly issued patents of third parties. In the event
that the manufacture, use, or sale of any of our clinical candidates infringes
on the patents or violates other proprietary rights of third parties, we may be
prevented from pursuing product development, manufacturing, and
commercialization of our drugs and may be required to pay costly damages. Such a
result may materially harm our business, financial condition, and results of
operations. Legal disputes are likely to be costly and time consuming to
defend.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We seek
to obtain licenses to patents when, in our judgment, such licenses are needed.
If any licenses are required, we may not be able to obtain such licenses on
commercially reasonable terms, if at all. The failure to obtain any such license
could prevent us from developing or commercializing any one or more of our
product candidates, which could severely harm our business. </FONT></P>
<P align=justify><B><FONT face=serif size=2>Regulatory and Litigation
Risks</FONT></B></P>
<P align=justify><B><I><FONT face=serif size=2>If we do not obtain regulatory
approval for our product candidates, we will not be able to market or sell them.
</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We cannot
sell or market products without regulatory approval. If we do not obtain and
maintain regulatory approval for our product candidates, including ARCALYST for
the treatment of diseases other than CAPS, the value of our company and our
results of operations will be harmed. In the United States, we must obtain and
maintain approval from the United States Food and Drug Administration (FDA) for
each drug we intend to sell. Obtaining FDA approval is typically a lengthy and
expensive process, and approval is highly uncertain. Foreign governments also
regulate drugs distributed in their country and approval in any country is
likely to be a lengthy and expensive process, and approval is highly uncertain.
Except for the FDA approval of ARCALYST for the treatment of CAPS, none of our
product candidates has ever received regulatory approval to be marketed and sold
in the United States or any other country. We may never receive regulatory
approval for any of our product candidates. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>The FDA
enforces good clinical practices and other regulations through periodic
inspections of trial sponsors, clinical research organizations (CROs), principal
investigators, and trial sites. If we or any of the third parties conducting our
clinical studies are determined to have failed to fully comply with Good
Clinical Practice regulations (GCPs), the study protocol or applicable
regulations, the clinical data generated in our studies may be deemed
unreliable. This could result in non-approval of our product candidates by the
FDA, or we or the FDA may decide to conduct additional audits or require
additional clinical studies, which would delay our development programs and
substantially harm our business.</FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>46</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Before
approving a new drug or biologic product, the FDA requires that the facilities
at which the product will be manufactured be in compliance with current Good
Manufacturing Practices, or cGMP requirements. Manufacturing product candidates
in compliance with these regulatory requirements is complex, time-consuming, and
expensive. To be successful, our products must be manufactured for development,
following approval, in commercial quantities, in compliance with regulatory
requirements, and at competitive costs. If we or any of our product
collaborators or third-party manufacturers, product packagers, or labelers are
unable to maintain regulatory compliance, the FDA can impose regulatory
sanctions, including, among other things, refusal to approve a pending
application for a new drug or biologic product, or revocation of a pre-existing
approval. As a result, our business, financial condition, and results of
operations may be materially harmed.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In
addition to the FDA and other regulatory agency regulations in the United
States, we are subject to a variety of foreign regulatory requirements governing
human clinical trials, manufacturing, marketing and approval of drugs, and
commercial sale and distribution of drugs in foreign countries. The foreign
regulatory approval process includes all of the risks associated with FDA
approval as well as country specific regulations. Whether or not we obtain FDA
approval for a product in the United States, we must obtain approval by the
comparable regulatory authorities of foreign countries before we can commence
clinical trials or marketing of rilonacept or any of our product candidates in
those countries.</FONT></P>
<P align=justify><B><I><FONT face=serif size=2>If the testing or use of our
products harms people, we could be subject to costly and damaging product
liability claims.</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>The
testing, manufacturing, marketing, and sale of drugs for use in people expose us
to product liability risk. Any informed consent or waivers obtained from people
who sign up for our clinical trials may not protect us from liability or the
cost of litigation. We may be subject to claims by CAPS patients who use
ARCALYST that they have been injured by a side effect associated with the drug.
Our product liability insurance may not cover all potential liabilities or may
not completely cover any liability arising from any such litigation. Moreover,
we may not have access to liability insurance or be able to maintain our
insurance on acceptable terms.</FONT></P>
<P align=justify><B><I><FONT face=serif size=2>If we market and sell
ARCALYST</FONT></I></B><B><SUP><FONT face=serif size=2>&#174;</FONT></SUP></B><B><I><FONT face=serif size=2> (rilonacept) in a way
that violates federal or state fraud and abuse laws, we may be subject to civil
or criminal penalties.</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In
addition to FDA and related regulatory requirements, we are subject to health
care &#147;fraud and abuse&#148; laws, such as the federal False Claims Act, the
anti-kickback provisions of the federal Social Security Act, and other state and
federal laws and regulations. Federal and state anti-kickback laws prohibit,
among other things, knowingly and willfully offering, paying, soliciting or
receiving remuneration to induce, or in return for, purchasing, leasing,
ordering or arranging for the purchase, lease or order of any health care item
or service reimbursable under Medicare, Medicaid, or other federally or state
financed health care programs.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Federal
false claims laws prohibit any person from knowingly presenting, or causing to
be presented, a false claim for payment to the federal government, or knowingly
making, or causing to be made, a false statement to get a false claim paid.
Pharmaceutical companies have been prosecuted under these laws for a variety of
alleged promotional and marketing activities, such as allegedly providing free
product to customers with the expectation that the customers would bill federal
programs for the product; reporting to pricing services inflated average
wholesale prices that were then used by federal programs to set reimbursement
rates; engaging in promotion for uses that the FDA has not approved, or
off-label uses, that caused claims to be submitted to Medicaid for non-covered
off-label uses; and submitting inflated best price information to the Medicaid
Rebate program. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>The
majority of states also have statutes or regulations similar to the federal
anti-kickback law and false claims laws, which apply to items and services
reimbursed under Medicaid and other state programs, or, in several states, apply
regardless of the payer. Sanctions under these federal and state laws may
include civil monetary penalties, exclusion of a manufacturer&#146;s products from
reimbursement under government programs, criminal fines, and
imprisonment.</FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>47</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Even if
we are not determined to have violated these laws, government investigations
into these issues typically require the expenditure of significant resources and
generate negative publicity, which would also harm our financial condition.
Because of the breadth of these laws and the narrowness of the safe harbors, it
is possible that some of our business activities could be subject to challenge
under one or more of such laws.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In recent
years, several states and localities, including California, the District of
Columbia, Massachusetts, Maine, Minnesota, Nevada, New Mexico, Vermont, and West
Virginia, have enacted legislation requiring pharmaceutical companies to
establish marketing compliance programs, and file periodic reports with the
state or make periodic public disclosures on sales, marketing, pricing, clinical
trials, and other activities. Similar legislation is being considered in other
states. Many of these requirements are new and uncertain, and the penalties for
failure to comply with these requirements are unclear. Nonetheless, if we are
found not to be in full compliance with these laws, we could face enforcement
action and fines and other penalties, and could receive adverse publicity.
</FONT></P>
<P align=justify><B><I><FONT face=serif size=2>Our operations may involve
hazardous materials and are subject to environmental, health, and safety laws
and regulations. We may incur substantial liability arising from our activities
involving the use of hazardous materials.</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>As a
biopharmaceutical company with significant manufacturing operations, we are
subject to extensive environmental, health, and safety laws and regulations,
including those governing the use of hazardous materials. Our research and
development and manufacturing activities involve the controlled use of
chemicals, viruses, radioactive compounds, and other hazardous materials. The
cost of compliance with environmental, health, and safety regulations is
substantial. If an accident involving these materials or an environmental
discharge were to occur, we could be held liable for any resulting damages, or
face regulatory actions, which could exceed our resources or insurance
coverage.</FONT></P>
<P align=justify><B><I><FONT face=serif size=2>Changes in the securities laws
and regulations have increased, and are likely to continue to increase, our
costs.</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>The
Sarbanes-Oxley Act of 2002, which became law in July 2002, has required changes
in some of our corporate governance, securities disclosure, and compliance
practices. In response to the requirements of that Act, the SEC and the NASDAQ
Stock Market have promulgated rules and listing standards covering a variety of
subjects. Compliance with these rules and listing standards has increased our
legal costs, and significantly increased our accounting and auditing costs, and
we expect these costs to continue. These developments may make it more difficult
and more expensive for us to obtain directors&#146; and officers&#146; liability
insurance. Likewise, these developments may make it more difficult for us to
attract and retain qualified members of our board of directors, particularly
independent directors, or qualified executive officers.</FONT></P>
<P align=justify><B><I><FONT face=serif size=2>In future years, if we are unable
to conclude that our internal control over financial reporting is effective, the
market value of our Common Stock could be adversely affected.
</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>As
directed by Section 404 of the Sarbanes-Oxley Act of 2002, the SEC adopted rules
requiring public companies to include a report of management on the Company&#146;s
internal control over financial reporting in their annual reports on Form 10-K
that contains an assessment by management of the effectiveness of our internal
control over financial reporting. In addition, the independent registered public
accounting firm auditing our financial statements must attest to and report on
the effectiveness of our internal control over financial reporting. Our
independent registered public accounting firm provided us with an unqualified
report as to the effectiveness of our internal control over financial reporting
as of December 31, 2008, which report is included in our Annual Report on Form
10-K for the fiscal year ended December 31, 2008. However, we cannot assure you
that management or our independent registered public accounting firm will be
able to provide such an unqualified report as of future year-ends. In this
event, investors could lose confidence in the reliability of our financial
statements, which could result in a decrease in the market value of our Common
Stock. In addition, if it is determined that deficiencies in the design or
operation of internal controls exist and that they are reasonably likely to
adversely affect our ability to record, process, summarize, and report financial
information, we would likely incur additional costs to remediate these
deficiencies and the costs of such remediation could be material. </FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>48</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><STRONG><EM><FONT size=2>Changes in laws and regulations
affecting the healthcare industry could adversely affect our
business.</FONT></EM></STRONG></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>All
aspects of our business, including research and development, manufacturing,
marketing, pricing, sales, litigation, and intellectual property rights, are
subject to extensive legislation and regulation. Changes in applicable federal
and state laws and agency regulations could have a material adverse effect on
our business. These include:</FONT></P>
<UL style="FONT-SIZE: 10pt; TEXT-ALIGN: justify">
  <LI><FONT face=serif size=2>changes in the FDA and foreign regulatory
  processes for new therapeutics that may delay or prevent the approval of any
  of our current or future product candidates;&nbsp;</FONT>
  <LI><FONT face=serif size=2>new laws, regulations, or judicial decisions
  related to healthcare availability or the payment for healthcare products and
  services, including prescription drugs, that would make it more difficult for
  us to market and sell products once they are approved by the FDA or foreign
  regulatory agencies; and&nbsp;</FONT>
  <LI><FONT face=serif size=2>changes in FDA and foreign regulations that may
  require additional safety monitoring prior to or after the introduction of new
  products to market, which could materially increase our costs of doing
  business. </FONT></LI></UL>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>The
enactment in the United States of the Medicare Prescription Drug Improvement and
Modernization Act of 2003 and current pending legislation which would ease the
entry of competing follow-on biologics into the marketplace are examples of
changes and possible changes in laws that could adversely affect our
business.</FONT></P>
<P align=justify><B><FONT face=serif size=2>Risks Related to Our Reliance on
Third Parties </FONT></B></P>
<P align=justify><B><I><FONT face=serif size=2>If our antibody collaboration
with sanofi-aventis is terminated, our business operations and our ability to
discover, develop, manufacture, and commercialize our pipeline of product
candidates in the time expected, or at all, would be materially
harmed.</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We rely
heavily on the funding from sanofi-aventis to support our target discovery and
antibody research and development programs. Sanofi-aventis has committed to pay
up to $400 million between 2009 and 2012 to fund our efforts to identify and
validate drug discovery targets and pre-clinically develop fully human
monoclonal antibodies against such targets. In addition, sanofi-aventis funds
almost all of the development expenses incurred by both companies in connection
with the clinical development of antibodies that sanofi-aventis elects to
co-develop with us. We rely on sanofi-aventis to fund these activities. In
addition, with respect to those antibodies that sanofi-aventis elects to
co-develop with us, such as REGN88, REGN421, and REGN475, we rely on
sanofi-aventis to lead much of the clinical development efforts and assist with
obtaining regulatory approval, particularly outside the United States. We also
rely on sanofi-aventis to lead the commercialization efforts to support all of
the antibody products that are co-developed by sanofi-aventis and us. If
sanofi-aventis does not elect to co-develop the antibodies that we discover or
opts-out of their development, we would be required to fund and oversee on our
own the clinical trials, any regulatory responsibilities, and the ensuing
commercialization efforts to support our antibody products. If sanofi-aventis
terminates the antibody collaboration or fails to comply with its payment
obligations thereunder, our business, financial condition, and results of
operations would be materially harmed. We would be required to either expend
substantially more resources than we have anticipated to support our research
and development efforts, which could require us to seek additional funding that
might not be available on favorable terms or at all, or materially cut back on
such activities. While we cannot assure you that any of the antibodies from this
collaboration will ever be successfully developed and commercialized, if
sanofi-aventis does not perform its obligations with respect to antibodies that
it elects to co-develop, our ability to develop, manufacture, and commercialize
these antibody product candidates will be significantly adversely
affected.</FONT></P>
<P align=justify><B><I><FONT face=serif size=2>If our collaboration with
sanofi-aventis for aflibercept (VEGF Trap) is terminated, or sanofi-aventis
materially breaches its obligations thereunder, our business operations and
financial condition, and our ability to develop, manufacture, and commercialize
aflibercept in the time expected, or at all, would be materially harmed.
</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We rely
heavily on sanofi-aventis to lead much of the development of aflibercept.
Sanofi-aventis funds all of the development expenses incurred by both companies
in connection with the aflibercept program. If the aflibercept program
continues, we will rely on sanofi-aventis to assist with funding the aflibercept
program, provide commercial manufacturing capacity, enroll and monitor clinical
trials, obtain regulatory approval, particularly outside the United States, and
lead the commercialization of aflibercept. While we cannot assure you that
aflibercept will ever be successfully developed and commercialized, if
sanofi-aventis does not perform its obligations in a timely manner, or at all,
our ability to develop, manufacture, and commercialize aflibercept in cancer
indications will be significantly adversely affected. Sanofi-aventis has the
right to terminate its collaboration agreement with us at any time upon twelve
months advance notice. If sanofi-aventis were to terminate its collaboration
agreement with us, we would not have the resources or skills to replace those of
our partner, which could require us to seek additional funding that might not be
available on favorable terms or at all, and could cause significant delays in
the development and/or manufacture of aflibercept and result in substantial
additional costs to us. We have limited commercial capabilities and would have
to develop or outsource these capabilities. Termination of the sanofi-aventis
collaboration agreement for aflibercept would create substantial new and
additional risks to the successful development and commercialization of
aflibercept.</FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>49</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><I><FONT face=serif size=2>If our collaboration with Bayer
HealthCare for VEGF Trap-Eye is terminated, or Bayer HealthCare materially
breaches its obligations thereunder, our business, operations and financial
condition, and our ability to develop and commercialize VEGF Trap-Eye in the
time expected, or at all, would be materially harmed. </FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We rely
heavily on Bayer HealthCare to assist with the development of VEGF Trap-Eye.
Under our agreement with them, Bayer HealthCare is required to fund
approximately half of the development expenses incurred by both companies in
connection with the global VEGF Trap-Eye development program. If the VEGF
Trap-Eye program continues, we will rely on Bayer HealthCare to assist with
funding the VEGF Trap-Eye development program, lead the development of VEGF
Trap-Eye outside the United States, obtain regulatory approval outside the
United States, and provide all sales, marketing, and commercial support for the
product outside the United States. In particular, Bayer HealthCare has
responsibility for selling VEGF Trap-Eye outside the United States using its
sales force. While we cannot assure you that VEGF Trap-Eye will ever be
successfully developed and commercialized, if Bayer HealthCare does not perform
its obligations in a timely manner, or at all, our ability to develop,
manufacture, and commercialize VEGF Trap-Eye outside the United States will be
significantly adversely affected. Bayer HealthCare has the right to terminate
its collaboration agreement with us at any time upon six or twelve months
advance notice, depending on the circumstances giving rise to termination. If
Bayer HealthCare were to terminate its collaboration agreement with us, we would
not have the resources or skills to replace those of our partner, which could
require us to seek additional funding that might not be available on favorable
terms or at all, and could cause significant delays in the development and/or
commercialization of VEGF Trap-Eye outside the United States and result in
substantial additional costs to us. We have limited commercial capabilities and
would have to develop or outsource these capabilities outside the United States.
Termination of the Bayer HealthCare collaboration agreement would create
substantial new and additional risks to the successful development and
commercialization of VEGF Trap-Eye.</FONT></P>
<P align=justify><B><I><FONT face=serif size=2>Our collaborators and service
providers may fail to perform adequately in their efforts to support the
development, manufacture, and commercialization of ARCALYST<SUP>&#174;</SUP>
(rilonacept) and our drug candidates. </FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We depend
upon third-party collaborators, including sanofi-aventis, Bayer HealthCare, and
service providers such as clinical research organizations, outside testing
laboratories, clinical investigator sites, and third-party manufacturers and
product packagers and labelers, to assist us in the manufacture and preclinical
and clinical development of our product candidates. If any of our existing
collaborators or service providers breaches or terminates its agreement with us
or does not perform its development or manufacturing services under an agreement
in a timely manner or in compliance with applicable Good Manufacturing Practices
(GMPs) or good clinical practices, we could experience additional costs, delays,
and difficulties in the manufacture or development or in obtaining approval by
regulatory authorities for our product candidates.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We rely
on third party service providers to support the distribution of ARCALYST and
many other related activities in connection with the commercialization of
ARCALYST for the treatment of CAPS. We cannot be certain that these third
parties will perform adequately. If these service providers do not perform their
services adequately, our efforts to market and sell ARCALYST for the treatment
of CAPS will not be successful.</FONT></P>
<P align=justify><B><FONT face=serif size=2>Risks Related to the Manufacture of
Our Product Candidates </FONT></B></P>
<P align=justify><B><I><FONT face=serif size=2>We have limited manufacturing
capacity, which could inhibit our ability to successfully develop or
commercialize our drugs.</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Our
manufacturing facility is likely to be inadequate to produce sufficient
quantities of product for commercial sale. We intend to rely on our corporate
collaborators, as well as contract manufacturers, to produce the large
quantities of drug material needed for commercialization of our products. We
rely entirely on third-party manufacturers for filling and finishing services.
We will have to depend on these manufacturers to deliver material on a timely
basis and to comply with regulatory requirements. If we are unable to supply
sufficient material on acceptable terms, or if we should encounter delays or
difficulties in our relationships with our corporate collaborators or contract
manufacturers, our business, financial condition, and results of operations may
be materially harmed.</FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>50</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We must
expand our own manufacturing capacity to support the planned growth of our
clinical pipeline. Moreover, we may expand our manufacturing capacity to support
commercial production of active pharmaceutical ingredients, or API, for our
product candidates. This will require substantial additional expenditures, and
we will need to hire and train significant numbers of employees and managerial
personnel to staff our facility. Start-up costs can be large and scale-up
entails significant risks related to process development and manufacturing
yields. We may be unable to develop manufacturing facilities that are sufficient
to produce drug material for clinical trials or commercial use. This may delay
our clinical development plans and interfere with our efforts to commercialize
our products. In addition, we may be unable to secure adequate filling and
finishing services to support our products. As a result, our business, financial
condition, and results of operations may be materially harmed.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We may be
unable to obtain key raw materials and supplies for the manufacture of ARCALYST<SUP>&#174;</SUP> (rilonacept)
and our product candidates. In addition, we may face difficulties in developing
or acquiring production technology and managerial personnel to manufacture
sufficient quantities of our product candidates at reasonable costs and in
compliance with applicable quality assurance and environmental regulations and
governmental permitting requirements.</FONT></P>
<P align=justify><B><I><FONT face=serif size=2>If any of our clinical programs
are discontinued, we may face costs related to the unused capacity at our
manufacturing facilities. </FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We have
large-scale manufacturing operations in Rensselaer, New York. We use our
facilities to produce bulk product for clinical and preclinical candidates for
ourselves and our collaborations. If our clinical candidates are discontinued,
we will have to absorb one hundred percent of related overhead costs and
inefficiencies. </FONT></P>
<P align=justify><B><I><FONT face=serif size=2>Third-party supply failures,
business interruptions, or natural disasters affecting our manufacturing
facilities in Rensselaer, New York could adversely affect our ability to supply
our products.</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We
manufacture all of our bulk drug materials for ARCALYST and our product
candidates at our manufacturing facilities in Rensselaer, New York. We would be
unable to supply our product requirements if we were to cease production due to
regulatory requirements or action, business interruptions, labor shortages or
disputes, contaminations, fire, natural disasters, or other problems at the
facilities.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Certain
raw materials necessary for manufacturing and formulation of ARCALYST and our
product candidates are provided by single-source unaffiliated third-party
suppliers. In addition, we rely on certain third parties to perform filling,
finishing, distribution, and other services related to the manufacture of our
products. We would be unable to obtain these raw materials or services for an
indeterminate period of time if any of these third-parties were to cease or
interrupt production or otherwise fail to supply these materials, products, or
services to us for any reason, including due to regulatory requirements or
action, adverse financial developments at or affecting the supplier, failure by
the supplier to comply with GMPs, business interruptions, or labor shortages or
disputes. This, in turn, could materially and adversely affect our ability to
manufacture or supply ARCALYST or our product candidates for use in clinical
trials, which could materially and adversely affect our business and future
prospects.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Also,
certain of the raw materials required in the manufacturing and the formulation
of our clinical candidates may be derived from biological sources, including
mammalian tissues, bovine serum, and human serum albumin. There are certain
European regulatory restrictions on using these biological source materials. If
we are required to substitute for these sources to comply with European
regulatory requirements, our clinical development activities may be delayed or
interrupted.</FONT></P>
<P align=center><FONT face=serif size=2>51</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><FONT face=serif size=2>Risks Related to Commercialization
of Products </FONT></B></P>
<P align=justify><B><I><FONT face=serif size=2>If we are unable to establish
sales, marketing, and distribution capabilities, or enter into agreements with
third parties to do so, we will be unable to successfully market and sell future
products. </FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We are
marketing and selling ARCALYST for the treatment of CAPS ourselves in the United
States, primarily through third party service providers. We have no sales or
distribution personnel in the United States and have only a small staff with
commercial capabilities. We have no sales, marketing, commercial, or
distribution capabilities outside the United States. If we are unable to obtain
those capabilities, either by developing our own organizations or entering into
agreements with service providers, even if our current or future product
candidates receive marketing approval, we will not be able to successfully sell
those products. In that event, we will not be able to generate significant
revenue, even if our product candidates are approved. We cannot guarantee that
we will be able to hire the qualified sales and marketing personnel we need or
that we will be able to enter into marketing or distribution agreements with
third-party providers on acceptable terms, if at all. Under the terms of our
collaboration agreement with sanofi-aventis, we currently rely on sanofi-aventis
for sales, marketing, and distribution of aflibercept in cancer indications,
should it be approved in the future by regulatory authorities for marketing. We
will have to rely on a third party or devote significant resources to develop
our own sales, marketing, and distribution capabilities for our other product
candidates, including VEGF Trap-Eye in the United States, and we may be
unsuccessful in developing our own sales, marketing, and distribution
organization.</FONT></P>
<P align=justify><B><I><FONT face=serif size=2>There may be too few patients
with CAPS to profitably commercialize ARCALYST<SUP>&#174;</SUP> (rilonacept) in this
indication.</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Our only
approved product is ARCALYST for the treatment of CAPS, a group of rare,
inherited auto-inflammatory diseases. These rare diseases affect a very small
group of people. The incidence of CAPS has been reported to be approximately 1
in 1,000,000 people in the United States. Although the incidence rate of CAPS in
Europe has not been reported, it is known to be a rare set of diseases. In June
2009, Novartis received marketing approval from the FDA for its IL-1 antibody
product for the treatment of CAPS, and it has filed an application with EMEA
seeking approval of its IL-1 antibody product for the treatment of CAPS in
Europe. Given the very rare nature of the disease and the competition from
Novartis&#146; IL-1 antibody product, we may be unable to profitably commercialize
ARCALYST in this indication.</FONT></P>
<P align=justify><B><I><FONT face=serif size=2>Even if our product candidates
are approved for marketing, their commercial success is highly uncertain because
our competitors have received approval for products with a similar mechanism of
action, and competitors may get to the marketplace with better or lower cost
drugs.</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>There is
substantial competition in the biotechnology and pharmaceutical industries from
pharmaceutical, biotechnology, and chemical companies. Many of our competitors
have substantially greater research, preclinical and clinical product
development and manufacturing capabilities, and financial, marketing, and human
resources than we do. Our smaller competitors may also enhance their competitive
position if they acquire or discover patentable inventions, form collaborative
arrangements, or merge with large pharmaceutical companies. Even if we achieve
product commercialization, our competitors have achieved, and may continue to
achieve, product commercialization before our products are approved for
marketing and sale.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Genentech has an approved VEGF antagonist, Avastin<SUP>&#174;</SUP>
(bevacizumab), on the market for treating
certain cancers and many different pharmaceutical and biotechnology companies
are working to develop competing VEGF antagonists, including Novartis, Amgen,
Imclone/Eli Lilly, Pfizer, AstraZeneca, and GlaxoSmithKline plc. Many of these
molecules are farther along in development than aflibercept and may offer
competitive advantages over our molecule. Each of Pfizer and Onyx
Pharmaceuticals, (together with its partner Bayer HealthCare) has received
approval from the FDA to market and sell an oral medication that targets tumor
cell growth and new vasculature formation that fuels the growth of tumors. The
marketing approvals for Genentech&#146;s VEGF antagonist, Avastin, and their
extensive, ongoing clinical development plan for Avastin in other cancer
indications, make it more difficult for us to enroll patients in clinical trials
to support aflibercept and to obtain regulatory approval of aflibercept in these
cancer settings. This may delay or impair our ability to successfully develop
and commercialize aflibercept. In addition, even if aflibercept is ever approved
for sale for the treatment of certain cancers, it will be difficult for our drug
to compete against Avastin and the FDA approved kinase
inhibitors, because doctors and patients will have significant experience using
these medicines. In addition, an oral medication may be considerably less
expensive for patients than a biologic medication, providing a competitive
advantage to companies that market such products.</FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>52</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>

<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>The
market for eye disease products is also very competitive. Novartis and Genentech are
collaborating on the commercialization and further development of a VEGF antibody
fragment, Lucentis<SUP>&#174; </SUP>(ranibizumab injection), marketed by Genentech, Inc.,
for the treatment of age-related macular degeneration (wet AMD) and other eye indications.
Lucentis was approved by the FDA in June 2006 for the treatment of wet AMD. Many other
companies are working on the development of product candidates for the potential treatment
of wet AMD and DME that act by blocking VEGF, VEGF receptors, and through the use of small
interfering ribonucleic acids (siRNAs) that modulate gene expression. In addition,
ophthalmologists are using off-label a third-party repackaged version of Genentech&#146;s
approved VEGF antagonist, Avastin<SUP>&#174; </SUP>(bevacizumab), with success for the
treatment of wet AMD. The National Eye Institute is conducting a Phase 3 trial comparing
Lucentis to Avastin in the treatment of wet AMD. The marketing approval of Lucentis and
the potential off-label use of Avastin make it more difficult for us to enroll patients in
our clinical trials and successfully develop VEGF Trap-Eye. Even if VEGF Trap-Eye is ever
approved for sale for the treatment of eye diseases, it may be difficult for our drug to
compete against Lucentis, because doctors and patients will have significant experience
using this medicine. Moreover, the relatively low cost of therapy with Avastin in patients
with wet AMD presents a further competitive challenge in this indication. While we believe
that aflibercept would not be well tolerated if administered directly to the eye, if
aflibercept is ever approved for the treatment of certain cancers, there is a risk that
third parties will attempt to repackage aflibercept for use and sale for the treatment of
wet AMD and other diseases of the eye, which would present a potential low-cost
competitive threat to the VEGF Trap-Eye if it is ever approved for sale. </FONT></P>

<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>The
availability of highly effective FDA approved TNF-antagonists such as
Enbrel<SUP>&#174;</SUP> (etanercept), marketed by Amgen Inc. and Wyeth Pharmaceuticals,
Inc., Remicade<SUP>&#174;</SUP> (infliximab), marketed by Centocor Ortho Biotech, Inc.,
Humira<SUP>&#174;</SUP> (adalimumab), marketed by Abbott Laboratories, and
Simponi<SUP>TM</SUP> (golimumab), marketed by Centocor Ortho Biotech, Inc., and the IL-1
receptor antagonist Kineret<SUP>&#174;</SUP> (anakinra) marketed by Biovitrum, and other
marketed therapies makes it more difficult to successfully develop and commercialize
ARCALYST<SUP>&#174;</SUP> (rilonacept). This is one of the reasons we discontinued the
development of ARCALYST in adult rheumatoid arthritis. In addition, even if ARCALYST is
ever approved for sale in indications where TNF-antagonists are approved, it will be
difficult for our drug to compete against these FDA approved TNF-antagonists because
doctors and patients will have significant experience using these effective medicines.
Moreover, in such indications these approved therapeutics may offer competitive advantages
over ARCALYST, such as requiring fewer injections. </FONT></P>

<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>There are
both small molecules and antibodies in development by other companies that are
designed to block the synthesis of interleukin-1 or inhibit the signaling of
interleukin-1. For example, Eli Lilly, Xoma, and Novartis are each developing
antibodies to interleukin-1 and Amgen is developing an antibody to the
interleukin-1 receptor. In June 2009, Novartis received marketing approval from
the FDA for its IL-1 antibody for the treatment of CAPS. Novartis has filed an
application with EMEA seeking approval of its IL-1 antibody product for the
treatment of CAPS in Europe. Novartis is also developing its IL-1 antibody in
gout and other inflammatory diseases. Novartis has stated that its IL-1 antibody
demonstrated long-lasting clinical remission in patients with CAPS and that its
clinical candidate could develop into a major therapeutic advance in the
treatment of CAPS. Novartis&#146; IL-1 antibody and these other drug candidates could
offer competitive advantages over ARCALYST. The successful development of these
competing molecules could impair our ability to successfully commercialize
ARCALYST.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We have
plans to develop ARCALYST for the treatment of certain gout indications. As
noted above, Novartis is testing its IL-1 antibody in gout. This product
candidate is dosed less frequently for the treatment of CAPS and may be
perceived as offering competitive advantages over ARCALYST in gout by some
physicians, which would make it difficult for us to successfully commercialize
ARCALYST in that disease.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Currently, inexpensive, oral therapies such as analgesics and other
non-steroidal anti-inflammatory drugs are used as the standard of care to treat
the symptoms of these gout diseases. These established, inexpensive, orally
delivered drugs may make it difficult for us to successfully commercialize
ARCALYST in these diseases. </FONT></P>
<P align=justify><B><I><FONT face=serif size=2>The successful commercialization
of ARCALYST<SUP>&#174;</SUP> (rilonacept) and our product candidates will depend on
obtaining coverage and reimbursement for use of these products from third-party
payers and these payers may not agree to cover or reimburse for use of our
products. </FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Our
product candidates, if commercialized, may be significantly more expensive than
traditional drug treatments. For example, we have announced plans to initiate a
Phase 3 program studying the use of ARCALYST for the treatment of certain gout
indications. Patients suffering from these gout indications are currently
treated with inexpensive therapies, including non-steroidal anti-inflammatory
drugs. These existing treatment options are likely to be considerably less
expensive and may be preferable to a biologic medication for some patients. Our
future revenues and profitability will be adversely affected if United States
and foreign governmental, private third-party insurers and payers, and other
third-party payers, including Medicare and Medicaid, do not agree to defray or
reimburse the cost of our products to the patients. If these entities refuse to
provide coverage and reimbursement with respect to our products or provide an
insufficient level of coverage and reimbursement, our products may be too costly
for many patients to afford them, and physicians may not prescribe them. Many
third-party payers cover only selected drugs, making drugs that are not
preferred by such payer more expensive for patients, and require prior
authorization or failure on another type of treatment before covering a
particular drug. Payers may especially impose these obstacles to coverage on
higher-priced drugs, as our product candidates are likely to be.</FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>53</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We market
and sell ARCALYST<SUP>&#174;</SUP> (rilonacept) in the United States for the treatment of a group of rare
genetic disorders called CAPS. There may be too few patients with CAPS to
profitably commercialize ARCALYST. Physicians may not prescribe ARCALYST, and
CAPS patients may not be able to afford ARCALYST, if third party payers do not
agree to reimburse the cost of ARCALYST therapy and this would adversely affect
our ability to commercialize ARCALYST profitably.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In
addition to potential restrictions on coverage, the amount of reimbursement for
our products may also reduce our profitability. In the United States, there have
been, and we expect will continue to be, actions and proposals to control and
reduce healthcare costs. Government and other third-party payers are challenging
the prices charged for healthcare products and increasingly limiting, and
attempting to limit, both coverage and level of reimbursement for prescription
drugs. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Since
ARCALYST and our product candidates in clinical development will likely be too
expensive for most patients to afford without health insurance coverage, if our
products are unable to obtain adequate coverage and reimbursement by third-party
payers our ability to successfully commercialize our product candidates may be
adversely impacted. Any limitation on the use of our products or any decrease in
the price of our products will have a material adverse effect on our ability to
achieve profitability. </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In
certain foreign countries, pricing, coverage, and level of reimbursement of
prescription drugs are subject to governmental control, and we may be unable to
negotiate coverage, pricing, and reimbursement on terms that are favorable to
us. In some foreign countries, the proposed pricing for a drug must be approved
before it may be lawfully marketed. The requirements governing drug pricing vary
widely from country to country. For example, the European Union provides options
for its member states to restrict the range of medicinal products for which
their national health insurance systems provide reimbursement and to control the
prices of medicinal products for human use. A member state may approve a
specific price for the medicinal product or it may instead adopt a system of
direct or indirect controls on the profitability of the company placing the
medicinal product on the market. Our results of operations may suffer if we are
unable to market our products in foreign countries or if coverage and
reimbursement for our products in foreign countries is limited.</FONT></P>
<P align=justify><B><FONT face=serif size=2>Risk Related to Employees
</FONT></B></P>
<P align=justify><B><I><FONT face=serif size=2>We are dependent on our key
personnel and if we cannot recruit and retain leaders in our research,
development, manufacturing, and commercial organizations, our business will be
harmed. </FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We are
highly dependent on certain of our executive officers. If we are not able to
retain any of these persons or our Chairman, our business may suffer. In
particular, we depend on the services of P. Roy Vagelos, M.D., the Chairman of
our board of directors, Leonard Schleifer, M.D., Ph.D., our President and Chief
Executive Officer, George D. Yancopoulos, M.D., Ph.D., our Executive Vice
President, Chief Scientific Officer and President, Regeneron Research
Laboratories, and Neil Stahl, Ph.D., our Senior Vice President, Research and
Development Sciences. There is intense competition in the biotechnology industry
for qualified scientists and managerial personnel in the development,
manufacture, and commercialization of drugs. We may not be able to continue to
attract and retain the qualified personnel necessary for developing our
business. </FONT></P>
<P align=justify><B><I><FONT face=serif size=2>Our move to new facilities in
mid-2009 could lead to disruptions in our business operations.
</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We plan
to move most of our laboratories and headquarters to new facilities in mid-2009.
There is a risk that this physical move could lead to damage to equipment or
other business assets or the loss of important data, or that we could encounter
problems with our new facilities, which could disrupt or delay our business
operations. </FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>54</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><FONT face=serif size=2>Risks Related to Our Common Stock
</FONT></B></P>
<P align=justify><B><I><FONT face=serif size=2>Our stock price is extremely
volatile. </FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>There has
been significant volatility in our stock price and generally in the market
prices of biotechnology companies&#146; securities. Various factors and events may
have a significant impact on the market price of our Common Stock. These factors
include, by way of example:</FONT></P>
<UL style="FONT-SIZE: 10pt; TEXT-ALIGN: justify">
  <LI><FONT face=serif size=2>progress, delays, or adverse results in clinical
  trials;&nbsp;</FONT>
  <LI><FONT face=serif size=2>announcement of technological innovations or
  product candidates by us or competitors;&nbsp;</FONT>
  <LI><FONT face=serif size=2>fluctuations in our operating
  results;&nbsp;</FONT>
  <LI><FONT face=serif size=2>third party claims that our products or
  technologies infringe their patents;&nbsp;</FONT>
  <LI><FONT face=serif size=2>public concern as to the safety or effectiveness
  of ARCALYST<SUP>&#174;</SUP> (rilonacept) or any of our product
  candidates;&nbsp;</FONT>
  <LI><FONT face=serif size=2>developments in our relationship with
  collaborative partners;&nbsp;</FONT>
  <LI><FONT face=serif size=2>developments in the biotechnology industry or in
  government regulation of healthcare;&nbsp;</FONT>
  <LI><FONT face=serif size=2>large sales of our common stock by our executive
  officers, directors, or significant shareholders;&nbsp;</FONT>
  <LI><FONT face=serif size=2>arrivals and departures of key personnel;
  and&nbsp;</FONT>
  <LI><FONT face=serif size=2>general market conditions.</FONT></LI></UL>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>The
trading price of our Common Stock has been, and could continue to be, subject to
wide fluctuations in response to these and other factors, including the sale or
attempted sale of a large amount of our Common Stock in the market. Broad market
fluctuations may also adversely affect the market price of our Common Stock.
</FONT></P>
<P align=justify><B><I><FONT face=serif size=2>Future sales of our Common Stock
by our significant shareholders or us may depress our stock price and impair our
ability to raise funds in new share offerings. </FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>A small
number of our shareholders beneficially own a substantial amount of our Common
Stock. As of April 14, 2009, our five largest shareholders plus Leonard S.
Schleifer, M.D. Ph.D., our Chief Executive Officer, beneficially owned 52.5% of
our outstanding shares of Common Stock, assuming, in the case of our Chief
Executive Officer, the conversion of his Class A Stock into Common Stock and the
exercise of all options held by him which are exercisable within 60 days of
April 14, 2009. As of April 14, 2009, sanofi-aventis beneficially owned
14,799,552 shares of Common Stock, representing approximately 19.0% of the
shares of Common Stock then outstanding. Under our investor agreement with
sanofi-aventis, sanofi-aventis may not sell these shares until December 20, 2012
except under limited circumstances and subject to earlier termination of these
restrictions upon the occurrence of certain events. Notwithstanding these
restrictions, if sanofi-aventis, or our other significant shareholders or we,
sell substantial amounts of our Common Stock in the public market, or the
perception that such sales may occur exists, the market price of our Common
Stock could fall. Sales of Common Stock by our significant shareholders,
including sanofi-aventis, also might make it more difficult for us to raise
funds by selling equity or equity-related securities in the future at a time and
price that we deem appropriate. </FONT></P>
<P align=justify><B><I><FONT face=serif size=2>Our existing shareholders may be
able to exert significant influence over matters requiring shareholder approval.
</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Holders
of Class A Stock, who are generally the shareholders who purchased their stock
from us before our initial public offering, are entitled to ten votes per share,
while holders of Common Stock are entitled to one vote per share. As of April
14, 2009, holders of Class A Stock held 22.4% of the combined voting power of
all shares of Common Stock and Class A Stock then outstanding, plus any voting
power associated with any shares of Common Stock beneficially owned by such
Class A Stock holders. These shareholders, if acting together, would be in a
position to significantly influence the election of our directors and to effect
or prevent certain corporate transactions that require majority or supermajority
approval of the combined classes, including mergers and other business
combinations. This may result in us taking corporate actions that you may not
consider to be in your best interest and may affect the price of our Common
Stock. As of April 14, 2009:</FONT></P>
<P align=center><FONT face=serif size=2>55</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<UL style="FONT-SIZE: 10pt; TEXT-ALIGN: justify">
  <LI><FONT face=serif size=2>our current executive officers and directors
  beneficially owned 13.3% of our outstanding shares of Common Stock, assuming
  conversion of their Class A Stock into Common Stock and the exercise of all
  options held by such persons which are exercisable within 60 days of April 14,
  2009, and 28.2% of the combined voting power of our outstanding shares of
  Common Stock and Class A Stock, assuming the exercise of all options held by
  such persons which are exercisable within 60 days of April 14, 2009; and
  </FONT>
  <LI><FONT face=serif size=2>our five largest shareholders plus Leonard S.
  Schleifer, M.D., Ph.D., our Chief Executive Officer, beneficially owned 52.5%
  of our outstanding shares of Common Stock, assuming, in the case of our Chief
  Executive Officer, the conversion of his Class A Stock into Common Stock and
  the exercise of all options held by him which are exercisable within 60 days
  of April 14, 2009. In addition, these six shareholders held 57.2% of the
  combined voting power of our outstanding shares of Common Stock and Class A
  Stock, assuming the exercise of all options held by our Chief Executive
  Officer which are exercisable within 60 days of April 14, 2009.</FONT></LI></UL>
<P align=justify><FONT face=serif size=2><FONT size=3>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Pursuant to an investor agreement,
sanofi-aventis has agreed to vote its shares, at sanofi-aventis&#146; election,
either as recommended by our board of directors or proportionally with the votes
cast by our other shareholders, except with respect to certain change of control
transactions, liquidation or dissolution, stock issuances equal to or exceeding
10% of the then outstanding shares or voting rights of Common Stock and Class A
Stock, and new equity compensation plans or amendments if not materially
consistent with our historical equity compensation practices.</FONT></P>
<P align=justify><B><I><FONT face=serif size=2>The anti-takeover effects of
provisions of our charter, by-laws, and of New York corporate law and the
contractual &#147;standstill&#148; provisions in our investor agreement with
sanofi-aventis, could deter, delay, or prevent an acquisition or other &#147;change
in control&#148; of us and could adversely affect the price of our Common Stock.
</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Our
amended and restated certificate of incorporation, our by-laws, and the New York
Business Corporation Law contain various provisions that could have the effect
of delaying or preventing a change in control of our company or our management
that shareholders may consider favorable or beneficial. Some of these provisions
could discourage proxy contests and make it more difficult for you and other
shareholders to elect directors and take other corporate actions. These
provisions could also limit the price that investors might be willing to pay in
the future for shares of our Common Stock. These provisions include:</FONT></P>
<UL style="FONT-SIZE: 10pt; TEXT-ALIGN: justify">
  <LI><FONT face=serif size=2>authorization to issue &#147;blank check&#148; preferred
  stock, which is preferred stock that can be created and issued by the board of
  directors without prior shareholder approval, with rights senior to those of
  our common shareholders;</FONT>
  <LI><FONT face=serif size=2>a staggered board of directors, so that it would
  take three successive annual meetings to replace all of our directors;</FONT>
  <LI><FONT face=serif size=2>a requirement that removal of directors may only
  be effected for cause and only upon the affirmative vote of at least eighty
  percent (80%) of the outstanding shares entitled to vote for directors, as
  well as a requirement that any vacancy on the board of directors may be filled
  only by the remaining directors;</FONT>
  <LI><FONT face=serif size=2>any action required or permitted to be taken at
  any meeting of shareholders may be taken without a meeting, only if, prior to
  such action, all of our shareholders consent, the effect of which is to
  require that shareholder action may only be taken at a duly convened
  meeting;</FONT>
  <LI><FONT face=serif size=2>any shareholder seeking to bring business before
  an annual meeting of shareholders must provide timely notice of this intention
  in writing and meet various other requirements; and</FONT>
  <LI><FONT face=serif size=2>under the New York Business Corporation Law, in
  addition to certain restrictions which may apply to &#147;business combinations&#148;
  involving the Company and an &#147;interested shareholder&#148;, a plan of merger or
  consolidation of the Company must be approved by two-thirds of the votes of
  all outstanding shares entitled to vote thereon. See the risk factor
  immediately above captioned </FONT><I><FONT face=serif size=2>&#147;Our existing
  shareholders may be able to exert significant influence over matters requiring
  shareholder approval.&#148;</FONT></I></LI></UL>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Until the
later of the fifth anniversaries of the expiration or earlier termination of our
antibody collaboration agreements with sanofi-aventis or our aflibercept
collaboration with sanofi-aventis, sanofi-aventis will be bound by certain
"standstill" provisions, which contractually prohibit sanofi-aventis from
acquiring more than certain specified percentages of our Class A Stock and
Common Stock (taken together) or otherwise seeking to obtain control of the
Company.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2><FONT face=serif>In
addition, we have a Change in Control Severance Plan and our Chief Executive
Officer has an employment agreement that provides severance benefits in the
event our officers are terminated as a result of a change in control </FONT>of
the Company. Many of our stock options issued under our Amended and Restated
2000 Long-Term Incentive Plan may become fully vested in connection with a
&#147;change in control&#148; of our company, as defined in the plan.</FONT></P>
<P align=center><FONT face=serif size=2>56</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><FONT face=serif size=2>ITEM 4. SUBMISSION OF MATTERS TO A
VOTE OF SECURITY HOLDERS </FONT></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>On June
12, 2009, we conducted our Annual Meeting of Shareholders pursuant to due
notice. A quorum being present either in person or by proxy, the shareholders
voted on the following matters: </FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>1. To
elect four directors to hold office for a three-year term as Class III
directors, and until their successors are duly elected and qualified.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>2. To
ratify the appointment of PricewaterhouseCoopers LLP as the Company&#146;s
independent registered public accounting firm for our fiscal year ending
December 31, 2009.</FONT></P>
<P align=justify><FONT face=serif size=2><FONT size=3>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>No other matters were voted on. The
number of votes cast was: </FONT></P>
<DIV align=center>
<TABLE cellSpacing=0 cellPadding=0 width="90%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="88%"></TD>
    <TD noWrap align=left width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%"><FONT face=serif size=2>For</FONT> </TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%"><FONT face=serif size=2>Withheld</FONT> </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%" bgColor=#c0c0c0><FONT face=serif size=2>1. Election of Class III Directors</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="5%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Charles A. Baker</FONT> </TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="5%"><FONT face=serif size=2>85,414,146</FONT>&nbsp; </TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>5,883,862</FONT>
    </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Michael S. Brown, M.D.</FONT> </TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>89,776,770</FONT>&nbsp; </TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>1,521,238</FONT> </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Arthur F. Ryan</FONT> </TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="5%"><FONT face=serif size=2>85,834,531</FONT>&nbsp; </TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>5,463,477</FONT>
    </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>George L. Sing</FONT> </TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>85,365,920</FONT>&nbsp; </TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>5,932,088</FONT> </TD></TR></TABLE></DIV><BR>
<P align=justify><FONT face=serif size=2><FONT size=3>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The terms of office of Leonard S.
Schleifer, M.D., Ph.D., Eric M. Shooter, Ph.D, George D. Yancopoulos, M.D.,
Ph.D., Alfred G. Gilman, M.D., Ph.D., Joseph L. Goldstein, M.D., and P. Roy
Vagelos, M.D. continued after the meeting. </FONT></P>
<DIV align=center>
<TABLE cellSpacing=0 cellPadding=0 width="90%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="85%"></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%"><FONT face=serif size=2>For</FONT> </TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%"><FONT face=serif size=2>Against</FONT> </TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%"><FONT face=serif size=2>Abstain</FONT> </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="85%" bgColor=#c0c0c0><FONT face=serif size=2>2. Ratification of the Appointment</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="85%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>of Independent Registered</FONT> </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="85%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Public Accounting Firm</FONT> </TD>
    <TD noWrap align=center width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>90,589,991</FONT> </TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>293,489</FONT> </TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>414,528</FONT> </TD></TR></TABLE></DIV><BR>
<P align=justify><B><FONT face=serif size=2></FONT></B><FONT face=serif size=2><FONT size=3>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>There were no broker
non-votes with respect to either matter voted on at the 2009 Annual Meeting of
Shareholders.</FONT></P>
<P align=justify><B><FONT face=serif size=2>ITEM 6. EXHIBITS </FONT></B></P>
<P align=justify><FONT face=serif size=2><FONT size=3>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>(a)</FONT><FONT face=sans-serif size=2> </FONT><FONT face=serif size=2>Exhibits </FONT></P>
<TABLE style="FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"><B><FONT face=serif size=2></FONT></B></TD>
    <TD noWrap align=left width="3%"><STRONG>Exhibit</STRONG></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="2%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=left width="91%" colSpan=2></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"><B><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;</FONT></B></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="3%"><STRONG>Number</STRONG></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="5%" colSpan=4><B><FONT face=serif size=2>Description</FONT></B></TD>
    <TD noWrap align=left width="90%">&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"></TD>
    <TD vAlign=top noWrap align=left width="3%"><FONT face=serif size=2>10.1*</FONT></TD>
    <TD vAlign=top noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD vAlign=top noWrap align=right width="2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD vAlign=top noWrap align=right width="1%"><FONT face=serif size=2>-</FONT></TD>
    <TD vAlign=top noWrap align=center width="1%">&nbsp;</TD>
    <TD vAlign=top align=left width="91%" colSpan=2>
      <P align=justify><FONT face=serif size=2>IL-1 Antibody Termination Agreement By and
      Between Novartis Pharma AG, Novartis Pharmaceuticals Corporation and
      Regeneron Pharmaceuticals, Inc., dated as of June 8,
2009.</FONT></P></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"></TD>
    <TD vAlign=top noWrap align=left width="3%"><FONT face=serif size=2>10.2*</FONT></TD>
    <TD vAlign=top noWrap align=center width="1%"></TD>
    <TD vAlign=top noWrap align=right width="2%"></TD>
    <TD vAlign=top noWrap align=right width="1%"><FONT face=serif size=2>-</FONT></TD>
    <TD vAlign=top noWrap align=center width="1%"></TD>
    <TD vAlign=top align=left width="91%" colSpan=2>
      <P align=justify><FONT face=serif size=2>Trap-2 Termination Agreement By
      and Between Novartis Pharma AG, Novartis Pharmaceuticals Corporation and
      Regeneron Pharmaceuticals, Inc., dated as of June 8,
2009.</FONT></P></TD></TR>
  <TR>
    <TD noWrap align=left width="1%"></TD>
    <TD vAlign=top noWrap align=left width="3%">10.3(a)</TD>
    <TD vAlign=top noWrap align=center width="1%"></TD>
    <TD vAlign=top noWrap align=right width="2%"></TD>
    <TD vAlign=top noWrap align=right width="1%">-</TD>
    <TD vAlign=top noWrap align=center width="1%"></TD>
    <TD vAlign=top align=left width="91%" colSpan=2>
      <P align=justify>Third Amendment to Lease by and between BMR-Landmark at
      Eastview LLC and Regeneron Pharmaceuticals, Inc. entered into as of April
      29, 2009.</P></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"></TD>
    <TD vAlign=top noWrap align=left width="3%"><FONT face=serif size=2>31.1</FONT></TD>
    <TD vAlign=top noWrap align=center width="1%"></TD>
    <TD vAlign=top noWrap align=right width="2%"></TD>
    <TD vAlign=top noWrap align=right width="1%"><FONT face=serif size=2>-</FONT></TD>
    <TD vAlign=top noWrap align=center width="1%"></TD>
    <TD vAlign=top align=left width="91%" colSpan=2>
      <P align=justify><FONT face=serif size=2>Certification of CEO pursuant to
      Rule 13a-14(a) under the Securities Exchange Act of 1934.</FONT></P></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"></TD>
    <TD vAlign=top noWrap align=left width="3%"><FONT face=serif size=2>31.2</FONT></TD>
    <TD vAlign=top noWrap align=center width="1%"></TD>
    <TD vAlign=top noWrap align=right width="2%"></TD>
    <TD vAlign=top noWrap align=right width="1%"><FONT face=serif size=2>-</FONT></TD>
    <TD vAlign=top noWrap align=center width="1%"></TD>
    <TD vAlign=top align=left width="91%" colSpan=2>
      <P align=justify><FONT size=2>Certification of CFO pursuant to Rule
      13a-14(a) under the Securities Exchange Act of 1934.</FONT></P></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"></TD>
    <TD vAlign=top noWrap align=left width="3%"><FONT face=serif size=2>32</FONT></TD>
    <TD vAlign=top noWrap align=center width="1%"></TD>
    <TD vAlign=top noWrap align=right width="2%"></TD>
    <TD vAlign=top noWrap align=right width="1%"><FONT face=serif size=2>-</FONT></TD>
    <TD vAlign=top noWrap align=center width="1%"></TD>
    <TD vAlign=top noWrap align=left width="91%" colSpan=2>
      <P align=justify><FONT face=serif size=2>Certification of CEO and CFO
      pursuant to 18 U.S.C. Section
1350.</FONT></P></TD></TR></TABLE>____________________<BR>&nbsp;<BR>
<TABLE style="TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD vAlign=top align=left width="1%"><FONT face=serif size=2>*</FONT></TD>
    <TD vAlign=top align=left width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD vAlign=top align=left width="97%">
      <P align=justify><FONT face=serif size=2>Portions of this document have
      been omitted and filed separately with the Commission pursuant to a request
      for confidential treatment pursuant to Rule 24b-2.</FONT></P></TD></TR>
  <TR vAlign=bottom>
    <TD vAlign=top align=left width="1%"><FONT size=2>(a)</FONT></TD>
    <TD vAlign=top align=left width="1%">&nbsp;</TD>
    <TD vAlign=top align=left width="97%">
      <P align=justify><FONT size=2>Incorporated by reference from the Form 10-Q
      for Regeneron Pharmaceuticals, Inc. for the quarter ended March 31, 2009,
      filed April 30, 2009.</FONT></P></TD></TR></TABLE><BR>
<P align=center><FONT face=serif size=2>57</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=center><B><U><FONT face=serif size=2>SIGNATURE</FONT></U></B><FONT face=serif size=2> </FONT></P>
<P align=justify><FONT face=serif size=2>Pursuant to the requirements of the
Securities Exchange Act of 1934, the Registrant has duly caused this report to
be signed on its behalf by the undersigned thereunto duly authorized.
</FONT></P>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD noWrap align=left width="50%"></TD>
    <TD noWrap align=left width="50%" colSpan=2><FONT size=2>Regeneron
      Pharmaceuticals, Inc.</FONT>&nbsp; </TD></TR>
  <TR>
    <TD noWrap align=left width="50%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="49%">&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="50%"><FONT face=serif size=2>Date: August 4,
      2009</FONT></TD>
    <TD noWrap align=left width="1%">
      <P><FONT face=serif size=2>By:&nbsp;</FONT></P></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="49%"><P><FONT face=serif size=2>/s/</FONT> <FONT style="FONT-VARIANT: small-caps" face=serif size=2>Murray A.
      Goldberg</FONT></P></TD></TR>
  <TR>
    <TD width="100%" colSpan=3>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="50%"></TD>
    <TD noWrap align=left width="50%" colSpan=2><FONT face=serif size=2>Murray
      A. Goldberg</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="50%"></TD>
    <TD noWrap align=left width="50%" colSpan=2><FONT face=serif size=2>Senior
      Vice President, Finance &amp; Administration,</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="50%"></TD>
    <TD noWrap align=left width="50%" colSpan=2><FONT face=serif size=2>Chief
      Financial Officer, Treasurer, and</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="50%"></TD>
    <TD noWrap align=left width="50%" colSpan=2><FONT face=serif size=2>Assistant Secretary</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="50%"></TD>
    <TD noWrap align=left width="50%" colSpan=2><FONT face=serif size=2>(Principal Financial Officer and</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="50%"></TD>
    <TD noWrap align=left width="50%" colSpan=2><FONT face=serif size=2>Duly
      Authorized Officer)</FONT></TD></TR></TABLE><BR>
<P align=center><FONT face=serif size=2>58</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

</BODY>

</HTML>

</TEXT>
</DOCUMENT>
